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Abstract 
Tuberculosis (TB) is an important communicable disease affecting the human 
population world-wide. Despite the efforts of the scientific community, 
national governments and WHO in controlling the disease, TB still remains a 
major killer in resource poor settings. New rapid assays and techniques that 
are simple and cost-effective are urgently needed to identify, treat and 
understand pathogenesis including the geographical distribution of the 
disease. The aim of the thesis is to develop a novel genomic mapping tool 
using Insertion Element, IS6110 that could aid in epidemiological studies of 
Mycobacterium tuberculosis complex (MTBC) in low and middle income 
countries.  
IS6110, a bacterial transposon, plays an essential role in changing the 
physical and biochemical traits of MTBC. Due to their transposition in TB 
genomes, they are used as epidemiological markers for differentiation of TB 
organisms and the mapping of these elements could also shed light on the 
putative altered function of adjacent genes. In the era of Whole Genome 
Sequencing (WGS) where repeat elements are difficult to sequence with 
short read technologies, a rapid and simple method of insertion site mapping 
using IS6110 FAFLP PCR was developed. This work is aimed at developing 
a rapid, cost-effective and robust genomic tool box exploiting the IS6110 
FAFLP PCR assay that can both identify and characterise the TB genotypes / 
genetic lineages in any geographical location. 
For the first time using the assay above, TB samples from Nepal were 
categorised into different genetic lineages. Fifty-five percent of the samples 
iii 
 
analysed belong to Principal Genetic Group 1 (PGG1), Beijing and Central 
Asian strains.  Also, new primers were designed targeting the Beijing and the 
T- groups using the FAFLP derived data that gave rise to the development of 
rapid lineage specific PCR assays. In addition, it was noticed that 3.9% of the 
Nepalese strains tested in this research work were likely multi-drug resistant 
(MDR-TB) using PCR targeting the Rifampicin-resistance-determining region 
(RRDR) of the rpoB region. 
It is demonstrated here that IS6110 FAFLP methodology could easily 
characterise the TB samples into different genetic lineages provided they 
have more than four IS6110 copies. In addition, lineage specific PCR does 
not need any expensive instruments or reagents except for PCR blocks and 
gel visualisers, and could be very effective in the rapid identification of 
different TB genotypes within hours. These data also add to knowledge about 
the circulating strains of TB in Nepal, currently a poorly characterised region 
of the world in this regard, and could help in contact tracing studies by 
epidemiologists. The IS6110 FAFLP technique thus can be employed in any 
geographical location to map TB genetic lineages where there is little or no 
information available on the prevailing TB strains. 
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Outline of the thesis 
This research work is divided into chapters that explain the development of 
an IS6110 FAFLP genomic tool box that could be used in resource poor 
settings.  
Chapter 1 sets the scene for this thesis by reviewing the literature 
extensively. It gives a brief introduction about tuberculosis infection including 
diagnostics, treatment and TB epidemiology. Then an extensive review of the 
available molecular epidemiological markers is discussed including the 
IS6110 marker. The chapter ends with the overview of the study setting 
(Nepal), leading to aims and objectives of this research work. 
Chapter 2 discusses the general methods that were used to achieve the 
objectives of this project. 
Chapter 3 describes in detail how the IS6110 FAFLP PCR assay was 
developed and standardised. 
Chapter 4 shows for the first time how the standardised method was tested 
by mapping the IS6110 insertion sites in the reference genome H37Rv and 
by showing the development of rapid detection PCR targeting specific 
lineages. 
Chapter 5 describes characterisation of TB samples from Nepal, a resource 
poor setting, into different TB genetic lineages for the first time using IS6110 
FAFLP PCR. 
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Chapter 6 describes rifampicin sensitivity in the Nepalese TB samples using 
RIF resistant PCR assay. 
Chapter 8 finally summarises all the above chapters and concludes by 
putting the results into context. 
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Chapter 1 Introduction  
2 
 
Tuberculosis (TB) caused by the Mycobacterium tuberculosis complex 
(MTBC), is ranked as one of the top ten causes of death worldwide (WHO 
2015) with an estimated 10.4 million people falling ill with TB and 1.3 million 
TB deaths in 2016, exacerbated by HIV co-infection and the development of 
drug resistance (1). 
1.1 Mycobacterium tuberculosis complex (MTBC)  
Mycobacterium tuberculosis belongs to the genus Mycobacterium in the 
family Mycobacteriaceae, order Corynebacteriales and phylum 
Actinobacteria (2). 
TB caused by the MTBC encompasses the following members including 
proposed new members that affect mongooses and meerkats (3–6). 
1. M. tuberculosis  
2.  M. africanum (phylogenetic variant of M. tuberculosis). 
3. M. bovis  
4. M. caprae  
5. M. microti  
6. M. pinnipedii  
7. “M. mungi” 
8. “M. orygis”  
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9. “M. suricattae”  
10. “M. canetti” 
1.2  TB Timeline 
Before Robert Koch, two French physicians Rene Theophile Hyacinthe 
Laennec and Jean-Antoine Villemin reported in 1821 and 1868 respectively 
the first accounts of tuberculosis, even though the causative organism was 
unidentified at that time (7,8). However, Robert Koch’s enormous body of 
work from identification of the microorganism, developing the staining 
technique and culture methods for Mycobacterium tuberculosis, illustrating 
the mode of transmission to recommending isolation of the patients with 
active TB has to be considered as the greatest achievement in the science of 
TB and has now paved the way for various studies. Koch’s failed study to 
treat tuberculosis by using supernatants from M.tuberculosis culture which is 
now known as ‘tuberculin’ when injected in the skin gave rise to cell-mediated 
immune responses which are responsible for the clinical manifestations of 
the disease (9,10). Subsequently in the years that followed, various scientists 
and physicians were able to relate that the host immune responses 
especially cell-mediated immune responses played a major role in the 
pathogenesis of TB (9). The important discoveries and outcomes in relation 
to the TB timeline is given in the table 1.1 (adapted from (11)). 
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Table 1-1 TB timeline showcasing the important discoveries and events from the 19th 
century to the 21st century 
 
(BCG- Bacille Calmette Guerin, UNICEF- United Nations Children’s fund, WHO- World 
Health Organisation, DOTS- Directly Observed treatment short-course) 
 
Koch's discovery
BCG vaccine
Streptomycin (S)
Randomised Control Trials (RCT)
Isoniazid's (H) use in treatment
Pyrazinamide (Z)
Rifampicin (R)
Ethambutol [E]
S+H+R+E therapy and drug resistance
UNICEF vaccination programme
H+R+Z+E
HIV impact
Global Impact
DOTS implementation
TB genome
WHO initiative for TB elimination
STOP TB framework
Post 2015 global TB strategy
TB elimination
1
8
8
2
1
9
2
1
1
9
4
3
1
9
4
8
1
9
5
2
1
9
5
4
1
9
5
7
1
9
6
1
1
9
7
0
-
1
9
7
4
1
9
8
0
-
1
9
8
9
1
9
9
1
1
9
9
5
1
9
9
9
2
0
1
4
2
0
1
5
2
0
2
0
2
0
5
0
Rober Koch discovers the causative organism of tuberculosis, M. 
tuberculosis
An attenuated vaccine from  M.bovis  developed by French scientists 
Albert Calmette and Camille Guerin was put into use in humans
Streptomycin discovered in 1943 by american scientists, Selman 
Waksman, Albert Schatz, and Elizabeth Bugie, was found to be 
exhibiting antibacterial properties along with para- amino salicylic acid 
(PAS) 
First successful use of streptomycin in trials in humans
Combination therapy of S+PAS+H for 24 months
Pyrazinamide discovery
Rifampicin discovery
Ethambutol discovery and replaces PAS in combination therapy for 18 
months
Rifampicin included in combination therapy for 9-12 months and first 
outbreak of drug resistant TB in US
BCG vaccination included in UNICEF's expanded immunisation 
programme
Short term course for 6-8 months was introduced
First meeting by WHO to discuss TB-HIV coinfection
WHO declares TB as major public health issue as the TB related 
mortality was higher than previous years
Anti-TB drug resistance survey and a new framework for TB control 
including DOTS
First genome sequencing of Mycobacterium tuberculosis
WHO framework to completely eliminate TB by 2050 by adopting 
STOP TB strategy globally
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According to WHO in 2016, the Millennium Development Goal (MDG) by the 
United Nations to stop the spread of TB by 2015 has already been achieved 
in all six WHO regions, and in sixteen of the 22 high burden countries that 
collectively accounts for more than 80% of the TB cases worldwide. TB 
incidence has dropped to a level by 1.5 % every year since 2000 and 
consequently, it is 18% lower than the levels of 2000. However, it is still a 
major global health problem of the developing world in heavily populated 
countries like India and China which account for more than a quarter of new 
TB cases in addition to sub- Saharan Africa. The number of incident TB 
cases varies from country to country and it is predominantly lower in high-
income countries. (fig.1.1) (12). The MDGs have now been replaced by 
Sustainable Development Goals (SDGs) and the Stop TB strategy to the End 
TB strategy as shown in the figure 1-2 
 
Figure 1-1 Estimated rates of incidence of new TB cases world-wide, 2015  
(Taken from WHO’s global tuberculosis report 2016). 
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Figure 1-2 Milestones set by WHO to control TB by adopting End TB strategy  
(Taken from http://www.who.int/tb/strategy/end-tb/en/) 
1.3 Morphology of Mycobacterium tuberculosis 
M. tuberculosis is a rod-shaped non-spore forming aerobic acid-fast 
bacterium (see figure 1-3) having a unique cell wall structure that supports 
their survival (13). 
 
Figure 1-3 Acid fast Ziehl Neelsen staining showing rod-shaped Mycobacterium 
tuberculosis bacteria  
(https://s-media-cacheak0.pinimg.com/originals/94/40/2d/94402db464e9849cd5aeb723cb90c91c.jpg) 
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The cell wall consists of mycolic acid covalently attached to the underlying 
peptidoglycan bound polysaccharide arabinogalactan providing a protective 
barrier against host defence mechanisms (fig 1-4) thus enabling the 
bacterium to be resistant to the action of antibiotics. In addition, the cell wall 
also contains lipoarabinomannan, a carbohydrate structural antigen on the 
outside of the organism that is immunogenic and facilitates the survival of 
mycobacteria within macrophages (14,15). 
 
Figure 1-4 Unique Cell wall structure of Mycobacterium tuberculosis  
(Taken from http://www.cell.com/cms/attachment/607349/4834477/gr1.jpg)  
 
1.4 Immunopathogenesis of Tuberculosis 
M. tuberculosis infection is caused by aerosols generated from a person 
infected with pulmonary or laryngeal tuberculosis. These droplets containing 
two to three M. tuberculosis organisms can stay airborne for minutes to hours 
after expectoration (16). The size (1-5 µm in range) and concentration of the 
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aerosols also have been suggested to increase the TB transmission risk in 
patients with intra thoracic disease (17). The number of bacilli in the droplets, 
the virulence of the bacilli, exposure of the bacilli to the UV light, degree of 
ventilation and occasions for aerosolisation all influence transmission (fig. 1-
5). M. tuberculosis not only affects the respiratory system when it enters the 
lungs but can also affect the lymphatic system, pleura, bones/joints, or 
meninges and thus cause extra pulmonary tuberculosis (14). 
 
Figure 1-5 Pathophysiology of Tuberculosis infection  
A) Inhalation of bacilli, B) Formation of granulomas containing Macrophages and T-
lymphocytes and C) Collapse of granuloma and release of alveoli to other alveoli or other 
organs (Adapted from CDCP).  
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1.5 Clinical signs and symptoms 
The active lung tuberculosis is characterised by cough with sputum (blood at 
times), chest pains, loss of appetite, general weakness, weight loss, fever, 
and night sweats.  
The various stages of disease presentation in TB are as follows (13) as 
shown in figure 1-5: 
 In early infection or primary disease, the hosts’ immune system 
combats the infection and the patients present with fever, paratracheal 
lymphadenopathy or dyspnoea. Infection may not progress to active 
disease and could be subclinical 
 There are two stages in the active disease presentation. In early 
primary progressive stage or active disease, the immune system fails 
to prevent the onset of infection and the inflammation of tissues 
follows. As the patients have nonspecific signs like fatigue, weight loss 
and fever followed by the development of non-productive cough, the 
diagnosis could be difficult: It is because the findings on chest 
radiographs might be normal and the sputum smear microscopy might 
not contain any mycobacteria (‘negative’ result). 
 In late primary progressive/ active disease or active tuberculosis, the 
symptoms seen are productive cough leading to purulent sputum, 
progressive weight loss, chills, night sweats, respiratory crackles and 
anaemia. This state is an infectious state harbouring more bacilli than 
latent infection (18). Due to the excessive loss of both fat and lean 
tissue, this disease is also called wasting disease. Diagnosis is carried 
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out by sputum cultures as sometimes the chest radiographs appear 
normal. 
 In latent infections or latent tuberculosis infection (LTBI), mycobacteria 
persist in the body without any clinical signs or symptoms and the 
disease could be reactivated when the immune system fails to 
counteract the infection or if immunosuppressed. Also, calcification 
and fibrosis of the granulomatous lesions are noticed in radiological 
findings. The formation of granulomas for persons with intact cell-
mediated immunity is an accumulation of activated T-lymphocytes and 
macrophages. This micro-environment destroys the macrophages and 
produces early solid necrosis at the centre of the lesion but the 
bacteria survive this condition by modifying its phenotypic expression  
as suggested by Li et al. (19), by altering its expression to changes to 
pH and anaerobic growth conditions. By two or three weeks, the 
necrotic environment resembles soft cheese called caseous necrosis 
characterised by low pH, low oxygen levels and limited nutrients which 
leads to latency. Persons with adequate immunity develop fibrosis and 
calcification which contains the bacilli in these lesions whereas in 
those with impaired immunity develop primary progressive TB (20). 
The necrotic material undergoes liquefaction and the fibrous wall loses 
structural integrity in less immunocompetent persons which can then 
drain into the bronchus or a nearby blood vessel. Unique 
histopathological features of the lungs (granulomas of multinuclear 
cells, giant cells and caseation) in pulmonary tuberculosis are seen in 
figure 1-6. If the infected person coughs, droplet infection can occur 
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and also if discharged into the blood vessel it leads to extra pulmonary 
tuberculosis (fig 1.5). 
 In extra pulmonary tuberculosis, if it affects the central nervous system 
it leads to meningitis which left untreated results in deaths. If it affects 
the circulatory system causing infection of the blood stream, it leads to 
disseminated or miliary tuberculosis. When it affects the lymphatic 
system, it is called lymphatic tuberculosis and the most common 
presentation is cervical lymphadenopathy. In some cases, it is also 
shown to affect the joints, bones, pleura and the urogenital system 
(13). 
 
 
Figure 1-6 Histopathological features of lung infected by pulmonary tuberculosis 
showing caseation and formation of granulomas  
(Accessed from http://intellectualventureslab.com/assets_uploads/pulmonary_diagram_inflammation.jpg) 
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1.6 Diagnosis of active tuberculosis 
For TB treatment to be effective, a rapid and accurate diagnosis of drug 
resistant TB is important in ensuring the timely clinical intervention and 
controlling the rise in drug resistant TB (21,22). According to the WHO Global 
Tuberculosis report 2014, only 64% of the estimated nine million people were 
reported for newly diagnosed TB cases and more than three million cases 
went unnoticed by the health authorities either because they were not 
diagnosed or not reported to National TB Programs (NTP) (23). The 
notification rate increased from 2013-2015 according to the recent report by 
WHO due to the increase in notification rate (34%) by India. In 2015, 6.1 
million new TB cases were notified out of 10.4 million incident cases (12). 
Even though TB diagnosis still depends on both the smear microscopy and 
sputum culture for identification in many countries, modern techniques are 
rapidly shifting the diagnostic landscape of tuberculosis.  
The diagnosis of TB disease generally is based on a combination of clinical 
symptoms, chest X-ray examination and laboratory tests. In a TB dedicated 
laboratory clinical setting, diagnosis of active tuberculosis involves sputum 
smear microscopy, identification of the TB bacillus using culture techniques, 
phenotypic drug susceptibility tests and molecular tests. If infection is 
suspected then tuberculin skin test (TST), the interferon gamma release 
assays (IGRA) and acid fast staining of the sputum smear are conducted. 
(21). 
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1.6.1 Chest radiographs 
Chest radiographs are important in the diagnosing of active tuberculosis with 
prominent features including upper lobe consolidation, cavitation and pleural 
effusions. Additional tests like computed tomography (CT) scanning are 
needed along with the other tests for the diagnosis of progressive primary 
tuberculosis or post primary tuberculosis which occurs at the first or second 
year after an initial infection (24,25). 
Following chest radiographs or the initial diagnosis by the clinical symptoms, 
the common tests used as initial screening tests to differentiate the TB 
infection from disease are the tuberculin skin test, interferon-gamma release 
assays (IGRA) and Acid Fast Bacilli (AFB) smear staining (26). 
1.6.2 Tuberculin Skin test (TST) or Mantoux test 
TST is a preliminary test to identify people who are suspected to have TB 
infection. A sterile concoction of antigens from seven strains of M. 
tuberculosis called purified protein derivative (PPD) or tuberculin is injected 
intradermally to test the sensitivity of the skin to the PPD after 48 and 72 
hours and the test is interpreted based on the size of induration. A positive 
reaction should be considered with caution as it does not exclude previous 
BCG vaccination, Mycobacteria other than tuberculosis (MOTT) infection and 
latent TB. Also due to the increased frequency of false negatives, a negative 
reaction does not exclude active or latent TB infection and it warrants extra 
tests. 
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1.6.3 Interferon- Gamma release assay (IGRA) 
The IGRA test is used in diagnosing TB infections and has been reported to 
be more sensitive than TST for both active and latent pulmonary TB 
infections. It quantifies the T-cell response especially the interferon-gamma 
(IFNƔ) by either directly measuring the concentration of IFNƔ in the serum 
(Commercial kit: Quantiferon TB Gold) or by counting the number of T-cells 
that releases IFNƔ (Commercial kit: TSPOT.TB)(26).  
1.6.4 Sputum microscopy 
Sputum smear microscopy is preceded by acid-fast staining (Ziehl-Neelsen 
or Auramine fluorochrome stains are currently used) of clinical material and is 
the most important test for the diagnosis and screening of active tuberculosis 
in poor and low-income countries (27). WHO describes the presence of at 
least one acid fast bacillus (AFB) in at least one sputum sample as a smear 
positive pulmonary TB case. The guidance for interpreting smear results by 
WHO (a similar but slightly different classification is followed by Centers for 
Disease Control and Prevention in the USA) is given in table 1-2. It is widely 
used and effective in countries where TB is endemic and the sensitivity of 
microscopy has been reported to be higher than 80% (28,29) but a recent 
report by WHO states that it is around 20% (30). Sensitivity of the test 
decreases in HIV positive patients than in HIV negative cases and thus been 
associated with poor prognosis including death (31,32). 
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Table 1-2 Acid Fast Bacilli (AFB) Smear classification  
(Adapted from WHO TB microscopy handbook)  
 
Number of AFB seen per stated field 
(100x objective) 
Smear Interpretation (Grade) 
0 AFB in 100 fields Negative 
1-9 AFB in 100 fields Record exact number of bacilli 
10-99 AFB in 100 fields 1+ 
1-10 AFB / field, check 50 fields 2+ 
>10 AFB / field, check 20 fields 3+ 
1.6.5 Sputum culture 
Culturing of mycobacteria follows the staining protocols either in a solid or a 
liquid medium after decontamination of the specimen. The recommended 
solid media by the European Respiratory Society, WHO, the American 
Thoracic Society and the International Union Against Tuberculosis (IUAT) are 
Lowenstein- Jensen (LJ) and Middlebrook 7H10 and 7H11 (MB) media (see 
fig 1-7 and 1-8). WHO has offered guidelines for the use of liquid media like 
Mycobacterium Growth Indicator Tube (MGIT) since they offer a more 
sensitive and quicker turnaround time than solid media (33,34). 
16 
 
 
Figure 1-7 LJ medium showing dry, rough, raised creamy white or yellow colour 
colonies, characteristic of M. tuberculosis 
(Taken from https://microbeonline.com/preparation-uses-lowenstein-jensen-lj-medium/) 
 
 
 
 
 
 
 
Figure 1-8 Bactec MGIT system for detection of M. tuberculosis drug resistance 
(Picture adapted from www.bd.com) 
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1.6.6 Molecular identification test and drug susceptibility tests 
As drug resistance is a major problem in controlling tuberculosis especially 
with the rise in multidrug resistant (MDR) and extensively drug resistant 
(XDR) TB, drug susceptibility tests are carried out before starting treatment 
for tuberculosis. These tests are either phenotypic tests involving culture 
techniques or by adopting molecular tests. Phenotypic methods are based on 
testing sensitivity to first line anti-TB drugs and the most common being 
rifampicin, isoniazid, ethambutol and pyrazinamide. As these tests are time-
consuming and may be ineffective in detecting low-level drug resistance, 
molecular tests are widely used. Commercial kits are available on the market 
based on the PCR amplification of specific genes including drug resistance 
genes and these molecular assays are grouped as either Nucleic Acid 
Amplification Tests (NAATs) or Line Probe Assays (LPA). The GeneXpert 
assay, a fully automated RT-PCR NAAT assay,  is most suitable for patients 
with suspected pulmonary tuberculosis and for specific forms of 
extrapulmonary tuberculosis as in the case of meningitis in people with HIV 
and lymphadenitis, but not pleural, pericardial, or abdominal tuberculosis (34) 
and also determine the resistance to one of the most common TB drugs, 
Rifampicin (34). In countries like Tanzania which is a TB endemic country, 
the GeneXpert assay has been cost effective in determining the rifampicin-
resistant status in the patient population (35). A second generation cartridge, 
the Xpert MTB/RIF Ultra (Ultra) is due to be launched on world TB day in 
2017 by Cepheid and Rutgers and assessed in the TB centres globally using 
the current GeneXpert instruments (12).  
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1.6.6.1 Line Probe assays (LPA) 
Line Probe Assays are based on the PCR amplification of specific fragments 
of the M. tuberculosis genome followed by hybridisation of PCR products to 
the oligonucleotide probes immobilised on membranes. The commercial kits 
that are available in the current market are INNO-LiPa Rif.Tb (Innogenetics, 
Belgium), GenoType MTBDR/ MTBDRplus (Hain Lifescience, Germany) and 
Genotype MTBDRsl (Hain Lifescience, Germany). GenoType MDRTBplus is 
the only kit that could detect isoniazid resistance and GenoType MTBDRsl 
detects resistance to fluoroquinolones and ethambutol , the second-line 
drugs that are used in MDR-TB and XDR-TB cases (36–40). There are 
several next generation technologies including GeneXpert cartridges and 
Hain MTBDRsl assays or rapid next generation whole genome sequencing 
methods, are in the advanced stages of development (41,42). 
1.6.7 Diagnosis of Latent tuberculosis 
Diagnosis of LTBI depends upon two factors: a. Likelihood of infection with 
M. tuberculosis and b. Likelihood of progression to TB disease (43). The 
treatment strategy for LTBI is shown below in table 1.3. 
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Table 1-3 Summary of recommendations for testing for latent tuberculosis infection 
(LTBI)  
(taken from 43). 
 
Though conventional technologies still play a major role in the diagnosis of 
TB, the recent availability of new rapid tests has the potential to improve TB 
care. For example, the introduction of GeneXpert MTB/RIF assay using the 
GeneXpert instruments has enabled the rapid detection of tuberculosis in 
hours, in countries participating in the STOP TB campaign. In addition this 
system, by detecting rifampicin resistance more rapidly,  has helped in the 
treatment of MDR-TB cases much more efficiently and also has been 
recommended for HIV-coinfected cases where smear microscopy tests could 
be less sensitive as described earlier (31,44). In the year 2015 alone, 6.2 
million test cartridges were procured in 122 of the 145 countries eligible to 
purchase them at concessional prices showing a shift in the diagnosis 
landscape of tuberculosis (12). There is still a requirement for newer 
technologies which are much more affordable than the currently available 
strategies (45). 
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The advancement in new diagnostics and drugs that has been progressing 
over the last decade would help in combatting tuberculosis by improving the 
diagnosis of the disease and also early detection of drug resistant 
tuberculosis (37,46). As per the review by Drobniewski et al., it is important to 
identify TB cases including the drug resistant strains, early and accurately 
(37) and to arrest TB transmission by providing appropriate therapy and 
curing patients. 
1.7 TB treatment  
A minimum of six months’ treatment is recommended which is divided into 
two phases, the initial phase and the continuation phase (44). The standard 
treatment regimen according to WHO (47) for both pulmonary TB including 
HIV-coinfected individuals and for extra-pulmonary TB cases is as follows: 
a. Initial phase: Daily medication or therapy five days/week under directly 
observed therapy (DOTS) with isoniazid (INH), rifampicin (RIF), pyrazinamide 
(PZA) and ethambutol (EMB) for 2 months. A sputum smear test is taken and 
the next phase is only started if the test is negative. 
b. Continuation phase: Daily medication or therapy five days/ week under 
DOT with isoniazid and rifampicin for the next four months. 
According to the review by Fonseca et al., (48) multidrug resistant (MDR) and 
extensively drug resistant (XDR) TB strains pose a significant threat to the 
control of tuberculosis as they develop resistance to first line drugs 
mentioned above and work still needs to be done to understand the 
mechanism of resistance. If there is resistance to two of the first line drugs, 
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RIF and INH, then these strains are termed as MDR- TB strains. The 
treatment course for MDR-TB lasts for more than 2 years with second line TB 
drugs like fluoroquinolones and injectable aminoglycosides like streptomycin. 
Anti-TB drug resistance occurs due to the chromosomal mutations at a rate 
of 10-3 to 10-9 in genes encoding drug targets (49,50). If the treatment is not 
completed or if the proper regimen is not followed then it results in the poor 
treatment of MDR-TB patients thus amplifying the resistance of the first line 
drugs and leading to the development of XDR-TB (34). 
1.7.1 Rifampicin (RIF) 
Rifampicin inhibits RNA transcription and thereby protein synthesis by 
binding to the rpoB encoded subunit of RNA polymerase. Mono resistance to 
RIF is a rare occurrence as nearly 85-90% of RIF resistant strains are also 
resistant to INH. RIF resistance therefore acts as a surrogate marker for 
MDR-TB (51–53). A high percentage of mutations (90-95%) occurs in the 
81bp rifampicin resistance-determining region (RRDR) of the rpoB gene 
between codons 507-533 and a lower level of resistance (5-10%) is seen in 
the N-terminal or cluster II region of rpoB / other genes at codon V146 
(51,54). It has been suggested that higher frequency of mutation is seen in 
some strains at certain positions of the RRDR, especially at the codon 531 
where serine is replaced by leucine, due to the higher relative strain fitness 
than other strains (55).  
1.7.2 Isoniazid (INH) 
INH a bactericidal drug which targets the NADH- specific enoyl acyl carrier 
protein (ACP) reductase (inhA) and prevents the production of mycolic acid 
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which leads to the inhibition of dividing mycobacterial cells (51,56). INH 
resistance is commonly noticed due to mutations within the katG gene at 
codon 315 or low level resistance mutations are seen in the inhA regulatory 
region (51,56,57). However, oxidative stress does not seem to impair the 
mutation rates in Isoniazid resistant strains (58). 
1.7.3 Pyrazinamide (PZA) 
PZA, activated by pyrazinamidase (pncA), is effective against M. tuberculosis 
by inactivating the fatty acid synthesis pathway. In addition, it also prevents 
protein translation and the ribosome sparing process of translation by binding 
to ribosomal protein S1 (rpsA) in M. tuberculosis.  PZA resistance is seen in 
strains containing mutations in pncA or rpsA (51,59). 
1.7.4 Ethambutol (EMB) 
EMB prevents the formation of cell wall assembly by inhibiting the synthesis 
and polymerisation of cell wall arabinan leading to the accumulation of free 
mycolic acid. Resistance mutations are commonly seen in three emb genes 
at codons 306, 406 and 497(60). 
1.7.5 Second line drugs 
Some of the second-line drugs used in TB treatment, which include 
Streptomycin (SM), Kanamycin (KAN) and Amikacin (AMI) inhibit protein 
synthesis and are bactericidal drugs. Fluoroquinolones are also widely used 
as anti-TB drugs especially Oflaxacin (OFX), Levofloxacin (LFX) as 
bacteriostatics and Gatifloxacin (GFX) and Moxifloxacin (MFX) as 
bactericidals by inhibiting DNA gyrase leading to cell apoptosis by preventing 
23 
 
DNA replication and repair as shown by the Rapid Evaluation of Moxifloxacin 
in Tuberculosis (REMox TB) phase 3 study trial by Gillespie et al  (61,62). 
1.7.6 Vaccination 
The BCG (Bacillus Calmette-Guerin) vaccine, designed to prevent 
tuberculosis is derived from continuous passaging of an M. bovis strain and 
has been in the public health domain for the last eighty years (63,64) This 
vaccine induces a strong T-cell response by activating the Th1 cells but it 
offers only limited protection in adults against pulmonary tuberculosis as the 
immune response is not prolonged enough to prevent M. tuberculosis 
infection developing in older individuals(65,66).(64), but is effective in infant 
TB meningitis (67). In the last decade there has been continuous research to 
develop an effective vaccine that could either complement the BCG vaccine 
or act independently to prevent TB infection and provide a long- term 
protective immunity. The Modified- Vaccinia – Ankara (MVA) 85A vaccine 
that was trialled in children, was found to be ineffective in children in offering 
protection against TB (68).  
1.8 Molecular markers in TB epidemiology 
Various molecular tools have been employed to study the epidemiology of 
tuberculosis based on the availability of the instruments and the ability to 
genotype clinical isolates. The molecular tools are broadly divided into non-
PCR based tools - Restriction Fragment Length Polymorphism (RFLP) and 
Polymorphic GC-rich Repetitive Sequences RFLP (PGRS-RFLP) and PCR 
based tools (Spoligotyping, Mycobacterial Interspersed Repetitive Unit – 
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Variable Number Tandem Repeat (MIRU-VNTR), Amplified Fragment Length 
Polymorphism (AFLP) and Whole Genome Sequencing (WGS) methods. 
1.8.1 IS6110 and IS6110 RFLP 
Bacterial transposons and Insertion Sequences (IS) are evolutionarily 
informative as they alter the genetic makeup of the host organisms during 
transposition (69). Insertion sequences are mobile genetic elements that 
code for transposases evolved to move the IS around the genome. A study in 
1991 (70) showed that the M. bovis BCG insertion element IS987 is virtually 
identical to the previously described IS elements IS986 (71) and IS6110 from 
M. tuberculosis. The only biologically significant difference is the presence, in 
IS987, of ORFa (Open Reading Frame) in one single ORF, whereas IS986 
and IS6110 contain ORFa, composed of two different ORFs (70,72) (see 
figure 1.9). 
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IS6110 ORFa1/a2: TAPACPETPVLGKDGVMSGGSSRRYPPELRERAVRMVAEIRGQHDSEWAAISEVARLLGVGCAETVRKWVRQAQVDAGARPGTTTEESAELKRLRRDNAELRRANAILKTASAFFAAELDRPAR 
 
IS986 ORFa1/a2 : TAPACPETPVLGKDGVMSGGSSRRYPPELRERAVRMVAEIRGQHDSEWAAISEIARLLGV- CAETVRKWVRQAQVDAGARPGTTTEESAEIKRLRRDNAELRRANAILKTASAFFAAELDRPAR 
IS987 ORFa:   TAPACPETPVLGKDGVMSGGSSRRYPPELRERAVRMVAEIRGQHDSEWAAISEVARLLGVGCAETVRKWVRQAQVDAGARPGTTTEESAELKRLRRDNAE 
     *********************************************************************   ********   ****************************************   ************ 
 
Figure 1-9 Translated sequence alignment of ORFa in IS6110 and IS986 both from M. tuberculosis and IS987 from M. bovis BCG  
(Asterisks denotes the matching amino acid residues in all three sequences) (Adapted from (70)). 
 
  
ORFa ORFa
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Tracing the movement of these elements in the host genomes is productive 
in the identification of different strains of microorganisms. IS can transpose 
within the genomes thereby altering the position and even function of the 
adjacent genes, for example insertion of an insertion element (IE), IS200-like 
element, into the genome of Yersinia pestis inactivates the invasin gene 
which enables the bacteria to invade the host organism (73). IS6110 
insertions have been found in some of the essential genes in drug resistant 
strains (74). These changes contribute to the evolution of microorganisms 
introducing genomic plasticity facilitating survival in different environmental 
conditions (75). 
IS elements have been used as taxonomic markers over the years in certain 
bacteria like Bordetella pertussis, Salmonella typhi etc. (76). An IS-like 
element IS6110, with inverted (28bp with 3 mismatched bases) and direct 
(3bp)repeats at its ends, was identified as a repeated sequence from an M. 
tuberculosis cosmid library constructed in pHC79 (77,78) by screening the 
library with labelled M. tuberculosis total DNA. This element is a 1.36kb 
insertion sequence found only in MTBC members and belongs to the 
enterobacterial Insertion Sequence 3 (IS3) family of insertion sequences. It 
contains an ORF encoding transposase of 1037bp length and has 28bp 
imperfect inverted repeats at both the ends of the sequence (78) (fig 1-10). 
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Figure 1-10 Pictorial representation of IS6110 sequence of M. tuberculosis genome showing Direct (DR in red colour) and inverted repeat (IR in 
green colour) sequences 
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The first instance of the use of IS6110 as a probe for the identification of 
MTBC was reported in 1990 (78). MTBC from uncultured specimens, were 
identified using primers designed from the IS6110 sequence in a PCR 
reaction and results were successfully correlated with other identification 
procedures (78). This element is still being used as a tool for DNA 
fingerprinting to the present day as it is conserved in the MTBC (79,80). 
IS6110 copy numbers vary from strain to strain; one in M. bovis and >25 in 
M. tuberculosis (81). Also, three to four nucleotides of the genomic sequence 
are repeated at the extremities of some IS6110 copies or the site of insertion 
suggesting a role of transposition of these elements in MTBC genomes (82). 
An oligonucleotide ligation assay (OLA) using fluorescently labelled IS6110 
oligonucleotides was employed to detect MTBC (83) Since then the location 
of the IS6110 element has been used a powerful tool for the rapid 
fingerprinting of isolates of MTBC (84–86),  including isolates of M. bovis 
(87,88). As there is variation in the copy numbers of IS6110 in different 
strains and because IS6110 does not induce in vivo any major genomic 
rearrangements for approximately five to eight years (90,91). IS6110 
Restriction Fragment Length Polymorphism (RFLP) was the ‘gold standard’ 
typing method in strains with more than five copies  before being replaced by 
the MIRU-VNTR technique (92–94) (see section 1.8.4). In a study reported 
by Warren et al in 2002, it was found that the rate of transposition occurs at a 
rate of 18.6% for every 6.5 years i.e. 2.9% per year, thereby altering the 
genotype of the organism (91) It has been suggested that there might be 
differences between different lineages, one change every 3 years in Euro-
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American lineage and it might take ten times longer to observe one change in 
East Asian lineage (95). 
Also, comparison of the number and length of fragments generated due to 
IS6110 insertion in isolates proved to be discriminatory (96). Sun et al., in 
2004 showed that spoligotyping and Variable Number Tandem Repeats 
(VNTR) (see section 1.8.4) analysis can further support the resolution of 
IS6110-defined low copy number isolates. With these advantages put aside, 
IS6110 RFLP is however considered a laborious procedure involving steps 
from culturing the mycobacteria, extraction of DNA, restriction enzyme 
digestion, Southern Blotting and IS6110 probing.  
1.8.1.1 Role of IS6110 in the biology of M. tuberculosis 
The advantages that transposition of this element brings to the host either via 
gene disruption, gene excision or by enhanced gene expression suggests 
that they offer the selective advantage to strain fitness and may influence the 
genomic plasticity of these organisms. It can up-regulate downstream genes 
through an outward-directed promoter in its 3' end, thus adding to the 
significance of this element. The ability to activate genes during infection 
suggests that IS6110 might have the potential to influence growth 
characteristics of different strains, and indicate another mechanism by which 
IS6110 can impact M. tuberculosis evolution (97). Gene disruption or 
excision leads to loss of gene expression and enhanced gene expression 
leads to over - expression of genes as seen in the Proline Glutamate- 
polymorphic GC rich Sequences (PE-PGRS gene -Rv1468c). This effect of 
supplying an outward-directed promoter-like sequence is also seen in ctpD 
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gene (a cation transporting ATPase) of a Beijing genotype useful for ctpD 
transcription (97,98). It is reported that the M. tuberculosis ctpD orthologue 
resists cellular redox stress by controlling the effects of cobalt and nickel ions 
on the bacterial cell (99). Several studies have shown that IS6110 insertion 
does not affect the replication machinery or the growth patterns but suggest 
that it definitely helps the organisms to adapt to the host and the 
environment. Transposition of IS elements varies from element to element 
within the genome (100) as an element situated within a transcriptionally 
active site or downstream from an external promoter will be more mobile than 
the ones located in the non–coding regions. 
Transposition of IS6110 occurs at random, independent of IS preferential loci 
or hot-spots. However, sites of integration were not thought to be entirely 
random as different ‘hot-spot’ insertion sites have been identified previously 
that include  the DR locus (70), the ipl locus (Fang and Forbes, 1997; Fang et 
al., 1999), dnaA- dnaN intergenic region (103), the phospholipase region 
(104) and the region between Rv1754c and Rv1762c (105). The property of 
transposition rendering a distinct signature to the genomes acts as a suitable 
genetic marker for studying the divergence of MTBC from its common 
ancestor. Mapping this element in the genomes of MTBC found that it does 
not favour particular nucleotide sequences (82,106) for its insertion. Insertion 
at the DR locus is unique as it is found in a majority of the M. tuberculosis 
complex strains especially in M. bovis in that it is its only site of insertion. It is 
also considered to be the primordial insertion site in the common ancestor 
before the two species diverged with further copies appearing due to the 
transposition of the element outside the DR region (70). In low copy strains, 
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lack of mobility of the IS element due to a low transcriptional activity at the 
site of insertion could play a role in the lack of IS6110 RFLP pattern diversity 
(107). It has been shown that insertion favours regions with low GC content 
as observed in the case of insertion into the PE/PPE gene family where PE 
(75% GC) is less favoured than PPE (64%) which was also complimented by 
another study showing a mini-transposon Tn5370  favouring lower GC 
content genomic regions in M. tuberculosis (98,106,108). When there are five 
or less copies of IS6110, this DNA fingerprinting technique is however not 
very reliable. So the use of polymorphic GC rich repetitive sequences 
(PGRSs) were highlighted along with DR spoligotyping and 16S rRNA 
sequences in tandem to identify strains containing few copies of IS6110, as 
in M. bovis or strains with no copy of IS6110 in their genomes (107,109) Dale 
et al. (107) suggests that there could be a low mobility rate of transposition in 
strains with low copy numbers. 
1.8.2 PGRS- RFLP 
A specific 3.4kb fragment of the PGRS cloned in plasmid pTBN12 was used 
as a probe for differentiation of unrelated strains of TB and identification of 
related strains using identical banding patterns (110). Interpretation of the 
banding patterns is more difficult as it does not contain as many variations as 
other markers like IS6110 and also requires a large amount of DNA as well 
as being laborious and time consuming and so this technique is no longer 
used (111).  
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1.8.3 Spoligotyping 
All the members of the MTBC have the Direct Repeat (DR) locus in their 
genomes. The DR locus is a member of the CRISPR family (Clustered 
regularly interspaced short palindromic repeats) and is susceptible to 
polymorphic changes. This property was exploited for a genetic strain typing 
technique called spacer-oligo typing or spoligotyping (112,113). There are 43 
unique non-repetitive spacer sequences (35-45bp in length) interspersed with 
direct repeat sequences (36bp in length) known as direct variable repeat 
(DVR) sequences. Due to the loss of single or consecutive DVR sequences 
caused either by homologous recombination between neighbouring or distant 
direct repeat sequences or by the loss of sequences caused by the excision 
of the IS6110 element, this method is useful for discriminating between 
strains. As the DVR sequences are numbered 1-43 and are well conserved 
between strains, spoligotyping is quite a quick and useful method (see figure 
1-11 below) to interpret into either octal or hexadecimal codes (102,114). 
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Figure 1-11. Principle of spoligotyping and the processing of signals  
 (A) M. tuberculosis genome with well-conserved 36-bp direct repeats (DRs) which are interspersed by 35-43 bp of unique spacer sequences. Genetic diversity depends on the 
deletion of these spacer regions. The spacer regions are amplified by primers, and the presence of at least one spacer fragment shows a PCR positive reaction. On the 
membrane, 43 probes targeting each spacer are spotted, and a unique pattern of spoligotyping is visualized after hybridization with PCR product. (B) Signals of reference strain 
H37Rv. (C) A typical signal pattern of Beijing family M. tuberculosis strain. (D) To analyze signal patterns, the signals are converted to binary code of ‘on (1) and off (0)’. (E) The 
43-digit binary code is converted to a 15-digit octal (i.e., base 8, having the digits 0-7) designation by a two-step process. First, the 43-digit binary code is divided into 14 sets of 
three digits (spacers 1 through 42) plus one additional digit (spacer 43). (F) Each 3-digit binary set is converted to its octal equivalent, with the final additional digit remaining as 
1 or 0. The translation of binary numbers to octal numbers is done as follows: 000 = 0; 001 = 1; 010 = 2; 011 = 3; 100 = 4; 101 = 5; 110 = 6; and 111 = 7 (Taken from (115)).. 
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Spoligotyping is a simple PCR based reverse hybridisation blotting technique 
where the DR locus is first amplified  followed by the hybridisation with 43 
synthetic spacer oligonucleotide probes covalently bound to the nylon 
membranes is visualised using a chemiluminescence system (112,115) for 
the presence of a ‘dark’ band (presence of a spacer) or ‘no’ band (absence of 
a spacer). There are at least nine spoligotype-defined families with specific 
hybridisation signatures (Haarlem, Beijing, LAM, CAS, EAI, S,T, X and AFRI 
families as seen in figure 1.12 which can be further divided into 36 
subfamilies of the MTBC (113,116). This technique has a lower sensitivity 
than IS6110 RFLP but is useful in delineating strains with fewer than five 
IS6110 copies (117,118) and is the gold standard typing method for M. bovis 
strains lacking spacers 39-43. 
Currently there is a database which can be accessed online 
(http://www.pasteur-guadeloupe.fr.8081) containing both octal and binary (as 
seen above in figure 1.12) spoligotype descriptions for strains of the MTBC 
species isolated globally known as SpolDB4 (113) (see figure 1-12). It 
contains 1939 shared-types (STs) representing a total of 39,295 clinical 
isolates originating from 122 countries. Due to the low resolution of the 
marker when used alone, a publicly available database known as 
SITVITWEB that utilises SpolDB4 data along with MIRU-VNTRs (see section 
1.8.4 below) is in place for high-resolution epidemiological studies (119). 
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Figure 1-12 Pictorial representation of SpolDB4 classification analysis of different TB 
lineages  
First column ST n°: Shared-type (ST) number of prototype pattern for the linage/sub lineage. Second 
column: lineage/sub lineage name. Third column: Binary spoligo display with black-white squares for 
respectively hybridizing-non-hybridizing spacers. Fourth column: Octal code (in red: defining octal rule). 
Fifth column: total absolute number of isolates of the subclass when variant ST spoligos are included 
(using SpolNet). Sixth column: same but expressed as percentage of total clustered isolates. * Total 
number and Frequency for these types are already included in their mother clade if known. 
Undesignated types are counted within the T1-ill-defined lineage. ** in red: octal rule defining the 
genotype (Taken from (113)). 
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1.8.4 MIRU-VNTR 
Mycobacterial interspersed repetitive units (MIRUs) in M. tuberculosis are 
grouped under minisatellites which are short highly repetitive DNA 
sequences and are 40-100 bp long. They are suggested to have a role in 
chromosome structure and rearrangement, tandem duplications, differential 
translation, transcriptional termination and antigenic variation (120). MIRUs 
are highly polymorphic at tandem repeat loci, and are useful in DNA typing 
studies in both prokaryotes and eukaryotes. They can also be referred to as 
variable number tandem repeats (VNTRs) and exact tandem repeats (ETRs). 
ETRs are 53-79bp long tandem repeats and another repeated region called 
Major Polymorphic Tandem Repeats (MPTRs) were first described in 1998. 
Some MIRU loci are positioned in the polycistronic operons and variability in 
copy number can affect the expression of the flanking genes (121). 
Mycobacterial Interspersed Repetitive Units (MIRU) first described by Supply 
et al., in 2000 and the Exact Tandem Repeats (ETR) both comprise MIRU-
VNTR, a typing technique useful in epidemiology, population genetics and 
phylogenetic studies (122). The technique involves the PCR amplification of 
the entire tandem repeat loci using primers in the DNA sequences flanking 
the repeats. The number of repeats or alleles is calculated from the amplicon 
sized by electrophoresis as the length of the repeats and the position of the 
primers are known.  Twelve MIRU loci (2, 4, 10, 16, 20, 23, 24, 26, 27, 31, 
39, 40) and five ETR loci have been used previously for this genetic 
fingerprinting technique. This method was widely adopted in the UK. There is 
some overlap of the nomenclature of these repeat schemes, for example 
MIRU 4 and MIRU 31 are the same loci as ETR-D and ETR-E respectively. 
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 Supply et al., Ii 2006 proposed a 24 loci typing technique comprising of 12 
MIRU loci, 3 ETR loci, six ‘Mtubs’ and three ‘QUB’loci. This was the gold 
standard typing method used in the UK until recently but now WGS has 
become the method of choice in the UK. A fifteen loci subset system with the 
highest evolutionary rates was proposed as the best system for first-line 
analysis of outbreak samples and the 24 loci subset for the phylogenetic 
studies which need higher resolution. The twelve loci subset, analysing the 
most variable regions, are also used for initial investigations along with data 
from other techniques like spoligotyping and IS6110 fingerprinting (123).The 
following table 1-4 shows the widely used MIRU-VNTR schemes worldwide. 
Table 1-4 Composition of the different MIRU-VNTR sets widely used  
(Taken from http://www.miru-vntrplus.org/MIRU/miruinfo.faces) 
Loci Alias 1 Alias 2 24 15 12 
154 MIRU02  X  X 
424 Mtub04  X X  
577 ETR-C  X X  
580 MIRU04 ETR-D X X X 
802 MIRU40  X X X 
960 MIRU10  X X X 
1644 MIRU16  X X X 
1955 Mtub21  X X  
2059 MIRU20  X  X 
2163b QUB11b  X X  
2165 ETR-A  X X  
2347 Mtub29  X   
2401 Mtub30  X X  
2461 ETR-B  X   
2531 MIRU23  X  X 
2687 MIRU24  X  X 
2996 MIRU26  X X X 
3007 MIRU27 QUB5 X  X 
3171 Mtub34  X   
3192 MIRU31 ETR-E X X X 
3690 Mtub39  X X  
4052 QUB26  X X  
4156 QUB4156  X X  
4348 MIRU39  X  X 
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1.8.5 AFLP and FAFLP 
1.8.5.1 AFLP 
Amplified Fragment Length Polymorphism (AFLP) was designed as an 
identification and typing method developed in the nineties by the 
biotechnology company called Keygene (124,125). It is a selective restriction 
fragment amplification technique based on the ligation of adapters to 
genomic restriction fragments and PCR amplification with adapter specific 
primers. A small amount of genomic DNA is digested with two restriction 
enzymes and then ligated with double-stranded oligonucleotide adapters 
designed specifically with a point mutation so that the initial restriction is not 
restored after ligation. With the aid of stringent PCR conditions and adapter-
specific primers at the 3’ ends, one of the three nucleotides is extended from 
the unknown restricted genome fragment. The primers initially were 
radioactive labelled for easy identification of the fragments in polyacrylamide 
gels which were later replaced by fluorescently labelled primers for 
visualisation in automated platforms (125–127). 
Since then, AFLP has been used as a diagnostic tool in plants and  animals 
in the field of genetic mapping, phylogenetic studies, microbial typing and for 
diagnostic purposes (124,128,129). 
1.8.5.2 FAFLP 
Fluorescent Amplified Fragment Length Polymorphism (FAFLP) exploits the 
use of fluorescently labelled primers and the resulting genomic restriction 
fragments are visualised using an automated platform. Since the restricted 
fragments with base substitutions are visualised using a platform such as the 
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ABI Genetic Analyser (Life Technologies, UK), this technique can give a snap 
shot of the insertion variation on a genomic level. It has been shown that a 
single fragment difference (± 1 bp) in the FAFLP profile signifies a new strain 
(130). FAFLP should, like all other techniques, be considered in tandem with 
epidemiological data if available. FAFLP has been successfully applied to 
several organisms and some of them have been shown below in the form of 
a table (see table 1-5). It has also been used in the identification of plant 
species with 98% accuracy (131). 
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 Table 1-5 List of some common microorganisms studied using FAFLP analysis 
Microorganism References 
Campylobacter jejuni (132) 
Escherichia coli K12 MG1655 (127) 
Escherichia coli O157  (127,133) 
Listeria monocytogenes (134) 
Mycobacterium tuberculosis (130,135) 
Neisseria gonorrhoeae (136) 
Neisseria meningitides (137) 
Streptococcus pyogenes serotype M1 (126) 
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Staphylococcus aureus (138) 
Bacillus thuringiensis (139) 
Candida tropicalis  (140) 
Acanthamoeba Sp. (141) 
Salmonella enteritidis (142) 
Leptospira borgpetersenii serovar Arborea (143) 
Pseudomonas aeruginosa (144) 
Legionella pneumophila serogroup 1 (145) 
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1.8.5.3 FAFLP for TB 
1.8.5.3.1 IS6110 FAFLP 
IS6110 RFLP is a time consuming and low-throughput technique. To 
overcome these drawbacks and utilise the superior resolution property of 
IS6110, IS6110 FAFLP was developed. FAFLP derived sequence data is 
congruent with the IS6110 typing of Mycobacterium tuberculosis but it should 
be used along with other techniques like spoligotyping and MIRU-VNTR to 
supplement epidemiological data (Goulding, Stanley, et al. 2000; Thorne et 
al. 2007). In a study by Thorne et al, in 2007, it was noticed that the FAFLP 
results of 57 (97%) of the 59 clustered isolates were congruent with the 
RFLP results. Use of coloured fluorescent primers can differentiate between 
recent transmission of strains and epidemiologically unrelated but genetically 
related strains (147). IS6110 FAFLP has been used recently to identify 
common fragments in MTBC that likely evolved from common ancestors and 
were thereby able to differentiate the strains phylogenetically into different TB 
lineages (135). This study also indicated that IS6110 FAFLP contains a 
strong phylogenetic signal in modern TB lineages by assigning common 
fragments to their respective spoligotypes/Principal Genetic Groups (PGGs).  
1.8.5.4 DNA Sequencing 
From Sanger sequencing to Next generation sequencing technologies, there 
are different sequencing methodologies that can be used to generate data for 
molecular epidemiological studies of tuberculosis (148). Due to the high cost 
and low quality of the sequences both in the first 15-40bp and after 700bp of 
sequenced product, Sanger sequencing is being replaced by Next 
Generation Sequencing (NGS), also known as Whole Genome Sequencing 
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(WGS). Over the last ten years, platforms including, Illumina, Roche, ABI 
SOLID, ION PGM, Heliscope, Pacific Biosciences Single Molecule Real Time 
(SMRT) and the Nanopore MinION (149) have been used. WGS is likely to 
become the gold standard approach in the future but specialist software to 
analyse the data and a skilled workforce are still required to interpret the 
results. 
1.9 Global TB lineages 
New species of mycobacteria have evolved over the years by many adaptive 
changes to different niches (6). This has led to the reduced function or 
inactivation of certain genes. A classic example is M. leprae which has 
transformed to become an obligate intracellular pathogen by losing many 
genes involved in metabolic and respiratory pathways (150). Genes can also 
be acquired by some species like M. abscessus which is one of the 
organisms responsible for causing infection in those suffering from cystic 
fibrosis. This organism was thought to originally be a soil saprophyte, and 
has acquired essential genes to survive phagocytosis enabling intra-
cellularisation in host organisms. Recently it has been shown that M. 
abscessus has acquired resistance to arsenic and mercury which are 
typically found in resistance plasmids of environmental organisms like M. 
marinum through horizontal gene flux (151). 
All the members of the MTBC share identical 16S rRNA sequences and more 
than 99% similarity at the genomic level and yet are phenotypically different 
causing different pathologies in different host species. M. canetti is unique in 
this group in that it does not share homogeneity with the MTBC in some 
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house-keeping genes, Insertion Sequence 1081 copy number, colony 
morphology and lipid content of the cell. Brosch et al., in 2002 showed that 
M. canetti might have diverged directly from the common ancestor of MTBC 
some 30,000 to 40,000 years ago as it has Regions of Difference (RD), 
H37Rv related deletions- RvD and TB specific deletions-TbD1 that are 
absent in the other six members (114) (fig1-6). Thus genetic polymorphism 
can occur in MTBC either due to a single nucleotide mutation in specific gene 
coding regions, or by the presence or absence of a gene or region, thereby 
altering the gene content of the microorganisms (fig. 1.13). Linkage 
Disequilibrium (LD) studies now support the theory that M. tuberculosis has 
evolved clonally (152,153). LD refers to the non-random association of alleles 
at two different loci, which are not independent of one another (154).
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Figure 1-13 Novel evolutionary scenario of MTBC proposed by Brosch et al in 2002 based on the regions of difference (RD) and sequence 
polymorphisms within five genes.  
Blue arrows indicate strains that are characterised as group one organisms, the green arrow is group two and the red arrow group three, as defined by katG463 
and gyrA95 codon sequence polymorphisms as described by Sreevatsan et al., in 1997 (153) as shown in figure 1.4 (Taken from .(114)) 
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Several clonal species of mycobacteria are not identifiable when they are 
isolated on solid media as they are thought to have descended from a 
common ancestor and MTBC fall under this category as previously 
discussed. 
1.9.1 Major Genetic Groups of MTBC and its global distribution 
Major Genetic Groups (MGG) classification is based on single nucleotide 
mutations or polymorphism (SNP). Generally, there are two types of SNPs 
synonymous and non-synonymous. The former are important to study 
evolution as they are not prone to divergence whereas the latter refers to 
translational changes that are not evolutionarily informative (155). 
Sreevatsan et al., in 1997 identified two SNPs; one in the catalase 
peroxidase (katG codon 463) and one gyrase A (gyrA codon 95) encoding 
genes and classified MTBC into three Major Genetic Groups (MGGs) or 
Principal Genetic Groups (PGGs). Here they showed that there are three 
MGGs- MGG1, MGG2 and MGG3 where MGG3 is derived from MGG2 and 
MGG2 from MGG1. An M. tuberculosis precursor or common ancestor would 
have given rise to MGG1 (153) (fig 1-14). 
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Figure 1-14 Evolutionary scenario proposed by Sreevatsan et al, in 1997 based on 
SNP polymorphism  
(Taken from.(153)) 
 
Several other studies by Gutacker et al., 2006, Baker et al., 2004, Rad et al., 
2003 have all classified the MTBC into different lineages either based on 
SNPs or the presence or absence of TB specific deletion regions (TbD1) 
(155–157). Brosch et al. in 2002 showed that the MTBC diverged from the 
most recent common ancestor over thousands of years by losing regions of 
deletion (RD) or due to large sequence polymorphisms (LSPs) in house-
keeping genes. It is important to note that the TbD1 deletion is common to all 
‘modern’ TB strains which include the Haarlem, Beijing and CAS spoligotype 
strains and that this deletion is irreversible because of the lack of DNA 
recombination between strains of the MTBC. The TbD1 deletion is therefore 
absent from ancient strains such as the East African-Indian (EAI) strains. The 
division of modern and ancient families (where DNA markers characterised, 
not the genomes themselves, are thought to be similar to those found in 
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modern or ancient strains) is based on spoligotyping, identifying the deletions 
or polymorphism in the DR locus (DVR24) in M.tuberculosis genomes (112). 
Different spoligotypes or families derived by adopting this technique, based 
on detection of the presence or absence of 43 unique sequences in the 
Direct Repeat region, are given below in the table 1-6.  
Table 1-6 Table showing the distribution of M. tuberculosis complex (MTBC) strains 
with respect to the Principal Genetic Groups (PGGs) and the TB spoligotypes families 
/ lineages 
Principal 
Genetic Groups 
Mycobacteria TB Spoligotype family / 
lineage 
PGG1 M. microti, M. africanum, M. 
tuberculosis and M. bovis 
Central Asian Strain 
(CAS) 
Beijing 
PGG2 M. tuberculosis S  
X 
T-Uganda 
Haarlem 
Latin American 
Mediterranean (LAM) 
PGG3 M. tuberculosis T 
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Due to the inclusion of various sub-species of MTBC (4) including the 
classification of TB genetic lineages according to the geographical migration 
(158), the evolutionary scenario originally proposed by Sreevatsan et al. in 
1997 and Brosch et al. in 2002 has been combined as shown in fig 1.15 
below. 
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Figure 1-15 Schematic representation of the proposed phylogenetic relationships between members of MTBC.  
The phylogeny is based on presence or absence of Region of Difference (RD) (114), SNPs (153) and Large Sequence Polymorphism (LSP) (159). (Taken 
from (4)). 
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1.9.2 Global distribution of TB genetic lineages including Co-Evolution 
of TB and Humans 
It has been suggested that M.tuberculosis might have co-evolved with the 
human host  and have followed the ‘out-of-and-back-to-Africa’ evolutionary 
scenario (159–161). In 2006, Gagneux and his colleagues addressed the co-
evolutionary scenario of both human and TB populations for the first time and 
also proposed six phylogeographical lineages (fig 1-16) (158). 
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Figure 1-16 The phylogeographical distribution of M. tuberculosis and its lineages  
(a) LSPs define a global phylogeny for M. tuberculosis. The names of the lineage-defining LSPs or regions of difference are shown in rectangles. The 
geographic regions associated with specific lineages are indicated. (b) The six main lineages of M. tuberculosis are geographically structured. Each dot 
corresponds to 1 of 80 countries represented in the global strain collection. The colours of the dots relate to the six main lineages defined in (a) and indicate 
the dominant lineage(s) in the respective countries (Taken from (158)) 
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1.9.3 Molecular Clocks in the evolution of M.tuberculosis 
Using different molecular markers (SNPs, RDs, TbD1 and spoligotypes), a 
time line of evolutionary events can be generated that strongly suggests that 
the currently circulating MTBC isolates might have originated from a common 
ancestor as shown in figure 1-17 below (162) as discussed in section 1.11 
and shown in fig 1-13 by Brosch et al (114).  
 
 Figure 1-17 Timeline of evolutionary events in Mycobacterium tuberculosis  
(Taken from (162)) 
 
Over recent years, data have accumulated suggesting that the different 
MTBC lineages might have adapted to different human populations and thus 
showing predominance in certain regions like CAS in Northern India (163) 
and Beijing in Tibet and China (164). Not only does MTBC exhibit a global 
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biogeographic population structure, but the associations between the 
particular MTBC lineages and human populations are maintained in 
cosmopolitan settings where human populations and their associated MTBC 
strains experience at least some degree of intermingling (161,165,166). 
Sequencing six housekeeping genes (katG, gyrB, gyrA, rpoB, hsp65 and 
sodA) and the complete 16SrRNA gene in smooth tubercle bacilli suggests 
that M. tuberculosis might have descended 3 million years ago (167). Also, 
ancient DNA studies (160) suggest that MTBC predates the arrival of the 
human population (fig 1-18), thus showing the adaptability of this ancient 
microorganism. 
 
Figure 1-18 Evolution of Mycobacterium tuberculosis complex along with human 
population  
(Taken from(160)). 
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1.9.4 Importance of genetic polymorphism 
Different markers have been used to study the phylogenetic relationships 
between the common ancestor and the currently circulating TB genetic 
lineages. As IS6110 is one of the earliest seen polymorphic changes in terms 
of evolution of TB, they could theoretically play an important role in the 
evolution of different TB genetic lineages. IS6110 insertions occur mainly in 
multi-gene families such as the PPE gene family and they could be beneficial 
for the organism to evade immunity (74) and cause disease  (168). In 
addition, several studies have suggested that drug resistance, formation of 
LSPs and high frequency of SNPs were noticed in regions flanked by IS6110 
(169). Thus, IS6110 transposition could be essential in the evolution of the 
M.tuberculosis genome.  
1.10 Molecular Epidemiology of TB in resource poor settings 
Among the estimated 9.4 million new TB cases reported in 2008, 55% and 
30% of the cases were reported in resource poor countries in Asia and Africa 
respectively (170). Depending on the availability of instruments and reagents, 
the techniques used to study the molecular epidemiology of TB are different 
in different countries. Epidemiological studies are however limited when 
compared to developed countries due to financial constraints in these areas 
despite the fact that tuberculosis is endemic. 
1.11 Currently used epidemiological tools, its suitability and 
constraints 
The tools used in a resource-limited country mainly depend on the country’s 
ability to afford equipment required for different technologies, their 
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maintenance and the availability of the skilled force to perform the 
techniques. Resource poor countries may need improved access to 
diagnosis and care (171). Without an effective surveillance strategy, TB 
control measures could be difficult to be monitored. So, routine surveillance 
methods will contribute in assessing drug resistance strains and monitoring. 
Within their limits these settings continue to contribute to the understanding 
of the molecular epidemiology of TB using the tools available to them 
including the most commonly used techniques IS6110 RFLP, MIRU-VNTR 
and spoligotyping. 
1.12 Nepal TB epidemiology 
Though the global TB burden has been falling globally in the last few years 
due to the introduction of the STOP TB programme by the WHO (1), the 
incidence of HIV-associated TB is high in Myanmar, Thailand, India and 
Indonesia. Nepal used to be one of the five countries listed in SE Asia region 
with a high burden of TB But the new global TB report from WHO (172) has 
excluded Nepal from the list of 30 high burden countries due to the effective 
STOP TB policy since 2006. But tuberculosis still remains a public health 
problem and ranked as the sixth leading cause of death among the top 20 
causes of death in Nepal according to the National Tuberculosis programme 
survey carried out in 2014 (173). 
1.12.1 TB in Nepal 
Nepal has 147,181 square kilometres of land mass area with a population of 
29 million people and is interlocked between the Indian subcontinent on three 
sides and China’s Tibet to the North. Nepal lies on the major trade route 
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between India and China (see figure.1-19) and has an 1200-km long 
controlled border with China in the north and an 1700-km long open border 
with India in the east, west and the south (174). It has been noted that 
migration across these international borders take place for reasons like  
work, study, tourism, religious purposes like pilgrimages and cultural 
exchanges like marriages. Kathmandu, the capital city of Nepal is highly 
populated with a high number of TB cases according to the Nepal’s National 
Tuberculosis programme.  
 
Figure 1-19 A map of Nepal showing the topography of Nepal interlocked between 
India (in the south, east and west of Nepal) and China (in the north)  
(Taken from http://www.echoway.org/graphic/oupartir/cartespays/nepal.gif) 
 
In 2014, the WHO estimated that 4600 (2100-7500) people died from TB in 
Nepal. Even though MDR-TB levels are low (2.2%) in new cases (high in 
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retreatment cases-15.4%), Drug-resistant TB (DR-TB) is still a major public 
health concern. The epidemiological indicators of the TB burden in Nepal 
according to the report published in 2014 by National Tuberculosis 
Programme is summarised below in the table 1-7. 
 
Table 1-7 Estimated TB burden in Nepal in 2014  
(Adapted from NTP, Nepal 2014 report) 
Epidemiology Indicators Estimated patient cases (Range) 
Prevalence 59 (27-100) x 1000 
Prevalence rate 211 (99-365) 
Incidence 43 (39-49) x 1000 
Incidence rate 156 (139-178) 
Cases notified to NTP 37025 
Annual case notification rate 136 / 100,000 
HIV negative / TB positive cases 4.6 (2.1-7.5) x1000 
HIV positive / TB positive cases 0.32 (0.17- 0.51) x1000 
 
1.12.2 Current diagnostic procedures in Nepal 
Sputum smear microscopy is used as the main method to detect TB and 
monitor treatment responses in patients. Culturing the bacteria and 
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phenotypic Drug Susceptibility Tests (DSTs) are the two principal procedures 
carried out to monitor new and relapsed cases within the 581 microscopy 
centres, two solid culture laboratory including capacity for first line drug (FLD) 
susceptibility testing (DST), first line probe assay (LPA), one liquid culture 
and one second line drug (SLD) DST facility and 26 GeneXpert centres 
spread all over this mountainous country. This is in addition to two other 
culture and DST facilities (NTC and GENETUP) functioning in Kathmandu 
valley.  
1.12.3 Constraints in diagnosis of TB in Nepal 
According to the NTCP’s annual report, the challenges faced by the 
authorities to control TB in Nepal are mainly due to the increase in MDR and 
XDR cases, low case notification by different districts, insufficient 
supervision, monitoring and evaluation of TB cases and lack of skilled labour 
(173). In a recent survey in 2014, it has been found that nearly 9.3% of new 
patients are resistant to at least one drug. Also, resistance to 
fluoroquinolones (26.4%) has led to a heavy burden of pre-XDR and XDR-TB 
among MDR-TB cases (8% of the cases were found to be XDR among MDR 
pateints). It has been speculated that it might be due to the fact that 
fluroquinolones could be purchased by the patients over the counter easily 
and also its unregulated use. Case Notification Rate (CNR) in 2015 was 123/ 
100,000 a drop of 11% compared to the previous survey in 2010 (173). 
Among different regions, there has been a drop in the CNR in the Eastern 
and the central regions of Nepal. So, an efficient, cost-effective and rapid 
epidemiological tool that can be useful in these settings was needed and thus 
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this research project aimed to develop a genomic tool box that can be easily 
used in these settings along with other techniques. 
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1.13 Aims and Objectives 
The aim of my PhD thesis is to develop a genomic tool box to aid 
epidemiological investigations using a novel IS6110 FAFLP sampling method 
for application in resource poor settings.  
1.14 Hypothesis 
Characterisation of IS6110 insertion sites in TB genomes of strains from 
poorly studied regions will give insight into the geographical distribution of 
disease and their relationships with different lineages thereby showing that 
IS6110 is not only a typing tool but also an effective evolutionary marker. 
The objectives of this thesis are as follows: 
 Chapter 1: To review the TB literature in detail focusing on the 
suitability of the technique and the sample population. 
 Chapter 2: To describe IS6110 FAFLP methodology in addition to the 
reagents needed for the technique. 
 Chapter 3: To optimise and develop the IS6110 FAFLP methodology 
using H37Rv and Nepal strains. 
 Chapter 4: To map the IS6110 insertion sites in the M. tuberculosis 
H37Rv genome and to rapidly detect TB genetic lineages using 
IS6110 FAFLP derived PCR. 
 Chapter 5: To classify the TB samples from Nepal into their different 
TB genetic lineages. 
 Chapter 6: To understand the Rifampicin resistance status in the TB 
samples from Nepal. 
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 Chapter 7: To contextualise that IS6110 FAFLP as a genomic 
mapping tool and discuss its suitability as a method to understand the 
phylogenetic relationships between TB genetic lineages and further 
indicate that IS6110 is a valuable tool to study the epidemiology and 
evolution of TB. 
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Chapter 2 General Materials and Methods 
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2.1 Bacterial samples 
2.1.1 Sample collection centres 
Sputum samples from consecutive new TB patients were collected over one 
year between 2007 and 2008 and cultured alongside routine diagnostic 
testing from two Nepalese tuberculosis reference centres located in the 
Kathmandu valley: the National Tuberculosis Centre (NTC) and the German 
Nepal Tuberculosis Project (GENETUP) (fig 2.1).  
 
 
 
 
 
 
 
 
 
 
 
Figure 2-1 Geographical location of the two Nepal TB treatment centres, GENETUP 
and NTC, where samples were collected  
(Adapted from http://www.nepalntp.gov.np/index.php?view=location) 
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Bacterial genomic DNA from the strains isolated from the above samples 
were extracted at the National Mycobacterial Research Laboratory (NMRL) in 
Nepal using Cetyltrimethyl Ammonium Bromide (CTAB)(175). 
2.1.2 Ethics 
Nepal Health Research Council (NHRC), the Ethics Approval Committee 
approved the research projects ongoing at MRL in general between 2006 
and 2008 when these samples were collected. During this time, the specific 
procedures including consent were approved by the Head of MRL, MRL Lab 
Manager, the Anandaban Medical Director, faculty of Tribhuvan University 
and Directors of both Tuberculosis centres where samples were collected.  
As sputum samples were classified as non-invasive samples during 
collection, written consents were not emphasised and only verbal consents 
were taken but not documented from the patients who attended the hospitals 
primarily for TB treatment. The anonymized DNA samples were then 
transported to Public Health England (PHE), Colindale in 2008 and this 
particular study started in 2011 and was solely conducted in Public Health 
England, Colindale.  
2.1.3 IS6110 Fluorescent Amplified Fragment Length Polymorphism 
(FAFLP)  
This method published by Thorne et al. (146) was optimised and developed 
as discussed in chapter 3. The method comprised of four major steps: 
Digestion of genomic DNA, Ligation of adapters, PCR and Capillary 
Electrophoresis (Figure 2-2). All reagents used in this study were risk 
assessed locally as the Genomic Services Development Unit (GSDU) 2D01 
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lab where this research was carried out already uses the FAFLP procedure 
for the day-to-day service work. 
 
Figure 2-2 Schematic representation of the IS6110 FAFLP methodology. 
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2.1.4 Genomic DNA Restriction Endonuclease digestion 
Reagents: 
1. MseI (New England Biolabs (NEB), UK) 
2. TaqI (NEB, UK) 
3. 1x MseI buffer II (NEB) 
4. Bovine Serum Albumin (BSA) , (NEB) 
5. Ribonuclease  A (RNase A) (Sigma Aldrich, UK) 
6. 1M proline (Sigma Aldrich, UK) 
7. 2mM betaine (Sigma Aldrich, UK) 
8. Molecular Biology Grade water (Fisher Scientific, UK). 
2.1.4.1 Protocol: 
Five µl of 200- 500 ng of bacterial genomic DNA quantified using Qubit 
(Thermofisher, UK) was digested with 5 U of MseI (New England Biolabs, 
UK) in a total reaction volume of 20µl containing  1x MseI buffer, 0.1mg/ml of 
bovine serum albumin, 0.5mg/ml of RNase A, 1M of L-proline and 2mM of 
betaine at 37°C for 2 h to release the DNA ready for a final digestion with 
10U of TaqI (New England Biolabs, UK) at 65°C for 3 h and the reaction was 
inactivated for endonucleases at 80°C for 10 min. 
68 
 
2.1.5 Ligation of digested DNA to double stranded adapters 
2.1.5.1 Reagents: 
1. T4 DNA Ligase (NEB, UK) 
2. 2 x T4 DNA Ligase buffer (NEB, UK) 
3. Double stranded Taq I adaptor ( Eurofins, UK) 
2.1.5.2 Protocol: 
Double stranded oligonucleotide adaptors specific to TaqI site (5’- 
TACTCAGGACTGGC) were ligated to the double- digested DNA in a total 
reaction volume of 25µl containing 40U of T4 DNA ligase (New England 
Biolabs, UK), 0.2µM of double stranded TaqI adaptor and 2x T4 ligase buffer 
(NEB, UK). The reaction mixture was then incubated at 12°C overnight 
followed by heating at 65 ̊C for 10 minutes to inactivate the ligase and later 
stored at -20̊ C. 
2.1.6 PCR amplification of fragments 
2.1.6.1 Reagents: 
1. 10 x PCR reaction buffer (Thermofisher, UK) 
2. 50mM MgCl2 (Thermofisher, UK) 
3. 10mM dNTPs (Thermofisher, UK) 
4. 5µM TaqI primer (Eurofins, UK) 
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2.1.6.2 Preparation of 10µM of 4-dye labelled TaqI primer 
10µM of each selective TaqI primer labelled with 6-FAM (blue), PET (red), 
VIC (green) and NED (Black) fluorescent dyes at the 5’ end and a selective 
base either A or C or G or T nucleotide respectively according to the dye 
listed above were made from 100µM stocks with molecular biology grade 
water. 10µl of each 10uM primer i.e. 40µl in total were then mixed with 60ul 
of water to make up 10uM TaqI primer stock. 
 
5. 5uM IS6110 specific primer (Eurofins, UK) 
6. Molecular Biology Grade water (Fisher Scientific, UK) 
7. Recombinant Taq DNA Polymerase (Thermofisher, UK) 
2.1.6.3 Protocol: 
Four labelled adapter-specific forward primers, each with a single unique 
selective nucleotide (A / C / T/G) at the 3’ end which extends into the 
unknown genomic DNA sequence of the fragment, together with an IS6110 
specific reverse primer, were used to amplify the fragments. In a total volume 
of 20 µl, 1µl of the adaptor ligated DNA was added to the reaction containing 
1X reaction buffer (Invitrogen, UK), 1.5 mM MgCl2 (Invitrogen, UK), 0.2 mM 
dNTPs (Invitrogen, UK), 1 µM of labelled selective TaqI forward primer (5’-
CGATGAGTCCTGACCGA/C/T/G- (see table 2-1), 1 µM of IS6110 reverse 
primer (5’- CTGACATGACCCCATCCTTT) and 1U of recombinant Taq 
polymerase (Invitrogen, UK). The following PCR conditions were carried out 
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in a Veriti thermocycler (Applied Biosystems, UK): 94°C for 15 min followed 
by 35 cycles of 94°C for 20 s, 66°C for 30 s and 72°C for 2 min with the 66°C 
annealing temperature reducing by 1°C every cycle for nine cycles and the 
last 25 cycles at 56°C. Finally, an extension of 72°C for 60 min was carried 
out before further manipulations. 
Table 2-1 List of TaqI fluorescently labelled selective primers 
Fluorescent labelled selective 
primer 
Primer Sequence (selective base 
(135,147) 
1) TaqI- A (labelled with 6- 
FAM dye) 
5’- CGATGAGTCCTGACCGA(A)-3’ 
2) TaqI- C (labelled with PET 
dye) 
5’- CGATGAGTCCTGACCGA(C)-3’ 
3) TaqI- T (labelled with NED 
dye) 
5’- CGATGAGTCCTGACCGA(T)-3’ 
4) TaqI- G (labelled with VIC 
dye) 
5’- CGATGAGTCCTGACCGA(G)-3’ 
 
2.1.7 Capillary Electrophoresis of fragments using ABI3730xl Genetic 
Analyser 
2.1.7.1 Reagents: 
1. Hi_Di formamide (Applied Biosystems, UK) 
2. Genescan Liz600 sizing standard (Applied Biosystems, UK) 
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2.1.7.2 Protocol: 
One microlitre of the IS6110 FAFLP PCR reaction from the PCR step  was 
mixed with 10µl of Hi-Di formamide (Applied Biosystems, UK) and 0.5 µl of 
the Genescan Liz600 sizing standard (Applied Biosystems, UK). The reaction 
was denatured at 95° C for 5 min before running the reaction on the ABI 
genetic analyser 3730xl. The run module settings are given in the table 2.2 
below: 
Table 2-2 Run Module settings for capillary electrophoresis of FAFLP fragments 
Run parameters Actual setting Range 
Oven temperature 63̊̊̊C 18-70̊̊C 
Buffer temperature 35̊̊C 30-35̊̊C 
Prerun voltage 15.0 kV 0-15 kV  
Prerun Time 180 sec 1-1800 sec 
Injection voltage 1.6 kV 0-15 kV 
Injection time 15 sec 1-90 sec 
First readout time 200 ms 100-16000 ms 
Second readout time 200 ms 100-16000 ms 
Run Voltage 15 kV 0-15 kV 
Voltage no. of steps 10  0-100 steps 
72 
 
Voltage step interval 20 sec 0-180 sec 
Voltage tolerance 0.6 kV 0-6.0 kV 
Current stability 30 µA 0-2000 µA 
Ramp Delay 1 sec 1-1800 sec 
Data Delay 500 sec 1-1800 sec 
Run Time 2700 sec 300-14000 sec 
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Chapter 3 Optimisation and Development of Insertion Element 
IS6110 Fluorescent Amplified Fragment Length Polymorphism 
(FAFLP) PCR 
.  
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3.1 Introduction 
Fluorescent Amplified Fragment Length Polymorphism (FAFLP) has been widely 
used as a strain typing tool for several bacteria like Listeria monocytogenes (134), 
Legionella pneumophila (145,176) and  Salmonella enteritidis (142). Using IS6110 
as a biomarker, the global phylogeny of MTBC has been studied using FAFLP (135). 
In the era of whole genome sequencing, where repeat elements are difficult to 
sequence with short read technologies (177),  and in the absence of an alternative 
approach to their characterisation in poorer resource settings, a simple but effective 
technique would enable the facilitation of outbreak samples by not only strain typing 
the bacterial strains but also to help in the classification of TB genetic lineages in any 
geographical location. A rapid and simple method of insertion site mapping using 
IS6110 fluorescent amplified fragment length polymorphism (FAFLP) PCR was 
developed using fluorescent labelled primers (147). Borrell et al. first used four 
different fluorescent labelled primers with the selective base at the 3’ end of the TaqI 
primer for increased resolution to differentiate between epidemiologically unrelated 
TB strains. Thorne et al. used fluorescent labelled primers to further distinguish the 
fragments (135,146). To suit the demands of a resource poor setting the technique 
was modified further by utilising the resolution of the fragments derived by this 
technique, and to develop a lineage specific PCR as described in chapter 4. 
3.1.1 Aims  
The main aim of this chapter was to modify, optimise and standardise the IS6110 
FAFLP PCR methodology so that it could be used to map and classify M. 
tuberculosis samples into different lineages.  
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3.1.2 Objectives 
• To test the IS6110 FAFLP methodology using DNA from different strains of M. 
tuberculosis and different PCR reagents/conditions. 
3.1.3 IS6110 FAFLP Methodology 
The technique was optimised so that the results obtained could be easily identified 
by the presence or absence of the fragments/peaks and by their respective colours 
as shown in the figure 3-1. Each fragment indicates the point of insertion of IS6110 
in the bacterial genome and also the number of fragments indicates the number of 
IS6110 insertion sites i.e. copy number of IS6110 in the genome. The PCR amplified 
fragments were run on ABI 3730XL (Thermofisher, U.K.) and visualised using 
software called Peak Scanner (Thermofisher, U.K.).  
 
 
Figure 3-1 Pictorial representation of the IS6110 FAFLP PCR methodology  
(Coloured fragments are amplified using uniquely labelled adapter specific primers. For example, blue 
coloured fragments are amplified if the primers are labelled with 6-FAM fluorescein ‘blue’ dye, red 
coloured fragments with PET dye, green coloured fragments with VIC dye and black coloured 
fragments with NED dye). 
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3.2 Materials and Methods 
The process to optimise the IS6110 FAFLP PCR methodology consisted of testing 
the DNA samples of adapter ligated H37Rv DNA from previous study by Kremer et 
al.(178), H37Rv and Nepal TB strains with different polymerases and optimising the 
PCR conditions. Approximately 200-500ng of bacterial genomic DNA was digested 
with 5U of MseI (New England Biolabs, UK) in a total reaction volume of 20µl 
containing  1x MseI buffer, 0.1mg/ml of BSA, 0.5mg/ml of RNase A, 1M of L-Proline 
and 2mM of Betaine at 37°C for 2h to release the DNA ready for a final digestion 
with 10U of TaqI (New England Biolabs, UK) at 65°C for 3 h and the reaction was 
inactivated for endonucleases at 80°C for 10 min. Double stranded oligonucleotide 
adaptors specific to TaqI site (5’- TACTCAGGACTGGC) were then ligated to the 
double- digested DNA in a total reaction volume of 25µl containing 40U of T4 DNA 
ligase (New England Biolabs, UK), 0.2µM of double stranded TaqI adaptor and 2x T4 
ligase buffer (NEB, UK). The reaction mixture was then incubated at 12°C for 17 h 
followed by heating at 65̊ C for 10 minutes to inactivate the ligase and later stored at 
-20̊ C. In a total volume of 25µl, 2.5µl of the DNA sample was mixed with 10x Pfx 
reaction buffer, 50mM MgSO4, 10mM dNTP, 1µM of TaqI primer, 1µM of IS6110 
specific primer and 1U PfX polymerase/ 1µl of Hotstar Taq plus mastermix or 10µl of 
My Taq Premix or 1U of recombinant Taq polymerase. The following PCR conditions 
were carried out in a Veriti thermocycler (Thermofisher, U.K.): 94°C for 15 min 
followed by 35 cycles of 94°C for 20 s, 66°C for 30 s and 72°C for 2 min with the 
66°C annealing temperature reducing by 1°C every cycle for nine cycles and the last 
25 cycles at 56°C. Finally, an extension of 60°C for 30 min was carried out before 
further manipulation. When there were no peaks or there was an anomaly in the 
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electropherogram such as amplification artefacts and double peaks, then the PCR 
extension was increased from 60°C for 30 min to 72°C for 30min and a final 
adjustment was carried out from 72°C for 30min to 72°C for 60min. The criteria for 
the peak characteristics seen in an electropherogram using Peak Scanner software 
were as follows: 
a. The fragment should be a single peak (Double peaks should be avoided). Two 
peaks over 0.5 base pair difference between them will be considered as two 
separate fragments. 
b. The fragment could be identified by the colour of the fluorescently labelled dye, 
either blue for FAM or red for PET or green for VIC or black for NED according to the 
dye incorporated. 
c. The peak should be a true peak shape and size (artefacts were discarded). A 
difference of ± 0.5bp in fragment sizes was considered as non-identical fragments or 
peaks. 
d. The relative fluorescent units (rfu) on the X-axis had been assigned a cut-off of 
500rfu. 
Some of the well-characterised artefacts are as follows: 
a. Stutter peaks: Stutter artefacts are observed as multiple peaks preceding the true 
allele peak. The number of peaks and their intensities are proportional to the length 
of the repeat and the number of repeats in the PCR product (Applied Biosystems 
Fact sheet).  
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b. Plus A additions or Double peaks: Plus A additions, caused by incomplete A 
nucleotide addition, also increase the complexity of the peak pattern, which makes 
recognition of true allele peaks more difficult (Applied Biosystems Fact sheet). 
c. Bleed through or Pull-up peaks: A Bleed-through or pull-up is a typical problem in 
multichannel capillary electrophoresis, which is caused by fluorescent dye cross-talk. 
A high signal in one fluorescent channel thereby gives rise to a pull-up peak in 
another channel (Applied Maths Inc., Belgium). 
 
 The step by step procedure to achieve the standardisation of IS6110 FAFLP PCR 
assay is given in the form of flowchart below in the figure 3-2. 
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Figure 3-2 Step-by-step procedure for optimising and developing the IS6110 FAFLP 
methodology 
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3.3 Results 
The IS6110 FAFLP PCR methodology was standardised by testing different DNA 
polymerases from different PCR kits and by changing the PCR extension step as 
shown in figure 3-3 using adapter ligated H37Rv DNA from a previous study by 
Kremer et al. (178), H37Rv and Nepal TB DNA samples. The sequential procedure 
undertaken to achieve this is described below in the form of a flowchart. 
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Figure 3-3 Step-by-step procedure of standardising IS6110 FAFLP methodology including the 
accepted methodology 
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3.3.1 Amplification of DNA fragments 
Amplification of the DNA fragments was first checked for the adapter ligated DNA by 
the presence or absence of peaks (fragments) in the PeakScanner analysis 
software. Absence of peaks (figure 3-4) except for the presence of LIZ600 indicated 
that either poor quality DNA or absence of DNA. 
 
Figure 3-4 Example of a Peakscanner screenshot showing the absence of amplification of 
fragments except for Liz600 marker in orange colour. 
 
3.3.2 Validation of the PCR reagents 
Different Taq polymerases (PfX polymerase, Hotstar Taq plus mastermix, My Taq 
Premix and recombinant Taq polymerase) were subjected on both H37Rv and Nepal 
TB DNA and the results were as follows. 
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3.3.2.1 Hotstar Taq Plus mastermix (Qiagen, U.K.) 
The fragments were not amplified except for the presence of the visualisation marker 
Liz600 using this mastermix and so the next reagent was tested. 
3.3.2.2 MyTaq PCR premix (Bioline, U.K.) 
Using this mastermix, strong amplification occurred but the interpretation was difficult 
as seen in figure 3-5 due to the strong signal intensity of more than 28000 relative 
fluorescent units (rfu). 
 
Figure 3-5 Example of a Peakscanner screenshot showing strong signals of more than 28000 
rfu when MyTaq mastermix was used 
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3.3.2.3 Platinum Pfx proof-reading polymerase (Invitrogen, U.K.) 
Here, the signal intensity of the samples under analysis was optimum but the 
interpretation of the data became difficult as there was more than one coloured 
fragment at any single position as seen in figures 3-6 and 3-7. 
 
Figure 3-6 Example of a Peakscanner screenshot showing amplification of fragments with 
correct signal intensity in a sample when Platinum Pfx Polymerase proof-reading enzyme 
mastermix was used 
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Figure 3-7 Second example of the Peakscanner screenshot showing amplification of fragments 
from the sample above in the previous figure but a mixture of fragments noticed at a single 
position leading to difficult interpretation of the data when Platinum Pfx Polymerase proof-
reading enzyme mastermix was used 
 
3.3.2.4 Recombinant Taq Polymerase (Invitrogen, U.K.) 
The majority of the samples analysed using this enzyme were amplified with 
optimum signals apart from a few samples which showed stronger signal intensity 
(figure 3-8) and double peaks (figure 3-9). The electropherogram for the reference 
strain, H37Rv, was very clean and the signal intensity was normal (see figure 3-
10).The negative control, water, did not show any amplification (see figure 3-11). 
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Figure 3-8 Example of a Peakscanner screenshot showing strong raw signal intensity in H37Rv 
sample using recombinant Taq Polymerase reagents 
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Figure 3-9 Example of a Peakscanner screenshot showing double peaks (green dye- VIC) in 
H37Rv sample using recombinant Taq Polymerase reagents 
 
 
 
88 
 
 
Figure 3-10 Example of a Peakscanner screenshot showing the presence of amplified 
fragments with single peaks in an H37Rv sample when using recombinant Taq Polymerase 
reagents. 
 
 
89 
 
 
Figure 3-11 Peakscanner screenshot showing the absence of amplification of fragments in the 
negative sample (water) using recombinant Taq Polymerase reagents. 
 
3.3.3 H37Rv and Nepal TB DNA study samples 
Changing the PCR conditions significantly increased the efficiency of the IS6110 
FAFLP assay and, together with enzyme optimisation development, the assay was 
standardised. So, using this technique, H37RV (see figure 3-9) and the 176 Nepal 
samples were characterised (see appendix 5- raw FAFLP data stored in CD format). 
It is not possible to include the electropherograms for all the 176 samples due to 
space constraints but the example below, figure 3-12, shows the amplification of 
fragments for two samples displaying well-defined fragments without artefacts. 
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Figure 3-12 Example of an electropherogram showing two Nepal samples, N03 and N06, 
identical to each other having the same fingerprint with well-defined and easily identifiable 
coloured fragments. 
 
3.4 Discussion 
Whilst testing the samples from already adapter-ligated DNA (178), it was apparent 
that using poor quality DNA was unsuccessful as there was no amplification of 
products as this DNA was from the 1999 study. This was overcome by testing fresh 
DNA samples from H37Rv and Nepal TB strains and the FAFLP procedure was 
carried out on the samples including restriction enzyme digestion, ligation and PCR. 
Unaltered PCR conditions and reagents led to the generation of double peaks (figure 
3-8), which created difficulty in interpreting the data. It was apparent that the PCR 
conditions required optimisation, including change of PCR reagents including PCR 
enzymes. The PCR final extension step was increased from 60°C to 72°C for 15 
minutes but otherwise all other conditions remained the same. Of four PCR reagents 
tested, the fragments were not amplified using Hotstar Taq Plus mastermix. With 
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regards to MyTaq mastermix, the signal intensity of 28000rfu was high and led to the 
difficulty in interpretation of data. The signal intensity for the third PCR reagent, Pfx 
Polymerase gave optimum signal intensity and also the background noise was low 
compared to former two reagents mentioned above but there were more than one 
fragment on one given location which made the analysis difficult. The fourth reagent 
tested, recombinant Taq polymerase mastermix, gave good signal intensity but also 
produced double bands which indicated that the PCR conditions needed further 
optimisation. A final extension of 72°C for 60 minutes was carried out instead of 15 
minutes as in previous protocols and gave well-defined, easily interpretable 
fragments and thus the standardisation was complete. This technique was used in 
chapter 4 for mapping the IS6110 insertion sites in H37RV genome and in chapter 6 
for characterisation of Nepalese TB strains into different TB genetic lineages. 
3.5 Summary 
In this chapter, the IS6110 FAFLP PCR procedure was standardised and  tested 
using the adapter ligated DNA products from a global TB collection (178), H37Rv 
and followed by samples from Nepal. I selected the latter for my thesis to develop 
the genomic tool box for resource poor settings as Nepalese samples were very 
poorly characterised when this study was started in 2011. 
.  
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Chapter 4 Mapping of Insertion sites (IS6110) in the M. tuberculosis 
H37Rv reference genome and rapid definition of genetic lineages  
(This chapter was published in the Journal of Microbiological Methods) (179)  
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4.1 Introduction 
Insertion elements play a significant role in the evolution of genomes of various 
organisms (69) and can transpose within the genomes thereby altering the position 
and even the function of the adjacent genes. These transpositional changes have 
contributed to the evolution of different microorganisms thereby exhibiting a genome 
plasticity function where the genome is altered to survive in different environmental 
niches (75,180). 
Tracing the movement of insertion sites can be useful in two ways, firstly by acting 
as genetic markers to define strains of different microorganisms and thus determine  
the transmission relationship between two strains (181) and secondly by mapping 
the exact position of IEs whose transposition could alter the phenotype of the strain. 
Mapping of IS6110 sites in the Zaragoza M. tuberculosis strain  that caused a 
sudden outbreak in Spain in the years between 2001 and 2004, has offered clues of 
the adaptability and virulence of M. tuberculosis (182). The Zaragoza strain belongs 
to PGG3 and is responsible for widespread outbreaks compared to PGG1 and 
PGG2 (refer section 1.9.1 for the descriptions about PGGs) in Spain. On further 
analysis of the mapping results, Millan-Lou et al. have found that there are twelve 
copies of IS6110 in this strain and that the IS6110 insertion in the DR region is found 
3bp away from the DR sequence which is different to the compared H37Rv strain. 
Also, five of the twelve insertion points were at positions already reported by other 
scientific groups over the years. Most importantly, one of the insertion locations, in 
the Rv2823c gene was unique and specific to the Zaragoza strain which then led to 
the development of multiplex PCR assay for the rapid detection of this strain of M. 
tuberculosis (182). 
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Genomic mapping identified that there are differences between two strains of Beijing 
family, W and 210. These two strains have seventeen IS6110 insertion sites, twelve 
are identical in terms of insertion locations in the genome but five are different. Two 
unique sites were found in W strain and also one IS6110 copy was found upstream 
of the ctpD gene wherein IS6110 was providing a promoter element for the 
transcription of this gene (98). Alonso et al., found specific IS6110 insertion sites in 
the Beijing genotype that helped in the mapping of this family of TB and also showed 
that the Beijing TB lineage displayed a higher frequency of IS6110 insertions than 
other lineages (183). TB genetic lineages, as described in chapter 1 section 1.9, are 
grouped mainly into two types, either by SNP classification (153) into 3 Principal 
genetic groups (PGG1, PGG2 and PGG3) or by LSP classification (184) into seven 
genetic lineages. These genetic families or lineages are important as it has been 
suggested that there is phenotypic diversity existing between M. tuberculosis clinical 
isolates (165). Also, it has been reported that Beijing/W lineages, with their unique 
phenotypic traits, have an increased ability to cause disease (185,186). Also, this 
strain has been shown to be predominantly distributed in Eastern Asia and due to 
human migration this genotype migrated from Beijing City to the other parts of the 
world over time. However, a high number of insertions in certain strains does not 
necessarily suggest pathogenicity but that the molecular clocks of IS6110 movement 
is faster in some strains than others, as it has been shown that low copy numbers 
are also highly pathogenic (107). 
As there is a lot of ambiguity in defining a specific TB genetic lineage using the 
available epidemiological markers, and because the techniques described above are 
complex in terms of technicality, a rapid definition assay will be helpful in providing 
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information about the TB genetic lineage and possibly then allowing improved 
management of the disease caused by a particular genetic lineage. 
4.1.1 Aims and Objectives 
The aim of this chapter is to locate or map the precise genomic IS6110 insertion 
sites in the M. tuberculosis H37Rv strain using IS6110 FAFLP PCR methodology 
and define the TB genetic lineages, H37Rv (PGG3 group) and Beijing (PGG1 
group). Rapidly defining TB lineages would help in identification of TB genetic 
lineages circulating in a given area of the outbreak and thereby indirectly help in the 
informed management of the disease including control and surveillance. 
The following specific objectives are used to achieve the aim mentioned above: 
 To carry out IS6110 FAFLP PCR methodology on H37RV genomic DNA 
 To decrease the number of fragments generated by FAFLP to enable 
sequencing of individual fragments so that it is easy to interpret the insertion points 
of IS6110 in the genome. 
 To identify the sequence of individual fragments generated and map the 
insertion site IS6110 position in the reference sequence of H37Rv. 
 To develop and perform lineage specific PCR to define lineages as PGG1-
Beijing and PGG3-H37Rv. 
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4.2 Materials and Methods 
H37Rv TB DNA was subjected to IS6110 FAFLP methodology as described in 
chapter 3 (chapter 3, section 3.1.3) and the fragments generated by capillary 
electrophoresis under the run conditions described in chapter 2 (chapter 2, table 
2.2), were analysed using PeakScanner software (Thermofisher, UK). To further 
reduce the number of fragments, new two base selective primers were designed with 
an addition of another selective base at the 3’end of the existing TaqI primers (see 
table 4-1 below) and subjected to the previously used PCR conditions using IS6110 
reverse primer. One microlitre of the PCR product is used to sequence in both 
directions using the same primers. The sequence data is then subjected to BLAST 
analysis to reveal the identity of the fragment thereby allowing the fragment of 
interest to be mapped at the genome level (see Tables 4-2 and 4-3) 
Table 4-1 List of unlabelled two base selective primers 
Two base selective TaqI primer Primer Sequence (Two selective 
bases at 3’ end)  
1) TaqI- AA  5’- CGATGAGTCCTGACCGA(AA)-3’ 
2) TaqI- AC  5’- CGATGAGTCCTGACCGA(AC)-3’ 
3) TaqI- AT  5’- CGATGAGTCCTGACCGA(AT)-3’ 
4) TaqI- AG  5’- CGATGAGTCCTGACCGA(AG)-3’ 
5) TaqI- CA  5’- CGATGAGTCCTGACCGA(CA)-3’ 
6) TaqI- CC  5’- CGATGAGTCCTGACCGA(CC)-3’ 
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7) TaqI- CT  5’- CGATGAGTCCTGACCGA(CT)-3’ 
8) TaqI- CG  5’- CGATGAGTCCTGACCGA(CG)-3’ 
9) TaqI- TA  5’- CGATGAGTCCTGACCGA(TA)-3’ 
10) TaqI- TC  5’- CGATGAGTCCTGACCGA(TC)-3’ 
11) TaqI- TT  5’- CGATGAGTCCTGACCGA(TT)-3’ 
12) TaqI- TG  5’- CGATGAGTCCTGACCGA(TG)-3’ 
13) TaqI- GA  5’- CGATGAGTCCTGACCGA(GA)-3’ 
14) TaqI- GC  5’- CGATGAGTCCTGACCGA(GC)-3’ 
15) TaqI- GT  5’- CGATGAGTCCTGACCGA(GT)-3’ 
16) TaqI- GG  5’- CGATGAGTCCTGACCGA(GG)-3’ 
 
4.2.1 Rapid definition of TB genetic lineages-PGG3 (H37Rv) and PGG1 
(Beijing) 
Samples: H37Rv and samples belonging to other lineages already assigned using 
FAFLP (chapter 5) (N10, N25, N34, N46, N62, N63 N70), were selected (appendix 
1) to test the proof of principle. Based on FAFLP, the following lineages were 
assigned to these samples above (Table 4-2). 
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Table 4-2 showing the selected samples and their IS6110 FAFLP derived lineages 
Sample ID FAFLP derived lineages (PGG) 
N10 CAS – PGG1 
N25 Unassigned 
N34 T (H37Rv-like)- PGG3 
N46 Unassigned 
N62 Unassigned 
N63 Unassigned 
N70 Beijing (PGG1) 
 
Following sequence determination (and therefore specific genomic insertion sites) of 
lineage specific fragments found only in defined lineage/spoligotype groups by 
FAFLP, primers were designed to amplify common fragments from the PGG1 (5’-
gggctccccagatcaa-3’) and PGG3 (5’-gtgtgccgcgaggtgg-3’) groups and comprised a 
200bp product and a 296bp product on a gel respectively, based on the hypothesis 
that a PCR product of a known size will be generated if the IS element is inserted at 
the exact same genomic region. In a total volume of 50µl, 1µl of the DNA extracted 
was added to the reaction containing 1X PCR reaction buffer, 1.5 mM MgCl2, 0.2 
mM dNTPs (Invitrogen, UK), 5 µM of the PGG1 or PGG3 group primer, 5 µM of 
IS6110 reverse primer as described above and 1U of recombinant Taq polymerase 
(Thermofisher, UK). The following PCR conditions were carried out in a Veriti 
thermocycler (Thermofisher, UK): 96°C for 15 min followed by 30 cycles of 96°C for 
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1 min, 60°C for 1 min and 72°C for 30 seconds with a final extension of 72°C for 1 
min was carried out before cleaning up the PCR products using AMPure XP 
magnetic beads. The products were then run on a gel to check the presence of the 
fragment, 296bp product for the PGG3 group and 200bp product for the PGG1 
lineage. 
 
4.3 Results 
4.3.1 Prediction of fragments using Seqbuilder (DNASTAR Lasergene version 
8, USA) software (in silico analysis) 
The genomic sequence of H37Rv (accession no: NC_000962.2) was digested in 
silico with TaqI enzyme followed by the identification of 59 bases of IS6110 
sequence 
(CTGACATGACCCCATCCTTTCCAAGAACTGGAGTCTCCGGACATGCCGGGGC
GGTTCAG) to indicate the size of the expected product by PCR using primers with a 
two base extension at the 3’ end to reduce the number of fragments generated as 
shown in Tables 4-3 and 4-4 and Appendix 1. The table shows the presence of 
sixteen insertion sites corresponding to the presence of sixteen IS6110 copies in 
H37Rv as was reported previously by Philipp et al in 1996 (187). 
4.3.2 Identification of fragments using Peak Scanner (Thermofisher Scientific, 
UK) software (in vitro analysis) 
Sixteen fragments were mapped as seen in columns 1 and 2 in tables 4-3 and 4-4 
using their fluorescent dye colours.  
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4.3.3 Mapping the insertion site IS6110 position in the genome of M. 
tuberculosis. 
All but two, 71.5 Y and 83.8 Y as seen in tables 4-3 and 4-4 in column 1, of the 
sixteen fragments generated could be identified by this method. Two fragments 
could not because the flanking genomic data contained in the sequence was too 
short to analyse as the restriction site was too close to the end of the transposon 
sequence. Although the two base selective primers are specific and generate a 
largely specific PCR product for sequencing, a degree of mis-priming does occur. 
These non-specific extension products are generated due to mis-priming occurring in 
the PCR. The data generated for the H37Rv genome fragmented using the 4-dye 
FAFLP PCR in Tables 4-3 and 4-4 and Appendix 1 correlate with the sequencing 
data and also the in silico data generated using DNASTAR Lasergene Seqbuilder as 
described above. 
Table 4-3 Mapping of H37Rv genome using 4-dye FAFLP PCR, DNA sequencing including 
BLAST results and in silico analysis with sequence orientation 5’-3’ according to Figure 3-1 
Method Schematic 
FAFLP 
fragment 
colour and 
size in 
base 
pairs* 
Sequence 
product size 
Insertion site BLAST 
result from sequence 
data 
In silico predicted 
insertion site 
99.1 G (102) Transcriptional regulator 
for LacI family protein 
Transcriptional regulator 
for LacI family protein 
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81.0B (87) Too short to analyse Cutinase1 
173.6R (175) Conserved membrane 
protein 
Conserved membrane 
protein 
736.6R (772) IS6110 IS6110 
 
* G=Green, B= Blue, R=Red, Y=Yellow 
Table 4-4 Mapping of H37Rv genome using 4-dye FAFLP PCR, DNA sequencing including 
BLAST results and in silico analysis with sequence orientation 3’-5’ according to Figure 3-1 
Method Schematic. 
FAFLP 
fragment 
colour 
and size 
in base 
pairs* 
Sequence 
product 
size/in 
silico 
predicted 
size in 
base pairs 
Insertion site BLAST 
result from sequence 
data 
In silico predicted gene 
insertion site 
206.4Y (201) Peroxidase BpoA Peroxidase BpoA 
140.4R (141) Molybdenum cofactor 
MoaC 
Molybdenum cofactor MoaC 
560.4B (561) PPE-family protein PPE-family protein 
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191.7R (196) Conserved hypothetical 
protein 
Conserved hypothetical 
protein 
71.5Y (58) Too short to analyse Cutinase1 
160.3Y 
(164) 
LytB related protein LytB related protein 
83.8Y (58) Too short to analyse  
Not seen 
in FAFLP 
data 
(289) Putative transposase for 
IS986 
Putative transposase for 
IS986? 
Not seen 
in FAFLP 
data 
(214) Integrase Integrase? 
329.2B (338) Glycerolphosphodiesterase Glycerolphosphodiesterase? 
124.9G (127) Transposase Transposase 
360.0R (360) Oxidoreductase Oxidoreductase 
 
* G=Green, B= Blue, R=Red, Y=Yellow 
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4.3.4 Rapid definition of TB genetic lineages- PGG3 and PGG1. 
For the seven samples tested as proof of principle, five belonged to the PGG3 
lineage: H37Rv, N25, N34, N46, N63, one belonged to the PGG1 lineage, N70 
according to FAFLP data, one belonged to the CAS lineage, N10 and one (N62) did 
not give any result (see figure. 4-1). N70 reacting to PGG3 primer shows there might 
be fragments shared by different PGG groups and needs to be looked into detail. 
 
 
A. 
  
 
 
 
 
296bp 
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B. 
 
Figure 4-1 Agarose Gel Electrophoresis showing M.tuberculosis strains , N10, N25, N34, N46, 
N62, N63, N70, H37Rv, amplified using PGG3 (A) and PGG1 (B) specific primers, amplifying 296 
bp and 200 bp products respectively 
200bp 
Generuler 
1 kb DNA ladder 
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4.4 Discussion 
Although a large number of studies have been published based on the fragment 
patterns generated by IS6110 RFLP, little or no data are available on the distribution 
of IS6110 genomic insertion sites in Mycobacterium tuberculosis complex strains. 
This will have an impact on the molecular epidemiological studies of M. tuberculosis. 
Knowledge of specific sites may lead the way to develop rapid techniques to identify 
specific lineages which could be validated in future using WGS technology. 
This technique exploits the use of selective bases at the 3’ end of primer sequences 
to reduce the fragment numbers generated during FAFLP PCR amplification. Also, 
use of differentially labelled fluorescent primers aids the identification of fragments. 
Using selective primers reduces the number of fragments amplified, which can then 
be sequenced and the position of the insertion site in the genome identified by 
BLAST analysis of the sequence. The BLAST results show that, except for the three 
fragments (81B, 71.5Y and 83.8Y) that were too short to analyse, the predicted and 
actual insertion sequence data correlate with each other and the FAFLP fragment 
size and colour. As every fragment generated always contained 75 bp of 
transposon/adaptor sequence, any fragments below 100bp were too small to identify 
flanking genomic sequence by this method. Sequencing data usually starts around 
25 bp past the sequencing primer which effectively cuts off 100bp in total. Apart from 
the fragments too small to analyse (this could be remedied by choosing an 
alternative enzyme for FAFLP), there were three fragments that were not predicted 
in silico. These were an IS986 transposase (corresponding to 289bp fragment in 
table 4-3), integrase (214bp in table 4-3) and glycerol phosphodiesterase (329.2B in 
table 4-3), involved in the glycerol metabolic process. That another transposon was 
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identified strongly suggests that a further transposition has occurred following the 
many cultural iterations of H37Rv since whole genome sequencing as seen in the 
case of IS986 transposase. If this was the case then these fragments would not be 
predicted from the genome sequence available. The predicted insertion sequences 
seen offer interesting avenues for further study, including characterisation of the 
surface genes disrupted by IS6110 including PPE and those affecting metabolism. 
The characterisation of insertion sites of this and other transposons is important for 
clonal organisms such as those belonging to the MTBC.  
In 2011 Alonso et al., showed the importance of mapping insertion sites by 
demonstrating that the IS6110 in the Beijing strains of MTBC can up-regulate 
downstream genes via an outward-directed promoter in its 3’end (Alonso et al. 
2011). Further mapping of the specific insertion sites will generate information on the 
nature of the gene disruption, whether the insertion has a detrimental effect, for 
example disrupts the proposed reading frame, or has a potentially beneficial effect 
through up regulation. The next steps for this work after it has been shown to map 
successfully the IS6110 insertion sites in H37Rv is to apply this knowledge to design 
a rapid tool for the definition of lineages.  
The principle of rapid detection of lineages was successful using the lineage specific 
fragments targeting the common fragments as described above (see figure 4.1). This 
assay needs a simple PCR thermocycler, reagents and facilities to run and visualise 
the gel and the ability to interpret the results. Direct detection from sputum would be 
a useful next step but sensitivity is likely to be low. Detection of lineages by the LSP 
or the SNP methods are time consuming as they need good quality DNA after 
bacterial DNA extraction and a bioinformatics approach to deduce the TB families. 
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They also need expensive instruments like the sequencers and extra manpower to 
accomplish the definition of lineages. Although an alternative approach would now 
be made if starting the project, the FAFLP approach was the only approach available 
at the time and as such it still forms the basis of genomic tool box development for 
the rapid assignation of TB genetic lineages based on IS6110. 
4.5 Summary 
The data presented shows that the IS6110 FAFLP PCR technique, though relatively 
simple, is robust and effective in mapping IS6110 insertion in H37Rv that could be 
applied to any bacterial species with similar repeated elements. Also in this chapter, 
rapid definition of TB genetic lineages using newly designed primers were carried out 
using PCR without the use of digestion and ligation, for the rapid detection of both 
H37Rv-like (T-group) and Beijing lineages to initiate the development of a suite of 
PCRs based on detection of lineage specific common IS6110 insertion points as a 
typing tool for resource poor settings. 
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Chapter 5 Classification of Nepalese TB clinical isolates into 
different TB genetic lineages 
(This chapter was published in the open access journal of Clinical Microbiology and 
Infectious Diseases (188).  
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5.1 Introduction  
Nepal is geographically interlocked between China and India, which together 
account for approximately a third of annual global new cases (11% and 24%, 
respectively) (WHO 2014) and is ranked 43rd in the world in terms of age-adjusted 
death rate, which is 27.80 / 100000 of the population. During the year ending of 
2014, there were 5506 deaths in Nepal due to tuberculosis that accounts to 3.5% of 
total deaths in Nepal. TB cases and deaths are more prevalent in men than women. 
In 2006 Nepal’s National Tuberculosis Programme (NTP) developed the STOP TB 
strategy to fight against tuberculosis, in line with WHO. The NTP is fully integrated 
with the national healthcare policy of the government of Nepal. The Millennium 
Development Goal (MDG), another initiative by WHO to tackle TB, was found to be 
effective in halting and reversing global TB prevalence. The prevalence rate (all per 
100,000 population) has gone down from 348 (162-602) in 1990 to 211 (99-365) in 
2015. The death rate (all per 100,000 population) has also reduced from 52 (32-70) 
in 1990 to 19 (13-25) in 2015. Due to all these efforts, Nepal is no longer in the list of 
high burden TB countries. TB programs were able to save 32,973 lives in 2014 but 
despite this progress, there were still 978 deaths. Overall treatment success rates of 
drug susceptible TB was 91.5% with 0.92 % failure rates, 2.17% failed to follow-up 
and 2.7% death rates. The proportion of MDR-TB was 2.2% among new TB cases 
and 15.4 % among retreatment cases based on a survey carried out in 2011-2012. 
New surveillance studies have not been carried out recently. There were a total of 22 
deaths among MDR cases and 3 deaths in XDR reported in 2014/15. For MDR the 
drug resistance pattern showed higher levels of resistance in fluoroquinolones and 
8% of those MDR patients further developed XDR. Sputum microscopy is still the 
gold standard method for the diagnosis of TB in Nepal. Currently there are 581 
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microscopy centres providing this smear microscopy service throughout the country. 
As a high proportion of rifampicin resistant strains are resistant to Isoniazid, 
detection of rifampicin resistance can be used as a marker for MDR-TB as described 
in chapter 1. Between 2011 and 2012, GeneXpert MTB/RIF assays were introduced 
in 3 centres and now there are 26 centres nationally (173). The STOP TB program 
has reduced the number infected from 29 million people, as estimated by WHO in 
2014, to 15 million people according to the recent report by NTC. Despite the efforts 
to control the spread of TB, there is still a long way to go to achieve the goals of 
STOP TB program as 40,000 people are infected every year, with 20,000 new 
primary cases and 5000-7000 deaths each year from tuberculosis in Nepal. 
It is important to understand the molecular diversity of the M. tuberculosis population 
in Nepal as it has been reported recently that there is a high similarity between TB 
strains in Nepal and in Northern India, with which Nepal shares an open border 
policy of human migration (189). This might indicate that the TB lineages that were 
found in India, especially the CAS lineage, have successfully established in Nepal 
due to the human migration from India into Nepal (190), enabling the TB lineages to 
be successful in any geographical location (189). 
Very limited data are available on the characterisation of Mycobacterium tuberculosis 
strains and genotypes circulating in Nepal. A recent study of 261 Nepalese isolates 
found drug resistance  in 12.8% of M. tuberculosis strains that were from new 
untreated cases, with the most frequent lineages reported as CAS/Delhi (40.6%), 
East Asian (including Beijing) (32.2%), Euro-American (15.7%) and Indo-oceanic 
(11.5%)(191). To gain further insight into the characteristics and diversity of 
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mycobacteria in Nepal, this study aimed to categorise isolates for the first time using 
IS6110 FAFLP PCR and to assign them to different genetic lineages. 
5.1.1 Aims and Objectives 
The main aim of this chapter is to classify the Nepal samples into different TB 
lineages to understand the genetic distribution of TB lineages in Nepal. 
The following objectives were used to achieve this aim: 
 To perform IS6110 FAFLP PCR on Nepal samples 
 To characterise the samples into different TB lineages 
5.1 Materials and Methods 
5.1.1 Strains 
(Refer General methods section 2.1  
Sputum samples from 176 consecutive new TB patients were collected between 
2007 and 2008 and cultured alongside routine diagnostic testing from two Nepalese 
tuberculosis reference centres located in the Kathmandu valley: the National 
Tuberculosis Centre (NTC) and the German Nepal Tuberculosis Project 
(GENETUP). The patient population represented local and referred cases from 
across Nepal. Bacterial genomic DNA from isolated strains was extracted by the 
Cetyltrimethylammonium Bromide (CTAB) method.  
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5.1.2  IS6110 FAFLP PCR, Fragment Sizing & Analysis 
(Refer to the General methods section 2.2 for IS6110 FAFLP methodology and 
fragment sizing.). The four-dye FAFLP data collected from the different profiles were 
recorded and compared with a well characterised reference collection of M. 
tuberculosis isolates (178) using BioNumerics software v6.1 (Applied Maths Inc., 
Belgium). These data were then used to build a dendrogram using the Dice 
coefficient of similarities to compare the similarity matrix and Unweighted Pair Group 
Method with Arithmetic Mean (UPGMA) derived cluster analysis with cophenetic 
correlation for the branch quality. Dice similarity coefficient and UPGMA clustering 
method was chosen because of the high correlation in terms of their similarity 
obtained (in this case, genetic similarity) between the samples to form a group or 
cluster compared to the simple matching coefficient.  
5.2 Results 
5.2.1 Analysis of Data using BioNumerics software v6.1 
Of the 176 DNA extracts from isolates analysed, the majority of the samples (97, 
55.4%) belonged to either the spoligotype-defined CAS lineage (64, 36.6%) or the 
Beijing lineage (33, 18.8%) grouping under PGG1 and the rest of the samples group 
under either PGG2 (1.7% S, 3.97% X, 7.95% Haarlem and 2.27% LAM, 2.27% T-
Uganda) or PGG3 (2.27% of T) (Table 5-1). Forty three samples (24.4%) were 
“unassigned”. Common fragments specific to different TB lineages seen were exactly 
the same as the earlier published report by Thorne et al, (2011) except for an 
additional fragment, 78.4 G, for the CAS lineage (135). These fragments specify 
different insertion points where IS6110 has inserted or transposed. A dendrogram 
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was generated using only the IS6110 FAFLP data confirming again the above 
mentioned lineages in relation to the PGGs (Fig. 5-1). 
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Table 5-1 Common fragments identified using IS6110 FAFLP PCR in TB genetic lineages of the 
176 bacterial DNA isolates in Nepal  
PGG-
spoligotype/sub-
lineage  
Common fragment 
sizes  
No. Of Nepal strains 
(Total=176) 
PGG1-CAS  78.4G, 92.0B, 
117.9R, 206.2G, 
275.1R  
64 
PGG1-Beijing  101.7B, 102.5Y, 
139.1R, 180.7Y, 
254.8G, 332.4R, 
353.5B  
33 
PGG2 –Haarlem  87.0Y, 89.4G, 
148.7B, 300.2R 
(H/X), 445.7Y  
14  
PGG2-LAM  71.5Y, 105.2R, 
116.1R  
4  
PGG2-S  88.0G, 112.9R, 
217.2R, 445.3G  
3  
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PGG2-X  83.8Y, 300.2R (H/X)  7  
PGG2-T Uganda  88.9Y, 119.5G, 
122.9Y, 228.4Y, 
266.8R  
4  
PGG3- T  81.3R, 192.4R, 360R  4  
Ungrouped  43 
(PGG represent Principal Genetic groups according to Sreevatsan et al, spoligotypes follow spolDB4 
classification and spoligotypes derived sub-lineages are grouped following Gagneux’s classification 
(153,158)). 
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Figure 5-1 UPGMA derived dendrogram showing the predominant genetic 
lineages/spoligotypes of 176 Nepalese Mycobacterium tuberculosis isolates.  
Coloured branches represent Nepalese samples following Gagneux’s global phylogeography of 
MTBC (158) and black branches represent the in-house global Mycobacterium tuberculosis collection. 
PGGs are numbered following Sreevatsan’s classification (153). PGG1 outliers share one IS6110 
copy with the PGG1 group. Those which contained one IS6110 copy but could not be assigned to any 
group (unassigned group in the figure) are shown within the green box. 
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Kremer 17016 (11)
Kremer IN50 (52)
Kremer 17929 (114)
Kremer 9400104 (44)
Kremer 17819 (50)
Kremer 14323 (15)
Kremer 9402092 (100)
N110
Kremer 9402251 (87)
N27
Kremer  16707 (47)
N122
N153
N164
N119
N152
N106
N169
Kremer 18151 (39)
Kremer 18153 (41)
Kremer 16700 (46)
Kremer 9401651 (80)
Kremer 9401652 (81)
Kremer 91-40 (18)
Kremer 91-42 (19)
N13
N20
Kremer 15496 (57)
Kremer 16240  (56)
Kremer 9402093 (101)
Kremer mis 222 (74)
N123
Kremer 9401016 (53)
M. bovis 61
M. bovis 60
Kremer 18150 (63)
M. bovis BCG 4
Kremer 15199 (66)
Kremer IN8 (30)
Kremer 14296 (64)
Kremer 17902 (67)
Kremer 17728 (49)
M. canetti 48
Kremer 17316 (68)
Kremer myc 2187 (71)
N22
N4
Kremer 13876 (55)
N21
N38
N157
N172
N52
N57
N98
N62
N60
N25
N162
Kremer ATCC14770 (73)
M. bovis BCG (58)
M. bovis BCG 59
Kremer 15437 (65)
Kremer 18152 (40)
Kremer ATCC 10143 (76)
Kremer ATCC 607 (75)
M. bovis 62
N1
N126
N129
N147
N15
N156
N16
N160
N2
N63
N66
N84
N86
N88
N89
N92
N94
N95
N96
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5.3 Discussion 
Thorne et al. showed that IS6110 FAFLP PCR can be used to delineate the 
phylogeny of MTBC as shared common fragments can identify the different lineages 
in a geographical location by comparison with a reference database collection(135). 
As very limited lineage information is available from strains in Nepal (up until 2012 
there was none), the IS6110 method (published recently) was applied to map the 
IS6110 sites in H37Rv (179) and also carried out rpoB sequencing to further 
characterize strains from this important region. 
Fifty five percent of the 176 Nepalese strains analysed belong to the CAS (36.6%) 
and Beijing (18.8%) modern genetic spoligotypes (PGG1). The remaining 24.4 % of 
the samples belong to the PGG2 and PGG3 groups (Haarlem, LAM, S, X, T-Uganda 
and T). However, a limitation of this technique is its difficulty to characterise the 
samples with less than 4-5 copies of IS6110 as seen in the unassigned group 
(24.4%) in figure 5-1, which can be overcome by the use of other typing techniques 
like MIRU-VNTR(146). The geographical position of Nepal is likely to have 
influenced this distribution of lineages, with a mixture of predominantly Beijing 
lineage from the North of the Himalayas and the CAS lineage from the south (190). 
The fairly high percentage of mainly European lineages (Haarlem, LAM and T, 
12.5%) indicates that there has also been mixing of the different lineages over an 
extended time and that European travellers/migrants to South East Asia and Nepal 
may have transmitted European strains to the local population, probably due to the 
rise in globalisation leading to increased human migration between countries as 
reviewed by Soto (192). The IS6110 FAFLP data from our study supports the 
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hypothesis that the geographic location of Nepal is the key for the circulation of 
PGG1 TB lineages, CAS and Beijing, which were predominant in India and China 
respectively. This shows that the human migration from India and China into Nepal 
has helped M. tuberculosis lineages, especially Beijing and CAS, establish in this 
country. A large number of people flow between these regions due to various 
reasons,  for example cheaper medical treatment facilities, work, study, trade, 
pilgrimage and cultural visits. It has been shown that there is a high prevalence of 
CAS lineages from North India circulating in Nepal due to the migration of Indian 
population from this region into Nepal for the purposes mentioned above 
(163,189,190). Likewise, the other predominant lineage, Beijing, found widely 
distributed in China and Tibet, is seen in Nepal (164,193,194). This simple and 
informative PCR-based molecular epidemiological technique might prove useful for 
the study of outbreaks of the disease and importantly also to detect cross-
contamination between different strains or isolates in resource poor settings, aiding 
cluster investigation and possibly informing outbreak management. 
5.4 Summary 
To summarise, in this chapter I utilised the IS6110 FAFLP methodology successfully 
on DNA from TB samples from a resource poor setting, Nepal, and characterised the 
samples into different TB lineages or genotypes. This method also showed that the 
majority of the Nepal samples belonged to the PGG1 groups particularly, CAS and 
the Beijing. 
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Chapter 6 Rifampicin Resistance status in Nepalese TB 
isolates from clinical samples  
(This chapter was published in the open access journal of Clinical 
Microbiology and Infectious Diseases (188). Also, this methodology was 
employed by another PhD student from Lahore University (Pakistan) 
supervised by me in a recent paper (195) whilst determining the rifampicin 
status from clinical samples in Pakistan).  
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6.1 Introduction  
6.1.1 Drug Resistant TB in Nepal (adapted from NTC, 2015) 
A recent Drug Resistance Survey in Nepal conducted between 2011 and 
2012, has shown that DR-TB levels are increasing with nearly 9.3% of new 
patient resistant to at least one drug. The issue of increasing proportion of 
resistance to fluoroquinolones (26.4%) is a major public health concern in 
Nepal. Among MDR cases, 8% of the cases were found to be XDR due to 
the fluoroquinolones resistance. So to prevent the increased death rate due 
to XDR-TB in Nepal, the government is performing DST for second line drugs 
of all MDR-TB cases at the start of treatment (173). Early case finding is 
important to decrease human suffering, duration of disease and / or control of 
DR-TB, decrease financial burden and improve treatment outcome (23). As 
part of the STOP TB strategy in 2010, Nepal is successfully managing to 
control TB due to the presence of 581 microscopic centres, 2 solid culture 
laboratories including capacity for first line (FLD) drug susceptibility testing 
(DST), first line probe assay (LPA), one liquid culture and one second line 
drug (SLD) DST facility and 26 GeneXpert centres spread all over this 
mountainous country. This is in addition to 2 other culture and DST facilities 
(NTC and GENETUP) functioning in Kathmandu valley. 
During the course of this research work the study of 261 Nepalese isolates 
by Malla et al., found that around 8.04% of the MDR-TB cases were new 
untreated cases. (191). This study reports that the two major TB genotypes 
circulating in Nepal are CAS and Beijing. According to the NTP’s annual 
report published in 2015, the national rate of MDR is low in new cases (2.2%) 
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and high in retreatment cases (15.4%). Since rifampicin resistance has been 
widely accepted as a ‘surrogate’ marker for MDR (53,196), it is useful to 
investigate the MDR-TB status in this set of samples and compare them to 
the results of Malla et al., as they are new untreated TB cases and, 
moreover, the phenotypic drug susceptibility test results were unavailable for 
these samples. It is also been reported that the predominant strains 
circulating in India and China, CAS and Beijing, are mostly MDR-TB and the 
same strains are also found in Nepal (164,189,190,193,194). It will be 
valuable to investigate if this finding is supported with this set of samples 
using the Rifampicin Resistance detection assay targeting the RRDR region 
of the rpoB gene. 
6.1.2 Aims and Objectives 
The aim of this chapter is to determine the status of rifampicin resistance as 
an indicator of Drug Resistance in the 176 bacterial DNA samples from 
Nepal. 
6.2 Materials and Methods 
6.2.1 rpoB Analysis 
The 81bp Rifampicin Resistant Determining Region (RRDR) of the rpoB gene 
in the M. tuberculosis genome of all strains was sequenced using published 
primers (Arnold et al. 2005) and analysed in BIOEDIT software using 
ClustalW alignment parameters (see appendix 3). The PCR was carried out 
in a total volume of 50µl where 1ng of the DNA was added to the reaction 
containing 1xPCR  reaction buffer, 1.5mM MgCl2, 0.2mM dNTPs 
(Thermofisher, UK), 20µM each of both rpoB-RRDRforward (5’- 
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CGATCACACCGCAGACGTTGA) and reverse primers (5’- 
GGCACGCTCACGTGACAGACC) and 5U recombinant Taq polymerase 
(Thermofisher, UK). The following PCR conditions were carried out using a 
Veriti thermocycler (Applied Biosystems, UK): 94˚C for 2 min followed by 35 
cycles of 94˚C for 30 sec, 60˚C for 30 sec and 72˚C for 1 min. Finally, an 
extension of 72˚C for 10 min was performed before cleaning the products 
using AmpureXP magnetic beads (Beckman Coulter, UK) and sequenced 
using the forward primer, rpoB-RRDR forward. 
6.3 Results 
Of 176 DNA extracts analysed for rpoB mutations, seven samples (3.9%) 
had a single non-synonymous base change which would likely confer 
resistance (see table 6-1 and appendix 3). Six of these seven samples also 
showed a second base mutation in a codon triplet whereas sample N70 
showed a first base mutation. There were no silent mutations observed in the 
RRDR region of any of these samples.  
Table 6-1 List of mutations seen in rpoB Rifampicin Resistance- Determining Region 
(RRDR) of rifampicin resistant M. tuberculosis isolates from Nepal. 
Sample 
Mutated 
locus 
 
Nucleotide 
modification 
Amino acid 
modification 
1. N70 516 GAC > TAC (Asp>Tyr) 
2. N10 522 TCG > TTG (Ser>Leu) 
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6.4 Discussion 
Inferred Rifampicin resistance status for all the Nepal samples was 
determined using rpoB analysis. According to a recent study (191), fifty 
strains had any drug resistance and sixteen (6.1%) out of 261 isolates were 
MDR. Among the fifty any drug resistant strains, 29 cases were previously 
treated and twenty-one were new untreated cases (8.04% of 261 total strains 
and 12.8% of 164 new untreated cases). In this study, MDR-TB was tested 
by using rifampicin as the resistance marker and 7 isolates out of 176 were 
found (3.9%) from new untreated cases possessing drug resistance 
genotypes. However, their reported MDR percentage was based on the total 
number of isolates, of which 37.2% of isolates were from previously treated 
cases, which may enhance a probability of drug resistance development 
compared to untreated cases. Our results indicate that the prevalence of 
Rifampicin (RIF) resistant TB (surrogate marker for MDR) was higher than 
the nationally reported 2.2% MDR in new untreated cases. Further, our 
results are concordant with a recently conducted study by Creswell et al., 
where they have shown that the genotypic rifampicin resistance in newly 
3. N25 526 CAC > CTC (His>Leu) 
4. N63 526 CAC > CGC (His>Arg) 
5. N34 531 TCG > TGG (Ser>Trp) 
6. N46 531 TCG > TTG (Ser>Leu) 
7. N62 531 TCG > TTG (Ser>Leu) 
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diagnosed TB patients to be 3.3% in Nepal (198). In this study, the most 
common mutation site in the RRDR is at codon 531 concordant with the 
global data and parallels the findings of earlier studies (190,197). It also 
demonstrated the successful use of a surrogate rifampicin marker in analysis 
of MDR in Mycobacterium tuberculosis strains isolated from newly diagnosed 
primary TB patients originating from different regions of Nepal.  
The major circulating genotypes in Nepal according to our study have been 
shown to be CAS and Beijing in chapter 5 table 5-1 which was concordant 
with Malla’s study (191) and Sharma’s study (189). Sharma et al. reported 
that the major circulating genotype in northern India was CAS and they were 
predominantly MDR (189). As Nepal shares an open border with India in the 
south, this had contributed to the spread of the CAS lineage into Nepal and 
thereby the MDR-TB (189,190). Again the same scenario is true for the 
Beijing lineages from China contributing to the MDR burden in Nepal 
(164,189,190,193). Despite the unavailability of the drug susceptibility tests, 
this rpoB assay was able to infer the rifampicin resistance status for this set 
of samples. 
The combination of the rapid lineage specific PCR assay as discussed in 
chapter 4 along with the RIF resistant PCR assay will be more useful in 
resource limited setting as there is a reduced requirement for highly 
specialised equipment/infrastructure and staff for these molecular tests. 
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6.5 Summary 
In this chapter by utilising the rpoB PCR assay targeting the 81bp RRDR 
region, seven samples (3.9%) of the 176 Nepal samples tested were found to 
be rifampicin resistant and is concordant with the other studies as described 
above. 
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Chapter 7 Final Discussion   
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7.1 Introduction 
Control of tuberculosis in high burden countries is of paramount importance 
for a global TB prevention strategy to be successful. India and China, along 
with Indonesia, account for 45% of the new TB cases according to the global 
tuberculosis report by WHO (12). Despite recent advances in drug 
development and rapid diagnostic assays, the majority of TB diagnostic 
centres are still dependent on clinical diagnosis and interpretation of bacterial 
cultures to formulate the drug regimen and treat TB infection (12). 
7.2 Discussion of findings in this study 
The hypothesis of this research work is to substantiate the analysis of the 
position and copy number of IS6110, a bacterial transposon, as a genomic 
tool to characterise the TB genetic lineages from Nepal, one of the low and 
middle income countries. TB strain typing can support molecular 
epidemiological investigations in controlling onward transmission and 
outbreaks, by identifying patients who are linked in the same chain of TB 
transmission (PHE, 2014).  
7.2.1 Optimisation and Development of Insertion Element IS6110 
Fluorescent Amplified Fragment Length Polymorphism (FAFLP) 
PCR 
The main aim of this thesis was to develop a molecular tool box using IS6110 
FAFLP PCR that can characterise Mycobacterium tuberculosis complex 
strains genotypically and be used to understand the distribution and 
evolutionary relationships between different TB genetic lineages in resource 
poor settings in any geographical location. Various practical issues/artefacts 
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were addressed by using a recombinant Taq polymerase and by increasing 
the extension temperature from 60̊C to 72̊C and the extension time from 15 
minutes to 1 hour, as shown in chapter 3. The increase in extension 
temperature reduced mis-priming of the polymerase, producing cleaner, 
more discrete products for more effective downstream analysis. 
7.2.2 Mapping of Insertion sites (IS6110) in the M. tuberculosis H37Rv 
reference genome and rapid definition of genetic lineages 
(published work- (179)) 
To test the developed assay the reference TB genome H37Rv, was mapped 
in silico and the predicted fragment sizes compared with laboratory results. In 
this study laboratory results showed that sixteen IS6110 insertion sites were 
found in H37Rv (chapter 4 figure) using IS6110 FAFLP PCR, which 
correlates with the study by Philipp et al. in 1996 (187), who showed that 
H37Rv has sixteen IS6110 insertion sites by pulse field electrophoresis. 
Here, all sixteen fragments were identified using a fluorescently labelled dye 
as shown in table 4-2 in chapter 4, together with the position of in silico 
predicted insertion sites. 
The IS6110 insertions have predilection to insert into mainly the surface 
proteins PPE (560.4B in table 4-2), cutinase1 (71.5Y in table 4-2) and those 
affecting glycerol metabolism such as IS986 and integrase (table 4-2) which 
was recently shown in Roychowdhury’s study, where it is shown that the 
majority of the transpositions of IS6110 occur in the surface proteins 
especially the PE/ PPE family of proteins (74). IS6110 has been shown by 
Alonso et al. to upregulate downstream genes with the help of the promoter 
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at its 3’end (199). One of the important properties of IS6110 is that it carries a 
promoter element upstream of the coding region, which has the potential to 
up-regulate expression of downstream genes (74,199,200). In a recent study, 
178 unique genes belonging to mainly PPEs / transposases and 
oxidoreductases, were found to be carrying the IS6110 promoter element 
upstream of the coding regions (74). This study also found one instance of 
IS6110 insertion upstream of the trpD gene (ATP-binding cassette 
transporter), a metabolic enzyme essential for the bacterial survival in 
activated macrophages whilst colonising the lungs during infection (74,201). 
Further analysis revealed insertions in MDR-TB isolates, 75bp upstream of 
the phoP region (a transcriptional regulation factor), suggested to be 
necessary for M. tuberculosis virulence by Soto et al. in that the IS6110 
insertion upregulates the over expression of phoP gene in M. bovis B strains 
(200). IS6110 insertions have been found upstream of early secretory 
antigenic target protein 6 (ESAT-6) that has been linked with mycobacterial 
virulence (202). It has been suggested that ESAT-6 interacts with the host 
protein Beta 2 microglobulin (β2M), a serum protein found associated with 
Major Histocompatibility Complex-1 (MHC-1), thereby inhibiting the 
expression of β2M- MHC-1 and down regulating the antigen presentation 
function  of class I MHCs (202,203). The identification and confirmation of 
IS6110 insertions in silico into different genes like PPE, IS986, cutinase1, 
integrase, oxidoreductase and glycerolphosphodiesterase as shown in table 
4-2 in chapter 4, indicates that IS6110 transposition might play a role in the 
pathogenesis of TB as suggested by other groups and the work presented in 
this thesis supports that theory. 
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In addition to the insertions at different genes, common IS6110 insertion 
points or fragments occur between lineages but some of them are unique to 
specific lineages as shown in chapter 5 and reported earlier by Thorne et al. 
(135). In this study, it has been shown that there are common IS6110 
insertion points / fragments between isolates in one lineage, but not shared 
with other lineages (see table 5-1), for example Lineage 3, PGG1-CAS (78.4 
G, 92.0B, 117.9R, 206.2G, 275.1R) does not share the same fragments as 
Lineage 4, PGG2-Haarlem (87.0Y, 89.4G, 148.7B, 300.2R, 445.7Y) or 
PGG3-T (81.3R, 192.4R, 360.0R,) This work was published in 2016 (188) 
and is concordant with the earlier study by Thorne et al. In the major study by 
Roychowdhury et al., a computational pipeline was developed to analyse the 
insertion sites of 1377 whole genome sequenced M. tuberculosis isolates, 
representing the 7 major global lineages, from all publically available 
datasets. Using density distribution studies, they found that different lineages 
have different copy numbers and insertion points and these insertions are 
unique to particular lineages (74). This property was observed in this study 
prior to Roychowdhury et al., as shown in chapter 5, where common 
fragments occur between lineages, together with some unique fragments 
within lineages. Part of the work in this thesis was cited by Roychowdhury et 
al. as being the first to identify this. In the East Asian- (Lineage 2, PGG1- 
Beijing) and Indian-East African (Lineage 3, PGG1- CAS) lineages, there is a 
high level of conservation in insertion sites as well as noticeable differences. 
Lineage 2, PGG1-Beijing isolates have extra IS6110 insertions in regions like 
Rv0001-Rv0002, Rv1371 and idsB, involved in biosynthesis of membrane 
ether-linked lipids (199). In Lineage 3 isolates, there are unique intergenic 
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regions mapping to regions such as Rv0395, Rv1504c and Rv3845-3846 that 
are not present in L2 (74).  
Another point of discussion is whether the insertion sites of IS6110 occurs at 
insertional hotspots, i.e. independent insertion at the exact same point in 
different strains, with little or no phylogenetic signal, or inherited and 
relatively stable over time with significant phylogenetic signal. In this study, it 
was found that some Beijing strains have high copy numbers of IS6110 
whereas the others have low copy numbers as shown in appendix 2. It might 
be possible that the rate of transposition is high in some of the strains 
compared to the others as reported earlier by Dale et al. (107). This was not 
studied in this thesis but could be investigated in future works. It also has 
been shown by Dale et al., that these insertions of IS6110 do not occur at hot 
spots but the transposition of IS6110 is slow in low copy number strains than 
high copy strains (107). Roychowdhury et al supported the previous work of 
this thesis in that the IS6110 hotspots observed are unique insertions 
subsequently inherited by daughter strains showing vertical transmission 
within genetic lineages, and confirmed by WGS analysis.  
Following mapping of insertion sites, the IS6110 FAFLP assay paved the way 
to initiate the development of a rapid PCR assay that could identify the TB 
genetic lineages directly from DNA via identification of lineage specific 
IS6110 insertion points, without the need for performing FAFLP. This tool 
could rapidly assign lineages to the strain collection in any geographical 
setting with a basic PCR set up. The IS6110 FAFLP method, though 
relatively simple and robust, would still be challenging to implement in 
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settings with very poor resources, as the procedure has multiple steps, needs 
good quality DNA to be extracted from isolates, uses relatively expensive 
molecular biology reagents and equipment and also requires a cold chain 
infrastructure. The development of lineage specific PCR was important so 
that identification of genetic lineages directly from sputum samples would be 
possible (not tested in this project). This assay will not directly affect the 
treatment regimen of a patient but it will give an informed decision about the 
TB lineage prevalent and could help to direct the control measures for that 
particular lineage. It has been noticed that in certain regions like India, 
Pakistan, China, certain TB lineages (CAS-Delhi in India and Pakistan, 
Beijing in China) are more prevalent than other lineages (163,164) and does 
not necessarily correlate with the increased drug resistance patterns seen in 
these lineages (204) but could be to do with either a high density of human 
population in these areas (205) or the ineffective or mismanagement of the 
antibiotic usage in these countries (23). 
In chapter 4, isolates representative of PGG3 and PGG1 lineages were 
selected and tested. This PCR method with specific primers targeting unique 
IS6110 fragments was able to identify PGG3 and PGG1 genetic lineages, by 
detecting the unique 296bp product of PGG3 (360 R fragment inserted into 
oxidoreductase as shown in chapter 4, table 4-2) and a 200bp product of 
PGG1. Thus, the proof of principle was established and it would be useful to 
design PCRs to common fragments in the remaining lineages. 
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7.2.3 Classification of Nepalese TB clinical isolates into different TB 
genetic lineages (published work - (188)) 
The main function of this genomic tool is to characterise the TB strains 
studied into different TB genetic lineages from any geographical location. 
This technique was applied on readily available TB DNA samples from Nepal 
as shown in chapter 5 as there was limited or no information present on the 
genetic diversity of the circulating TB lineages in Nepal when this study 
started in 2011. However, a study published by Malla et al., in 2012, 
described the initial characterisation of these lineages and the importance of 
understanding their distribution in Nepal (191). Nepal’s position 
geographically, sharing its borders between India and China, also proved 
relevant as one third of the total human TB cases are from these two 
countries (23). This emphasised that Nepal’s location would have acted as a 
mixing pot for the strains originating from infections in India and China, 
reflected in our results in chapter 6 that 55% of the strains were either Beijing 
or CAS belonging to PGG1 group (188). 
The findings of this study corroborates Malla’s study (191) in that the majority 
of strains circulating in this geographical location in Nepal are from Lineages 
2 and 3, PGG1- CAS and Beijing. These strains are predominantly found in 
India (CAS) and China (Beijing). Migration of the human population carrying 
these strains from these countries would have settled in Nepal and mixed 
with the local population thereby passing on these successful TB lineages as 
discussed in chapter 5). In chapter 5, IS6110 FAFLP derived phylogeny also 
clearly demonstrates that in the majority of Nepalese TB patients, although 
usually infected with strains belonging to PGG1, can also be infected with a 
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range of genetic lineages. This scenario clearly shows that various TB 
genetic lineages have entered Nepal at some point of time and the most 
successful lineages among them are the Beijing and the CAS lineages. This 
again focuses the discussion on human migration between the open borders 
of India in the south and China in the north of Nepal. In Northern India, the 
CAS- Delhi lineages are commonly seen and in China, Beijing lineages are 
predominant and this is evident in this study too (163,164,190). In chapter 5, 
the distribution of Beijing and CAS lineages are shown as 18.8 % and 36.6% 
respectively as seen in table 5-1. The perfect scenario is being offered by 
Nepal for the adaptation of M. tuberculosis strains by means of human 
migration for the purposes of tourism, religious travel like the pilgrimage to 
the famous religious shrines, work, and also cheaper treatment facilities 
(190). 
In chapter 5, it was shown by IS6110 FAFLP that there are a high number of 
strains belonging to the CAS lineages compared to the Beijing lineages 
which was also the case in Malla’s study (191) where CAS lineages were 
more predominant than Beijing lineages. In Northern India, the predominant 
lineage seen is CAS and Beijing in China as shown in the figure 7-1 which 
shows that the geographical location of  Nepal has played an important role 
in the TB lineages’ distribution in Nepal (189), by being a perfect 
geographical location for the intermingling of different lineages from these 
two high burden countries. 
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Figure 7-1 A. Distribution of different TB lineages in Nepal from this study and B. the distribution of different lineages seen in India, China and 
other countries near the Indian subcontinent  
(this figure has been adapted from (189)). 
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7.2.4 Rifampicin Resistance status in Nepalese TB isolates from 
clinical samples (published work - (188,195). 
Finally, as shown in chapter 6 by the rpoB PCR assay, seven of the 176 
isolates were found to be likely resistant to rifampicin and all the seven 
mutations identified were in the RRDR region of rpoB. They were found to be 
non-synonymous thereby likely affecting the sensitivity of the strain. All 176 
isolates in this study were primary untreated cases and this incidence of 
resistance seemed to be higher (3.9%) than the average national average of 
new, untreated cases (2.2%) (173,188). However the result was concordant 
with the recent study by Creswell et al., that showed the resistance as 3.3% 
(198) by analysing the resistance patterns using GeneXpert MTB/RIF kits. 
Again the increase in drug resistant TB in Nepal is probably due to the 
increase in drug resistant strains in India and China. The most frequently 
mutated codon is 531 followed by 526, 522 and 516 (see table 6-1), as 
observed by Poudel et al in his study (190). In Northern India, it has been 
reported that the majority of rifampicin mutation occur at codon 531 situated 
in the RRDR region (53,206) which reinforces the fact that the movement of 
human population helps the transmission of TB (159). One drawback of this 
technique is that it tests resistance to rifampicin by analysis of mutation in the 
RRDR only, even though sequencing of this region of rpoB has been 
suggested as a surrogate marker for MDR (53,196,207,208), it will not pick 
up 100% of mutations associated with resistance to this drug. This strategy 
will not be as useful for successful treatment of the patients if they are multi-
resistant to other TB drugs and ideally the inclusion of a test to identify katG 
315, the marker most commonly associated with isoniazid resistance, and 
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other front line drugs, could also be included in a PCR screen for optimum 
assay sensitivity directly from samples. 
Nepal, the main setting of this study is no longer classified as a high burden 
TB country (172). However it is considered as a resource limited setting due 
to the poor infrastructure in remote villages and the lack of technologically 
advanced diagnostic assays and skilled labour for analysing the results, thus 
preventing routine molecular analysis. The priority of these settings is to 
identify tuberculosis infection by collecting samples for bacterial isolation and 
to inform treatment. The period of time taken to identify TB and start patient 
specific therapy is where these settings fail to keep up pace with a resourced 
setting. An assay such as IS6110 FAFLP PCR and, in particular the rapid 
PCR lineage detection method, although not a TB diagnostic test, could be 
useful to characterise TB isolates into different TB lineages directly from the 
clinical sample and thereby aid in contact tracing and indirectly in the control 
of outbreak. The resources needed are thermal cyclers, PCR reagents and 
trained staff for analysis and interpretation of results, which are already 
available in these settings. As contamination of cultures is potentially a major 
issue in outbreak investigation, the highly specific and sensitive nature of the 
assay could aid epidemiological investigations if implemented. The rapid 
PCR assay described in chapter 5 identifies lineage related strains and, with 
an expanded panel of PCRs for epidemiological investigations, control 
measures can be implemented within 2-3 days. If more information is needed 
on drug sensitivity then additional tests could also be added to this assay. 
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Novel diagnostic methods and assays are always needed for the effective 
and timely treatment of tuberculosis in resource limited settings. As the 
expenses incurred by the patients and their families accounted to 53% of 
annual household income per capita (209), the treatment of TB patients 
becomes extremely challenging in low income/high burden TB countries. 
Different technologies evolved during the timeframe of this thesis work. WGS 
can now be performed relatively easily in high resource settings. Within a 
short period of time, strains could be identified and characterised using NGS 
technologies. In terms of rapid diagnosis however no other technology apart 
from single molecule WGS has shown promise in this area. Oxford 
Nanopore’s MinION sequencing could sequence TB genomic DNA directly 
from samples following extraction and depletion of human DNA. Currently 
however there is still an issue with the cost and availability of this technique 
in resource limited settings (148). 
The advantages and disadvantages of the IS6110 FAFLP genomic tool are 
summarised in the table 7-1. 
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Table 7-1 Brief summary of the advantages and disadvantages of IS6110 FAFLP 
Advantages Disadvantages 
High resolution marker and precise 
as 0.5bp difference can be a different 
lineage or strain (116.R is CAS and 
117.1 R is Haarlem- table 5-1 and 
figure 5-1) 
Difficult to characterise strains with 
less than 5 IS6110 copies as shown 
in table 5-1 and figure 5-1 in chapter 
5 where nearly 24% of the Nepalese 
samples were ungrouped and 
warrants another high resolution 
marker like MIRU-VNTR. 
Simple, reproducible and robust 
technique than RFLP. 
Although more rapid than RFLP, it 
can take up to several days to 
perform the technique, get the results 
and analyse them but the rapid 
lineage specific PCR described in 
chapter 4 overcomes this and the 
requirement for multiple enzymatic 
steps on extracted DNA from 
cultures. 
Variations of the assay can suit both 
a high throughput modern lab and a 
resource poor setting depending on 
the equipment available 
Basic equipment like PCR machines, 
heat blocks, gel electrophoresis and 
centrifuges are still needed, even if 
rapid tests are employed. 
Continuous screening of the samples 
using the technique would aid 
contact tracing for immediate 
epidemiological intervention 
Additional sequencing or other 
mutational studies like the rpoB PCR 
assay used in chapter 6 needed as 
this study does not detect any 
mutational changes like SNP. 
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7.3 Future work 
A full toolbox of lineage specific PCRs could be developed and multiplex 
panels created. WGS may offer more information regarding the biological 
impact of IS6110 insertion. Some insertion sites have remained in lineages 
for thousands of years and it is likely that they may confer a biological 
advantage. Knowing that they are present in specific locations could inform 
disease progression or pathogenicity in certain demographic groups. 
Characterisation of these and development of rapid PCRs will be useful for 
intervention. In terms of Nepal’s story, it would be interesting to study the 
pattern of resistance in Nepal’s TB strains and compare the resistance 
between the bordering countries. This will help in understanding the 
measures taken by the organism in developing resistance in a new niche. 
Also, it would be important to study the effect of different IS6110 copy 
numbers in different TB lineages and their pathogenicity and if there is a 
relation between the two concepts. 
7.4 Summary 
The findings of all chapters have been summarised and tabulated below in 
table 7-2. 
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Table 7-2 Summary of the results from all chapters in this thesis 
Chapter Headings Aims Approach Main Findings Page 
Numbers 
1. Introduction To set the scene for the 
thesis work 
Extensive review of the 
literature 
-Several epidemiological and 
genetic markers available to 
type TB. 
-Among others, IS6110 found 
to contain phylogenetic signal 
and could therefore be used 
to develop a genomic tool 
box for resource poor 
settings. 
1-62 
2. General Materials and 
Methods 
To document the 
standard methods used 
throughout the thesis. 
Systematic approach from 
conception of idea, followed 
by development and 
implementation of the 
methods to achieve the 
IS6110 FAFLP PCR method 
using specific primers found 
to be the principal tool used 
in the project. 
63-72 
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primary aim of the project. 
3. Optimisation and 
Development of IS6110 
FAFLP PCR 
To develop and 
standardise IS6110 
FAFLP PCR that is both 
sensitive and specific. 
Test the samples using 
different conditions and 
reagents to achieve the 
desired result. 
The method was 
standardised and was ready 
to be validated. 
73-91 
4. Mapping of Insertion 
sites (IS6110) in the M. 
tuberculosis H37Rv 
reference genome and 
rapid definition of genetic 
lineage 
- To prove that IS6110 
FAFLP PCR is accurate 
and could map insertion 
sites in the completely 
sequenced H37Rv 
strain. 
- To achieve the aim of 
developing a rapid 
lineage specific PCR 
- H37Rv was subjected to 
IS6110 FAFLP and then 
insertion sites were mapped 
using two base selective 
primers. 
- Primers designed for the 
PGG1 and PGG3 strains 
were used in PCR reactions 
and tested for specificity 
- Sixteen insertion sites were 
mapped onto the H37Rv 
genome, thereby proving the 
accuracy of the technique. 
- Proof of principle was 
established by detecting 
100bp and 296bp products 
specific for PGG1 and PGG3 
groups respectively 
92-107 
(published) 
(179) 
 
 
. 
5. Classification of 
Nepalese TB clinical 
To characterise the TB 
strains from Nepal, a 
Bacterial DNA from all 176 TB 
isolates was subjected to 
-All 176 isolates were 
delineated into different TB 
108-118 
(published) 
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isolates into different TB 
genetic lineages 
resource poor setting, 
using IS6110 FAFLP 
PCR. 
IS6110 FAFLP PCR and then 
characterised using 
BioNumerics software. 
genetic lineages. 
-55% of the strains belonged 
to PGG1 group, either Beijing 
or CAS strains. 
(188) 
6. Rifampicin Resistance 
status in Nepalese TB 
isolates from clinical 
samples 
To infer the drug-
resistance status in the 
Nepalese TB samples. 
Using rpoB resistant PCR, all 
176 samples were checked 
for inferred drug-resistance by 
observing the mutations in the 
RRDR region of the rpoB 
gene. 
-Seven isolates were found to 
have mutations at the 
normally reported mutation 
sites. 
-3.9% of the strains were 
found to be MDR-TB  
-Prevalence of MDR-TB is 
high  
- Results concordant with 
previously published results 
119-125 
(published) 
(188,195) 
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7. Final Discussion To contextualise the 
results obtained and 
make judgement of the 
aims of the thesis. 
Summarise the results 
obtained and discuss the 
relevance of the results with 
respect to the aim and 
objectives of the thesis. 
-Summarised the results of 
all the chapters. 
-Discussion of different 
results sections in detail. 
-Showed the efficacy of the 
IS6110 FAFLP PCR assay as 
a genomic tool in a resource 
poor setting. 
126-146 
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7.5 Conclusions 
The aim of this thesis was to develop a genomic mapping tool using IS6110 
FAFLP that could be used in resource poor settings as an assay for the 
characterisation of M. tuberculosis strains. This aim was achieved by first 
optimising the assay (chapter 3), testing it on H37Rv (chapter 4) by mapping 
the IS6110 insertion sites followed by the delineation of Nepalese TB strains 
into different TB lineages as shown  in chapter 5.  The IS6110 FAFLP PCR 
data led to the development of the rapid lineage specific PCR assay (chapter 
4) that can identify the circulating TB genotypes in a specific geographic 
area. Though a rapid PCR assay was not developed for all the lineages or 
genotypes, the proof of principle was established by the identification of 
PGG1 and PGG3 strains. This work has successfully developed a simple, 
rapid and robust method to characterise different strains of M. tuberculosis 
complex that could aid and inform epidemiological investigation and 
intervention that could be used in resource poor settings. 
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Appendices 
Appendix 1. Sequences (genes of interest, see Table 4-1) using the 
DNASTAR Lasergene8 software where the IS6110 insertion flanks 
the genome 
1. IS6110 Sequence orientation per se in the whole genome: 
a) 1543249 to 1543307(58bp) to next TaqI site 
CCGCGCCGGCTGGCAACCGTTCCCGCT (27bp) ~102bp 
b) 1989000 to 1989058 (58bp) to next TaqI site 
AGAGGACTTCAT (12bp) ~87bp  
c) 2431414 to 2431472 (58bp) to next TaqI site 
GGGCTTCCCGAGACTGCGATTCCCAAACGATGACGCCCAAACAAAAAGCGGGA
CCGCCGATGGCTGCCCCGCTGCCGCTGGTTGCGTTCGGCTTACTCGT 
(100bp) ~ 175bp 
d) 3121821- 3121879 (58bp) to next TaqI site 
GTTTTGGGTCTGACGACTCGCGGCGAGCACGTCTCACCCAGCAGGCGGTGAG
GTTGGGTTTCCGTCCCCTCTCGGGGTTTTGGGTCTGACGACACGGACGAGCTG
GACCGCATCAGCGATGCTGAGCTGAGGGTTTCCGTCCCCTCTCGGGGTTTTGG
GTCTGACGACTTGTCTCAATCGTGCCGTCTGCGGTGACACGCTCCAAGTTTCC
GTCCCCTCTCGGGGTTTTGGGTCTGACGACCACCAGGATCAGCGCCAAGCCA
GTTAGCGCAATCCAGTTTCCGTCCCCTCTCGGGGTTTTGGGTCTGACGACCTC
CCGGACCATCTGCAGCTCGCCCGGGTCCATGCGGTTTCCGTCCCCTCTCGGG
GTTTTGGGTCTGACGACCGGAGTCATCCGCGCGGGCCGGCGCGATTGTTGCC
GGGTTTCCGTCCCCTCTCGGGGTTTTGGGTCTGACGACTGGCGATTTACGACG
CTGACGGGAACTCGTGCGAATGTTTCCGTCCCCTCTCGGGGTTTTGGGTCTGA
TCCGCGAAATTCACTGCGCGTTATTCAAGGTTTCCGTCCCCTCTCGGGGTTTTG
182 
 
GGTCTGACGACCCGAGCCGACCATCCGCATCACACCGAAAGGGTTGGCGCAA
GTTTCCGTCCCCTCTCGGGGTTTTGGGTCTGACGACACGTGGGGAGAGGGAAT
GGCAATGATGGT (697bp) ~772bp 
2. Reverse Complement of the whole genome and the IS6110 
Sequence orientation per se: 
a) 520697 to 520755 (58bp) to next TaqI site 
TCCGTATCGTCGCCGACCGCTTGGGAGACCCGCGAGCGCGTGCCGTGGTGTT
CTTGCATGGCGGTGGACAGACGCGACGCTCATGGGGTCGGGCCGCAGCCGCT
GTCGCCGAACGTGGCTGGCAAGCGGTCACGAT (136bp~201bp 
b) 701094 to 701152 (58bp) to next TaqI site 
TGTCCATAACAAGCGGTCGGTGCGGTTGACTTGTTGGACGCGCCAGATGCACT
GTTTGACTCGCGT (66bp) ~141bp 
c) 1775899 to 1775957 (58bp) to next TaqI site 
AAACTTCGGTAGCCAAAACCTGGGTAGCGGCAACATCGGCAGCACCAACGTGG
GCAGCGGCAACATCGGCAGCACCAACGTGGGCAGCGGCAACATCGGCGACAC
GAACTTCGGTAACGGAAACAACGGCAACTTCAACTTTGGTAGCGGCAATACCG
GCAGTAACAACATCGGCTTCGGAAACACCGGCAGCGGGAATTTCGGTTTCGGA
AACACGGGCAACAACAACATCGGTATCGGGCTCACCGGCGATGGTCAGATCG
GCATCGGCGGACTGAACTCGGGCAGCGGAAACATCGGTTTCGGGAACTCCGG
CACCGGAAACGTCGGTTTGTTCAACTCCGGCACCGGCAACGTAGGCTTCGGGA
ACTCCGGTACTGCGAACACTGGATTCGGGAACGCGGGCAACGTCAACACCGG
ATTTTGGAACGGCGGCAGCACAAACACTGGCCTCGCTAACGCCGGCGCCGGC
AACACAGGCTTTTT (486bp) ~561bp 
d) 2415375 to 2415433 (58bp) to next TaqI site 
GTTGCCGACCTTTGTCCTGTTGATCCTGTTGGCGGCGGTGACTGCCGTCTACG
183 
 
CACTACGCGGCGCGTTACGCGCTGCCACCTCACTCATGCGCGGCCGGCGCGG
TGCCGACCGGTAGCGT (121bp) ~196bp 
3. IS6110 Sequence orientation per se in the whole genome 
(terminal G replaced) 
a) 2785912 to 2785969 (58bp) to next TaqI site 
Too short to be seen in vitro 
b) 3796355 to 3796412 (58bp) to next TaqI site 
AATCAAGTCCCCGCGTCCGTTGCGAATCGTGGTTGTCATTGCGCGCGAACCTG
TTTGGGAAGGCCGAATCGCACCGTCTCGGTCGCTAT (89bp) ~164bp 
4. Reverse Complement of the whole genome and the IS6110 
Sequence orientation per se (terminal G replaced) 
a) 858763 to 858820 (58 bases) to next TaqI site 
AATCCGTACAACCGCGACGCGGCGGAACAGGCTGGACGGCGGAATAGAGGCT
GATCTGGACGTATGAGACCGACCGCGATGGGAGAGATTGCGACTGGTTAGCTC
ATAACCCAGAGGTCGCAGGTTCGTGAACCGCCCCGGTGAGTCCGGAGACTCT
CTGATCTGAGACCTCAGCCGGCGGCTGGTCTCTGGCGTTGAGCGTAGTAGGC
AGCCT (214bp) ~289bp 
b)         b) 1439367 to 1439424 (58bp) to next TaqI site 
GAAGATGAGCTGCGCAAGCGTGGACGTGAGCGTCGCCCGTTGGACAAGTTGC
CGCCGGGGCCCATCCCGGGCACCGGCGGTCAGCCGCTCCAACCGTTTAAACC
ATCCCGGTAGCCAGCTTCGCTGCGGGTTGCGTTGT (139bp) ~214bp 
c) 1861462 to 1861519 (58 bases) to next TaqI site 
GGTGGCGCTGGTGATCGCCTTGGGAGGGACTTGCGGTGTGGCGGATGCTTTG
CCGCTGGGCCAGACTGACGACCCGATGATTGTCGCGCATCGCGCGGGTACGC
184 
 
GCGATTTTCCCGAGAACACCGTTCTGGCGATTACCAACGCAGTCGCAGCTGGT
GTGGATGGCATGTGGCTGACCGTCCAGGTCAGCAGCGATGGCGTGCCGGTGC
TGTATCGTCCGTCCGATCTGGCAACGTTGACCGACGGCGCCGGCCCGGTGAA
TT (263bp) ~338bp 
d) 2046062 to 2046119 (58 bases) to next TaqI site 
CGCGCGGCTACAAAAAAGCTTGTATCACTAGCTAGAGTGGAGTCGGTTTGCT 
(52bp) ~127bp 
e) 3522455 to 3522512 (58 bases) to next TaqI site 
CCTCCTTCACTTGAGGGGGTGTTGAGGTTGGGCCGGTCGGCGGACACATCTC
AGTCGGGGCGAAAGCCACGCTCCTATCAAGTCACGCCGGCCGGTCCTTCTCA
CCTAGTGCCGGCAATACTGCTCAACGCCAACCCCAAGAGGACGGCAGACGCA
AAGTGAGCCAGACACCAGGTGATCCGGAACAAACCACCGCGACACGGCGTCT
GTCACACCGACACACCCACCTCGCGGCACACACAACACCGACACTGAGACATA
AAGGTCCCTTTTCGCACGGCGTGT (285bp) ~360bp 
185 
 
Appendix 2: Nepal strains 
N1-N176 
Each strain has a list of fragments that are generated from differing insertion points of the IS6110 element. Each fragment is listed 
as a size in base pairs and can be one of four colours, R = red, B = blue, G = green and Y = yellow. For example 80.4Y is an 80.0 
base pair fragment which is yellow. 
If two strains share an identical IS6110 insertion site then they will each possess a fragment of the EXACT same size and colour. 
For example, below N36 and N34 share most of the same fragments, including: 81.0B, 100.0G, 124.9G, 140.4R, 197.2B, 207.1Y, 
264.2G, 360.0R, 401.5B and 560.4B. The majority of these fragments are also shared by H37Rv and H37Ra but not all (i.e. they 
are not identical but very similar). 
Unassigned 
N102 
84.4R, 106.6G, 312.8G 
N107 
186 
 
84.4R, 106.6G, 312.8G 
N104 
84.4R, 106.6G, 312.8G 
N25 
178.1R, 237.8 G, 300.8G 
N62 
74.9Y, 78.2R 
 
PGG3 T group (H37Rv-like) 
N108 
88.9Y, 106.2G, 179.1B, 183.6R, 254.3Y, 301.5G, 312.2G, 360.0R, 443.1R 
187 
 
N36 
80.4Y, 81.0B, 83.8Y, 100.0G, 124.9G, 140.4R, 193.2R, 197.2B, 207.1Y, 264.2G, 360.0R, 401.5B, 560.4B 
N34 
81.0B, 100.0G, 124.9G, 139.1R, 140.4R, 192.4R, 197.2B, 207.1Y, 264.2G, 360.0R, 401.5B, 560.4B 
N163 
81.0B, 83.61Y, 99.4G, 119.54G, 137.58Y, 139.91R, 193.44R, 197.6B, 207.14Y, 264.24G, 312.29G, 360.71R, 561.33B 
CAS group 
N103 
78.4G, 88.2R, 92.0B, 93.5B, 114.3Y, 127.7R, 148.4R, 207.1G, 249.6G, 275.1R, 394.7R, 434.3R 
N101 
74.4G, 92.0B, 115.6B, 116.8G, 123.9B, 127.7R, 136.0Y, 157.8G, 275.1R, 316.4R, 432.9R 
188 
 
N116 
106.6G, 116.8G, 117.9R, 127.7R, 206.5G, 244.7R, 275.1R, 286.9G, 394.7R, 433.6R 
N109 
92.0B, 116.1Y, 117.9R, 171.9R, 195.8R, 206.2G, 263.2B, 268.3R, 275.1R, 341.4G, 434.3R, 461.1G 
N111 
84.4R, 106.6G, 121.6B, 142.0B, 142.5Y, 145.1R, 147.6B, 159.5Y, 186.4B, 194.2R, 240.9Y, 285.6B, 312.2G, 326.4Y 
N113 
77.3R, 83.5G, 87.0Y, 96.7B, 97.8G, 100.8R, 105.5R, 112.4G, 124.0R, 127.1R 133.7R, 169.7Y, 176.8Y, 220.5B, 320.5R, 376.5R, 
432.9R 
N114 
84.9B, 102.1B, 102.5Y, 112.4G, 127.1R, 139.5R, 158.5Y, 181.2Y, 248.3R, 255.3G, 334.9R, 354.3B, 461.1G 
189 
 
N12 
74.4G, 92.0B, 111.4G, 117.9R, 127.7R, 131.2Y, 170.7R, 206.2G, 232.3R, 275.1R, 393.0R, 432.9R, 560.0G 
N50 
78.4G, 92.0B, 117.9R, 127.7R, 131.2Y, 178.1R, 206.2G, 275.1R, 321.6R, 393.0R, 432.9R, 560.0G 
N73 
77.3G, 86.1G, 92.0B, 117.9R, 127.7R, 206.2G, 275.1R, 393.0R, 432.9R, 493.1G,  
N36 
78.4G, 83.3R, 92.0B, 127.7R, 188.9Y, 192.8R, 198.3B, 206.2G, 275.1R, 324.7G, 393.0R, 432.9R, 
N37 
78.4G, 92.0B, 117.9R, 127.7R, 206.2G, 275.1R, 393.0R, 432.9R, 
N67 
190 
 
78.4G, 92.0B, 117.9R, 127.7R, 142.6R, 150.8R, 206.2G, 275.1R, 316.4R, 318.7Y, 393.0R, 432.9R, 493.1G,  
N68 
77.3G, 92.0B, 117.9R, 127.7R, 142.6R, 150.8R, 206.2G, 275.1R, 316.4R, 318.7Y, 393.0R, 432.9R, 
N7 
77.3G, 92.0B, 106.6G, 117.9R, 127.7R, 131.1G, 150.8R, 206.2G, 247.3R, 275.1R, 316.4R, 393.0R, 432.9R, 
N18 
74.4G, 78.4G, 92.0B, 127.7R, 150.8R, 157.8G, 178.1R, 178.2Y, 206.2G, 229.5R, 275.1R, 316.4R, 321.6R, 393.0R, 432.9R, 778B 
N17 
78.4G, 92.0B, 115.6B, 116.8G, 127.7R, 136.0Y, 157.8G, 275.1R, 316.4R, 393.0R, 432.9R, 
N10 
74.4G, 92.0B, 127.7R, 149.4Y, 150.8R, 206.2G, 230.1Y, 247.3R, 275.1R, 316.4R, 379.7R, 393.0R, 432.9R, 
191 
 
N72 
78.4G, 92.0B, 127.7R, 149.4Y, 150.8R, 206.2G, 230.1Y, 247.3R, 275.1R, 316.4R, 379.7R, 393.0R, 432.9R, 
N19 
78.4G, 92.0B, 96.2R, 114.5B, 127.7R, 136.0Y, 148.0Y, 150.8R, 171.9R, 206.2G, 275.1R, 316.4R, 393.0R, 432.9R, 
N6 
77.3G, 88.2R, 92.0B, 93.5B, 114.3Y, 117.9R, 127.7R, 148.4R, 206.2G, 275.1R, 328.4G, 393.0R, 432.9R, 455.9G,  
N3 
77.3G, 88.2R, 92.0B, 93.5B, 114.3Y, 117.9R, 127.7R, 148.4R, 206.2G, 275.1R, 393.0R, 455.9G, 
N91 
78.4G, 88.2R, 92.0B, 93.5B, 114.3Y, 117.9R, 127.7R, 138.9G, 206.2G,299.2Y, 
N5 
192 
 
78.4G, 92.7B, 101.5Y, 107.1R, 116.7R, 117.9R, 183.8G, 206.2G, 251.8R, 275.1R, 321.6R, 393.0R, 432.9R, 
N56 
92.0B, 117.9R, 160.3Y, 206.2G, 318.0B, 352.9G, 393.0R, 432.9R, 
N65 
77.3G, 92.0B, 101.2B, 129.8G, 132.0R, 305.9R, 352.9G, 393.0R, 432.9R, 
N29 
78.4G, 81.0B, 92.0B, 100.5Y, 117.9R, 127.7R, 194.2R, 354.2Y,  
N69 
78.4G, 81.0B, 92.0B, 100.5Y, 117.9R, 127.7R, 194.2R, 266.1G, 275.1R, 310.6B, 316.5B, 353.7Y, 393.0R, 494.3B,  
N48 
94.8B, 117.9R, 275.1R, 296.9Y, 297.4R, 302.4G, 393.0R, 432.9R, 437.5B,  
193 
 
N58 
94.8B, 117.9R, 275.1R, 296.9Y, 297.4R, 302.4G, 393.0R, 432.9R, 437.5B, 
N54 
78.4G, 81.7Y, 91.0R, 92.0B, 107.5Y, 112.4G, 127.7R, 142.6R, 150.8R, 216.3R, 318.7Y, 393.0R, 
N81 
78.4G, 81.7Y, 91.0R, 92.0B, 107.5Y, 114.3Y, 127.7R, 142.6R, 150.8R, 318.7Y, 345.5R,  
N28 
78.4G, 92.0B, 129.8G, 136.1G, 206.2G, 275.1R, 283.0R, 303.3G, 354.0G, 393.0R, 432.9R, 565.5R,  
N93 
78.4G, 92.0B, 122.8B, 136.1G, 176.8Y, 185.3G, 187.0Y, 275.1R, 393.0R, 432.9R, 563.6R 
N26 
194 
 
73.4Y, 78.4G, 79.0Y, 79.4G, 87.4R, 127.7R, 206.2G, 239.3G, 256.2B, 275.1R, 321.6R, 393.0R, 432.9R, 445.3G, 868Y 
N32 
78.4G, 79.0Y, 92.0B, 127.7R, 206.2G, 239.3G, 256.2B, 273.1Y, 275.1R, 321.6R, 393.0R, 432.9R, 868Y 
N45 
87.3Y, 92.0B, 93.0G, 94.5R, 118.0G, 127.7R, 156.0Y, 206.5R, 279.5Y, 393.0R, 432.9R, 
N75 
92.0B, 115.6B, 116.8G, 127.7R, 135.9R, 151.4R, 275.1R, 317.0R, 370.5G, 393.0R, 432.9R, 461.1G,  
N61 
94.8B, 129.8G, 160.3Y, 206.2G, 275.1R, 318.0B, 353.5G, 393.0R, 432.9R, 
N78 
91.5G, 100.3R, 120.0R, 132.2Y, 152.4R, 173.2B, 206.2G, 275.1R, 317.0R, 351.9R, 393.0R, 432.9R, 
195 
 
N51 
92.0B, 93.0G, 206.5G, 593.2G 
N124 
78.21G, 84.4R, 93.09G, 96.01R, 124.97Y, 127.59R, 139.5678.21G, 84.4R, 93.09G, 96.01R, 124.97Y, 127.59R, 139.56Y, 206.16G, 
256.05Y, 275.31R, 316.82R, 326.61R, 433.6R, 445.51R 
N135 
78.25G, 83.63Y, 87.15R, 130.04G, 133.82R, 136.22Y, 138.89R, 155.07R, 167.53Y, 206.67G, 261.98B, 275.49R, 354.6G, 394.57R, 
434.01R, 450.43R 
N138 
78.15G, 92.07B, 101.69B, 115.49G, 129.93G, 306.59R, 353.9G, 394.41G, 433.88R 
N139 
78.07G, 115.02G, 129.43G, 203.71G, 305.58R, 309.28G, 352.67G, 393.1R 
196 
 
N140 
78.15G, 88.2Y, 91.65R, 95.98R, 101.58B, 110.94B, 115.58G, 129.99G, 266.22G, 274.13G, 306.57R, 353.84G, 394.28R, 433.81R 
N141 
84.48R, 86.86Y, 89.24G, 92.51R, 106.18G, 128.76G, 191.13G, 194.09R, 255.86R, 333.21G, 431.28R 
N143 
78.24G, 92.13B, 101.68B, 124.35G, 129.99G, 306.74R, 331.35G, 354.06G, 394.66R, 434.09R 
N144 
78.14G, 93.22G, 101.69B, 130.09G, 144.17G, 306.74R, 354.05G, 394.66R, 434R 
, N145, N146, N148, N155, N158, N161, N165, N167, N168, N173, N174, N176 
Haarlem 
N39 
197 
 
87.0Y, 148.7B, 149.6G, 151.4R, 224.3G, 265.6B, 300.2R, 311.0G, 445.7Y, 
N87 
87.0Y, 116.1R, 148.7B, 151.4R, 224.3G, 265.6B, 300.2R, 311.0G, 445.7Y, 787.0B 
 N110 
87.0Y, 116.1R, 148.7B, 151.4R, 167.7G, 177.5R, 224.3G, 265.6B, 301.1R, 312.2G, 446.6Y, 787.0B 
N106 
87.3Y, 89.2B, 124.0R, 149.1B, 194.2R, 224.3G, 266.1B, 301.1R, 312.8G, 446.6Y 
N137, N152, N153, N157, n160 
 
X group 
N27 
198 
 
311.0G, 300.2R 
N77 
80.4Y, 83.7Y, 301.1R 311.0G 
N42 
80.4Y, 83.7Y, 148.4R, 301.1R, 410.3R 
N129 
 
LAM group 
N53 
71.5Y, 96.7B, 105.2R, 116.1R, 121.2R, 161.2B, 164.6Y, 338.6Y, 441.9Y 
N64 
199 
 
88.6G, 96.7B, 102.4G, 105.2R, 116.1R, 136.9Y, 227.5R, 431.9R, 444.1Y,  
N9 
71.5Y, 96.7B, 103.0B, 105.2R, 191.3G, 198.6R, 256.5R, 333.9G, 431.9R, 463.2R, 606.6B 
N127 
 
Beijing 
N115 
84.5Y, 95.7Y, 101.7B, 102.5Y, 112.4G, 115.6B, 127.1R, 139.1R, 180.7Y, 195.1Y, 199.5B, 254.8G, 334.9R, 354.3B, 389.8Y, 
461.1G 
 
N24 
200 
 
84.5Y, 95.7Y, 101.7B, 102.5Y, 103.0B, 112.4G, 127.1R, 131.2Y, 139.1R, 180.7Y, 234.8G, 254.8G, 265.7G, 309.9R, 332.4R, 
353.5B, 389.8Y, 433.6B,  
N8 
80.0R, 84.5Y, 95.7Y, 101.2B, 102.5Y, 112.4G, 127.1R, 139.1R, 180.3R, 254.8G, 265.1G, 309.9R, 332.4R, 353.5B, 389.8Y, 432.7B, 
458.8G,  
N23 
84.5Y, 95.7Y, 101.7B, 102.5Y, 112.4G, 127.1R, 135.5G, 139.1R, 140.7R, 180.7Y, 254.8G, 332.4R, 353.5B, 389.8Y, 433.6B, 
460.3G,  
N70 
84.5Y, 93.5B, 95.7Y, 101.7B, 102.5Y, 112.4G, 127.1R, 139.1R, 147.7Y, 180.7Y, 201.1G, 254.8G, 266.1G, 309.9R, 332.4R, 353.5B, 
389.8Y, 433.6B, 460.3G, 
N40 
201 
 
84.5Y, 95.7Y, 101.7B, 102.5Y, 112.4G, 115.5B, 127.1R, 139.1R, 180.7Y, 254.8G, 265.7G, 309.9R, 332.4R, 353.5B, 389.8Y, 
433.6B, 460.3G,  
N33 
84.5Y, 95.7Y, 101.7B, 102.5Y, 112.4G, 127.1R, 139.1R, 180.7Y, 309.9R, 332.4R, 353.5B 
N82 
84.5Y, 95.7Y, 101.7B, 102.5Y, 112.4G, 127.1R, 135.5G, 139.1R, 140.7R, 180.7Y, 254.8G, 332.4R, 333.5R, 353.5B, 389.8Y, 
433.6B, 460.3G,  
N35 
84.5Y, 95.7Y, 101.7B, 102.5Y, 112.4G, 127.1R, 139.1R, 180.7Y, 246.5B, 254.8G, 266.1G, 309.9R, 332.4R, 353.5B, 389.8Y, 
433.6B, 460.3G 
 
N14 
202 
 
84.5Y, 95.7Y, 101.7B, 102.5Y, 107.5Y, 112.4G, 125.2Y, 127.1R, 139.1R, 180.7Y, 254.8G, 332.4R, 353.5B, 390.5Y, 434.5B, 
460.3G,  
N74 
84.5Y, 95.7Y, 101.7B, 112.4G, 127.1R, 139.1R, 180.7Y, 254.8G, 266.1G, 309.9R, 332.4R, 353.5B, 389.8Y, 433.6B, 460.3G, 
N76 
95.7Y, 101.7B, 112.4G, 114.9B, 127.1R, 139.1R, 181.2Y, 195.1Y, 253.2B, 254.8G, 266.1G, 332.4R, 309.9R, 353.5B, 389.8Y, 
433.6B, 460.3G,  
N90 
95.7Y, 101.7B, 112.4G, 127.1R, 139.1R, 181.2Y, 253.2B, 254.8G, 266.1G, 309.9R, 332.4R, 353.5B, 389.8Y, 433.6B, 460.3G,  
N47 
95.7Y, 101.7B, 112.4G, 127.1R, 129.8G, 182.8G, 254.8G, 353.5B, 433.6B, 460.3G,  
N55 
203 
 
95.7Y, 101.7B, 112.4G, 254.8G, 266.1G, 460.3G,  
N59 
95.7Y, 101.7B, 112.4G, 127.1R, 223.7G, 246.5B, 254.8G, 266.1G, 353.5B, 460.3G,  
N120, N125, N136, N130, N131, N132, N133, N134, N149, N151, N154, N175 
 
M. africanum 
N31 
87.1B, 88.6G, 134.7Y, 140.4R, 152.4R, 183.6R, 195.1R, 195.8R, 239.3Y, 287.2R, 302.5R, 598.0R 
N164 
 
PGG1 Outliers 
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N13 
87.4R, 90.2B, 95.6B, 96.4G, 187.2R, 219.8R, 311.0G, 374.6R, 445.3G,  
N20 
95.6B, 311.4G 
N21 
137.1R, 150.8G, 224.6R, 310.5G, 435.4Y 
N38 
107.3G, 117.8Y, 137.1R, 150.8G, 166.3R 
N22 
190.3R, 224.6R, 239.9B, 253.4G, 263.2G, 309.9G, 404.3G, 
N4 
205 
 
171.9B, 196.1G, 225.8Y, 253.4G, 262.7G, 272.7R, 308.7G, 356.4Y, 403.5G, 505.2Y,  
N121, N122, N123, N142, N150, N159, N162, N166, N169, N170, N171, N172 
206 
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Abstract
Nepal is geographically located between India and China, a region containing significant Tuberculosis (TB) and Multi-Drug Resistance (MDR-TB) burdens. 
However, limited information is available on the phylogenetic diversity of Mycobacterium tuberculosis (Mtb) in Nepal. To gain further insight into the diversity 
of Mtb in Nepal, consecutive clinical samples from 176 newly diagnosed pulmonary tuberculosis patients were collected from two hospitals in Nepal. Insertion Site 
IS6110 Fluorescent Amplified Fragment Length Polymorphism (FAFLP) PCR and rpoB sequence analysis were carried out on genomic DNA extracts of cultured 
strains to assign them to accepted genetic lineages and identify MDR-TB. In this study, the IS6110 based characterisation showed a prevalence of 36.36% Central 
Asian Strain (CAS), 18.75% Beijing, 7.95% Haarlem, 3.97% X, 2.2% each of Latin American Mediterranean (LAM), T-Uganda and T, 1.7% S and 24.4% were 
unassigned. Further, 3.9% of total M. tuberculosis isolates were of rifampicin resistant genotypes thus indicating that the prevalence of MDR could be higher than 
the country wide prevalence of MDR among new TB cases (2.2%) as reported by the national drug resistance survey carried out in 2011/2012.
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Introduction
TB is ranked as the sixth leading cause of death among the top 20 
causes of death in Nepal. According to National Tuberculosis Control 
Programme (NTCP) in Nepal, in 2014 37,025 TB cases were registered 
and among them 15,947 (43%) cases were new sputum smear positive 
TB cases. It was estimated by WHO [1] that 4.6 (2.1-7.5) thousand 
people in Nepal died from TB in 2014. Even though short course TB 
drug treatment regimen could cure around 89% of cases, TB mortality 
was still unacceptably high in Nepal. Since 2006, the STOP TB strategy 
has been adopted by NTCP. However Drug resistant TB (DR-TB) still 
threatens national TB control and is a major public health concern. The 
proportion of MDR-TB cases in new cases was 2.2% and retreatment 
cases were 15.4%. Even though the Millennium Development Goal 
(MDG) to halt and reverse TB incidence has been achieved in all six 
WHO regions, work remains to be done to prevent the deaths from this 
dreadful disease [1]. 
The identification of the number and position of Insertion 
Sequence IS6110 elements in the Mtb genome has been widely used as a 
genomic tool for the rapid fingerprinting of isolates of Mycobacterium 
tuberculosis complex (MTBC) [2]. IS6110 based Restriction Fragment 
Length Polymorphism (RFLP) is considered as the ‘gold standard’ 
typing method for strains with more than five copies [3-5]. As IS6110 
transposition is among the first genetic changes to occur in strains from 
a transmission chain [6], this marker has also been used for outbreak 
analysis [5]. 
Modification of the conventional IS6110 typing method, using 
differentially labelled primers has allowed characterisation of Mtb 
isolates into the key genetic lineages more rapidly than traditional 
methods [7]. This approach can be facilitated with automation, which 
enables this technique to be performed in a high throughput setting. 
The fragment patterns generated indicates both copy number and 
insertion site of IS6110 in the genome [8,9]. The patterns generated 
correlates directly with other independent markers and can be used 
for transmission investigation locally or internationally. Specific 
fragments are common in genetically related lineages and do not occur 
in other groups (e.g. spoligotype groups such as Beijing and the Euro-
American lineage which contain the Latin American Mediterranean 
(LAM), Haarlem, S, T and X spoligotype groups). The patterns 
generated correlate directly with other independent markers and can 
be used for transmission investigation locally/internationally. Principal 
Genetic Groups (PGGs) can be assigned to Mtb strains based on the 
combination of polymorphism located at katG codon463 and gyrA 
codon95 in the respective genomes [10] or spoligotypes [11] or global 
phylogeny classification based on whole genome sequences [12].
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Limited data are available on the characterisation of Mtb strains 
and genotypes circulating in Nepal. A key factor is the geographical 
location of Nepal, interlocked between China and India, two countries, 
which together account for approximately a third of annual global 
new cases (11% and 24%, respectively) [1]. A recent study of 261 
Nepalese isolates found any drug resistance (any drug resistance has 
been defined as resistance to isoniazid, rifampicin, streptomycin, 
ethambutol, fluoroquinolones, and/or aminoglycosides) in 12.8%% 
of Mtb strains that were new untreated cases, with the most frequent 
lineages reported as CAS/Delhi (40.6%), East Asian (including Beijing) 
(32.2%), Euro-American (15.7%) and Indo-oceanic (11.5%) [13]. To 
gain further insight into the characteristics and diversity of Mtb in 
Nepal, our study aimed to categorise isolates for the first time using 
IS6110 FAFLP PCR and to assign them to different genetic lineages. 
Secondly, the level of MDR would be characterized in the population 
using rpoB (rpoB gene encodes for the Beta subunit of bacterial RNA 
polymerase) sequencing of the Rifampicin Resistant Determining 
Region (RRDR) as a predictive surrogate [14-17].
Methods
Strains
Sputum samples from 176 consecutive new TB patients over one 
year were collected between 2007 and 2008 and cultured alongside 
routine diagnostics from two Nepalese tuberculosis reference centres 
located in the Kathmandu valley: the National Tuberculosis Centre 
(NTC) and the German Nepal Tuberculosis Project (GENETUP). The 
patient population represented local and referred cases from across 
Nepal. Bacterial genomic DNA from isolated strains was extracted by 
the Cetyltrimethylammonium Bromide (CTAB) method [18] at the 
Mycobacterial Research Laboratories (MRL) in Anandaban Hospital. 
Informed consent was not required at the time of this study, as samples 
were collected with routine clinical care and all patient identifiers were 
anonymized; however, all patients were provided an explanation and 
were only included upon provision of verbal informed consent. Study 
procedures were reviewed and approved by NTC and GENETUP. The 
results for the drug sensitivity tests were unavailable during the entire 
duration of this study.
IS6110 FAFLP PCR, Fragment Sizing and Analysis
Genomic DNA was digested with the restriction enzymes 
MseI and TaqI followed by ligation with double stranded TaqI 
restriction site specific adaptors. The adaptor ligated DNA was 
amplified following previously published PCR conditions using four 
fluorescently labelled adaptor specific TaqI forward primers - 5’- 
CGATGAGTCCTGACCGA*/C*/T*/G* each labelled with a single 
unique selective nucleotide at the 3’ end and an IS6110 sequence 
specific reverse primer- 5’- CTGACATGACCCCATCCTTT [9]. In a 
total volume of 20 µl, 1 µl of the adaptor ligated DNA was added to 
the reaction containing 1X reaction buffer, 1.5 mM MgCl2, 0.2 mM 
dNTPs (Invitrogen, UK) , 1 µM of labelled Taq I forward primer, 1 
µM of IS6110 reverse primer and 1 U of recombinant Taq polymerase 
(Invitrogen, UK). The following PCR conditions were carried out in 
a Veriti thermocycler (Applied Biosystems, UK): 94°C for 15min 
followed by 35 cycles of 94°C for 20s, 66°C for 30s and 72°C for 2 min 
with the 66°C annealing temperature reducing by 1°C every cycle for 
nine cycles and the last 25 cycles at 56°C. Finally, an extension of 72°C 
for 60min was carried out before further manipulations. The fragments 
were separated on an ABI genetic analyser 3730XL (Applied Biosystems, 
UK), sized using PeakScanner v1.0 software (Applied Biosystems) 
and identified using their fluorescent tag (Figure 1). The four-dye 
FAFLP data collected from the different profiles were then recorded 
and compared with a reference collection of Mtb isolates [19] using 
BioNumerics software v6.1 (Applied Maths Inc., Belgium). Fragments 
common to different lineages (defined as being present in >50% of 
strains in a particular genetic lineage) were recorded for each Nepalese 
strain and compared with a fully characterised global collection as 
detailed by Thorne et al. [20]. These data were then used to build a 
dendrogram using the Dice coefficient of similarities to compare the 
similarity matrix and Unweighted Pair Group Method with Arithmetic 
Mean (UPGMA) derived cluster analysis with cophenetic correlation 
for the branch quality. 
rpoB analysis
The 81 bp Rifampicin Resistant Determining Region (RRDR) of 
the rpoB gene of all strains were sequenced using published primers 
[21] and analysed in BIOEDIT software using ClustalW alignment 
parameters. The PCR was carried out in a total volume of 50 µl where 
1 µl of the DNA was added to the reaction containing 1xPCR reaction 
buffer, 1.5 mM MgCl2, 0.2 mM dNTPs (Invitrogen, UK), 20 µM each 
of both rpoB-RRDRforward (5’-CGATCACACCGCAGACGTTGA) 
and reverse primers (5’- GGCACGCTCACGTGACAGACC) and 5U 
recombinant Taq polymerase (Invitrogen, UK). The following PCR 
conditions were carried out using a Veriti thermocycler (Applied 
Biosystems, UK): 94°C for 2 min followed by 35 cycles of 94°C for 
30 sec, 60°C for 30 sec and 72°C for 1 min. Finally, an extension of 
72°C for 10 min was performed before cleaning the products using 
AmpureXP magnetic beads (Beckman Coulter, UK) according to the 
manufacturer’s protocol and sequencing using the forward primer, 
rpoB-RRDR forward.
 
Figure 1. Pictorial representation of the IS6110 FAFLP PCR methodology. Coloured fragments are amplified using uniquely labelled adapter specific primers. For example, blue coloured 
fragments are amplified if the primers are labelled with 6-FAM fluorescein ‘blue’ dye, red coloured fragments with PET dye, green coloured fragments with VIC dye and black coloured 
fragments with NED dye.
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Results 
Analysis of Data using BioNumerics software v6.1
Of the 176 DNA extracts from isolates analysed, the majority of the 
samples 97 (55.4%) belonged to either the spoligotype-defined Central 
Asian Strain (CAS) lineage (64 i.e., 36.6%) or the Beijing lineage (33 
i.e., 18.8%) grouping under PGG1 and the rest of the samples group 
under either PGG2 (1.7% S, 3.97% X, 7.95% Haarlem and 2.27% LAM, 
2.27% T-Uganda) or PGG3 (2.27% of T) (Table 1). Forty three samples 
(24.4%) grouped under “unassigned” group. Common fragments seen 
were exactly the same as the earlier published report by Thorne et al., 
(2011) except for an additional fragment, 78.4 G, for the CAS lineage. A 
dendrogram was generated using only the IS6110 FAFLP data (Figure 
2) confirming again the above mentioned lineages in relation to the 
PGGs.
rpoB Analysis
Of 176 DNA extracts analysed for rpoB mutations, seven samples 
(3.9%) had a single non-synonymous base change which would likely 
confer resistance to rifampicin (Table 2). Six of these seven samples 
showed a second base mutation in a codon triplet whereas sample N70 
showed a first base mutation. 
Discussion
It has been demonstrated previously that IS6110 FAFLP PCR 
can be used to delineate the phylogeny of MTBC as shared common 
fragments can determine the different lineages in a geographical 
location by comparison with a reference database collection [7]. As 
limited lineage information is available from strains in Nepal, we have 
applied the IS6110 method published recently on mapping the IS6110 
sites in H37Rv [9] and also carried out rpoB sequencing to further 
characterize strains from this important region.
Fifty five percent of the 176 Nepalese strains analysed belong to 
the CAS (36.6%) and Beijing (18.8%) modern genetic spoligotypes 
(PGG1). The remaining 24.4% of the samples belong to the PGG2 and 
PGG3 groups (Haarlem, LAM, S, X, T-Uganda and T). However, a 
limitation of this technique is its difficulty to characterise the samples 
with less than 4-5 copies of IS6110 as seen in the unassigned group 
(24.4%) in figure 2, which can be overcome by the use of other typing 
techniques like Mycobacterial Interspersed Repetitive Units- Variable 
Number Tandem Repeats (MIRU-VNTR) [20]. The geographical 
position of Nepal is likely to have influenced this distribution, with 
a mixture of predominantly Beijing lineage from the North of the 
Himalayas and the CAS lineage from the south [22]. The fairly high 
PGG /spoligotype/ sub-lineage Common fragment sizes No. Of Nepal strains 
PGG1-CAS 78.4G ,92.0B , 117.9R, 206.2G , 275.1R 64/176
PGG1-Beijing 101.7B, 102.5Y, 139.1R, 180.7Y, 254.8G, 332.4R, 353.5B 33/176
PGG2 –Haarlem 87.0Y, 89.4G, 148.7B, 300.2R (H/X), 445.7Y 14/ 176 
PGG2-LAM 71.5Y, 105.2R, 116.1R 4/ 176 
PGG2-S 88.0G, 112.9R, 217.2R, 445.3G 3/ 176 
PGG2-X 83.8Y, 300.2R(H/X) 7/ 176 
PGG2-T Uganda 88.9Y, 119.5G, 122.9Y, 228.4Y, 266.8R 4/ 176 
PGG3- T 81.3R, 192.4R, 360R 4/176 
Ungrouped 43/176
Where B-Blue coloured fragment R-Red coloured fragment G-Green coloured fragment and Y-Black/ Yellow coloured fragment seen in the electropherogram. PGG represents Principal 
Genetic groups according to Sreevatsan et al. [10], spoligotypes follow spolDB4 classification[4] and sub-lineages are grouped following Gagneux’s classification [8].
Table 1: Common fragments identified using IS6110 FAFLP PCR in TB genetic lineages between the 176 bacterial DNA isolates in Nepal.
Sample Mutated locus Nucleotide modification Amino acid modification FAFLP derived
1. N70 516 GAC > TAC (Asp>Tyr) PGG1- Beijing group
2. N10 522 TCG > TTG (Ser>Leu) PGG1- CAS group
3. N25 526 CAC > CTC (His>Leu) PGG3 -like
4. N63 526 CAC > CGC (His>Arg) PGG3-like
5. N34 531 TCG > TGG (Ser>Trp) PGG3- T group (H37Rv-like)
6. N46 531 TCG > TTG (Ser>Leu) PGG3 (H37Rv-like)
7. N62 531 TCG > TTG (Ser>Leu) Ungrouped
* PGG represents Principal Genetic Group.
Table 2: List of mutations seen in rpoB Rifampicin Resistance-Determining Region (RRDR) of rifampicin resistant M. tuberculosis isolates from Nepal.
 
Figure 2. UPGMA derived dendrogram showing the predominant genetic lineages / 
spoligotypes of 176 Nepalese Mtb isolates. 
Coloured branches represent Nepal samples following Gagneux’s global phylogeography 
of MTBC [12] and black branches represent the in-house global Mtb collection. PGG1 
outliers share one IS6110 copy with the PGG1 group. Those which contained one IS6110 
copy but could not be assigned to any group (unassigned group in the figure) are shown 
within the green box.
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percentage of mainly European lineages (Haarlem, LAM and T, 12.5%) 
indicates that there has also been mixing of the different lineages over 
an extended time and that European travellers/migrants to South East 
Asia and Nepal may have transmitted European strains to the local 
population. According to Malla et al. [13], fifty strains had any drug 
resistance and sixteen (6.1%) out of 261 isolates were MDR. Among 
the fifty any drug resistant strains, 29 cases were previously treated 
and twenty-one were new untreated cases (8.04% of 261 total strains 
and 12.8% of 164 new untreated cases). In this study, MDR-TB was 
tested by using rifampicin as the resistance marker and 7 isolates 
out of 176 were found (3.9%) from new untreated cases possessing 
drug resistance genotypes. However, their reported MDR percentage 
was based on the total number of isolates, of which 37.2% of isolates 
were from previously treated cases, which may enhance a probability 
of drug resistance development compared to untreated cases. Our 
results indicate that the prevalence of Rifampicin (RIF) resistant TB 
(surrogate marker for MDR) was higher than the nationally reported 
2.2% MDR in new untreated cases. Further, our results are concordant 
with a recently conducted study by Creswell et al. [23], where they have 
shown that the genotypic rifampicin resistance in newly diagnosed TB 
patients to be 3.3% in Nepal [23].
Conclusions
The IS6110 FAFLP data from our study reiterates the fact that the 
geographic location of Nepal is the key for the circulation of PGG1 
TB lineages, CAS and Beijing, which were predominant in India and 
China respectively. Further the RRDR study correlates with the recent 
work by Creswell et al. showing that prevalence of MDR-TB may 
be marginally higher than the national average in new untreated TB 
cases. As the monitoring of TB is important in Nepal, this simple and 
informative PCR-based molecular epidemiological technique would 
prove useful for the study of outbreaks of the disease and also to detect 
cross-contamination between different strains or isolates in resource 
poor settings.  The most common mutation site in the RRDR is at 
codon 531 and parallels the findings of earlier studies [21,22].
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Abstract
Molecular screening of new patients suspected for TB could help in the effective control of
TB in Pakistan as it is a high TB burden country. It will be informative to understand the prev-
alence of multi drug resistance for a better drug regimen management in this geographical
area. The Rifampicin resistance determining region (RRDR) sequencing was used to iden-
tify mutations associated with drug resistance in DNA extracts from 130 known multidrug
resistant (MDR) cultured strains and compared with mutations observed in DNA extracts
directly from 86 sputum samples from consecutive newly diagnosed cases in Lahore, Paki-
stan. These newly diagnosed samples were positive for smear microscopy, chest X-ray and
presumed sensitive to first line drugs. In the known MDR group the most frequent mutations
conferring resistance were found in rpoB531 (n = 51, 39.2%). In the newly diagnosed tuber-
culosis group with no history of MDR, mutations in rpoB531 were seen in 10 of the samples
(11.6%). Collectively, all mutations in the RRDR region studied were observed in 80
(61.5%) of known MDR cases and in 14 (16.3%) of the newly diagnosed cases. Using the
RRDR as a surrogate marker for MDR, sequences for the newly diagnosed (presumed sen-
sitive) group indicate much higher levels of MDR than the 3.9% WHO 2015 global estimate
and suggests that molecular screening directly from sputum is urgently required to effec-
tively address the detection and treatment gaps to combat MDR in this high burden country.
Introduction
Pakistan is among the top 20 countries with a high TB and MDR-TB burden [1]. Chest X-ray,
acid fast bacilli (AFB) smear microscopy and culture on Lowenstein-Jensen (LJ) media are the
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conventional methods of investigation for tuberculosis [2] but require additional analysis to
define the species of Mycobacteria as well as the mechanism of drug resistance. M. tuberculosis
drug resistance detection using conventional methods is by culture of bacilli on a medium
containing antibiotic and can require several weeks. However, with the development of rapid
molecular methods it is possible to detect mutations in genes associated with resistance in a
much shorter time [3]. Resistance to two first line predominant anti-TB drugs i.e., isoniazid
(INH) and rifampicin (RIF), is termed as ‘multidrug resistance tuberculosis’ [4]. Molecular
methods for this are diverse and each method has its benefits and drawbacks; for example
PCR-RFLP [5] and allele-specific PCR [6]. Several molecular techniques have been evolved to
detect the gene mutation related to resistance. These include hybridization methods; single
strand polymorphism, DNA sequencing and other PCR based methods [5, 7, 8]. Multiplex
Allele Specific (MAS) PCR, a rapid and cost-effective method simultaneously detects INH, RIF
and Ethambutol (EMB) resistance associated genetic mutations [9]. PCR technology can pro-
vide many advantages over traditional techniques. Many PCR tests can be rapidly performed
and interpreted on the same day of submission of samples. A major advantage of PCR over tra-
ditional techniques includes the ability to rapidly identify organisms that are difficult to culture
and the DNA of interest can be amplified with the DNA from just one cell. The sensitivity of
PCR is also its major disadvantage since very small amounts of contaminating DNA (from a
different sample) can also be amplified. One major limitation of PCR is that prior information
about the target sequence is necessary in order to generate the primers that will allow its selec-
tive amplification [10]. Whole Genome Sequencing (WGS) sequences the whole genome
rather than specific genes. So, drug resistance prediction from the whole genome sequence is
possible using publically available software which rapidly analyses all known gene targets and
identifies mutations associated with resistance thus enabling targeted treatment [11] but
requires culture and is currently prohibitively expensive for high burden countries. Identifica-
tion of MDR-TB is a crucial step as treatment of multi drug resistant tuberculosis (MDR-TB)
is a considerable challenge. Globally in 2015, an estimated 3.9% (95% confidence interval [CI]:
2.7–5.1%) of new cases and 21% (95% CI: 15–28%) of previously treated cases had MDR/
RR-TB [1]. Resistance to rifampicin is the result of mutations in the rifampicin resistance
determining region (RRDR) of rpoB, particularly mutations at codons 516, 526 and 531.
MDR-TB is defined as resistance to rifampicin and isoniazid, the two most effective anti-TB
drugs. In December 2010, WHO recommended the use of the GeneXpert MTB/RIF to detect
and infer resistance to rifampicin directly from sputum [12]. In May 2016, WHO issued guid-
ance that “people with TB resistant to rifampicin, with or without resistance to other drugs,
should be treated with an MDR-TB treatment regimen.” Together with MDR-TB, these are
referred to as MDR/RR-TB.
This work was carried out in Pakistan to characterize mutations associated with rifampicin
resistance directly from sputum samples from newly diagnosed (ND) patients with no history
of drug resistance and identify their key risk factors in this setting. Identifying resistance in
presumed resistant samples and inferring resistance profiles directly from sputum may enable
a better tailored drug regimen where possible. It will also inform patient management more
rapidly and consequently reduce the rate of onward transmission of MDR tuberculosis in high
burden countries such as Pakistan.
Materials and methods
Sampling
Tuberculosis patients attending the Ghulab Devi Chest Hospital, Lahore, Pakistan in collabo-
ration with University of Health Sciences, Lahore were enrolled in this study over 18 months
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between 2013 and 2015, based on the following inclusion criteria. For the MDR group, patients
diagnosed previously with TB, and with a history of resistance to first line anti-tuberculosis
drugs, were included. Sputum samples were taken from this group and culture and Drug Sus-
ceptibility Testing (DST) were performed. The second group of patients included freshly diag-
nosed consecutive cases, presumed drug susceptible with clinical symptoms of TB, positive in
sputum smear microscopy AFB, chest X-ray positive and no history of resistance to any first
line tuberculosis drugs. Sputum samples were taken from this group and culture was not per-
formed. Not all individuals were included; those with clinical complications in addition to
tuberculosis were not included in this study.
Patient history
The patient’s history was collected using a proforma and included age, gender, area, economic
status (earning less than 300 US dollars per month), information of previous anti-tuberculosis
therapy, chest x-ray, AFB test and family history of TB. The environmental parameters studied
were animal contact, source of drinking water, un-boiled milk use and smoking or drug use.
GeneXpert testing
GeneXpert testing was carried out only for six samples of the MDR group only due to lack of
global funding, according to the manufacturer’s instructions. Newly diagnosed presumed sus-
ceptible samples were not tested due to the reason that these samples have no history of drug
resistance. This test was performed in order to confirm the samples of MDR group before car-
rying out DST.
Initial sputum culturing on drug free LJ medium
For the MDR group, sputum suspension of each patient was made by mixing 0.5ml sputum in
equal volume of autoclaved deionized water under aseptic conditions. 0.1ml of sputum sample
was spread on LJ medium for M. tuberculosis culture under strict aseptic conditions. The colo-
nies appeared on the LJ medium after 4–6 weeks of culturing at 37˚C.
Drug susceptibility testing (DST)
Sub culturing of M. tuberculosis colonies from the MDR group was carried out on LJ medium
containing the different first line anti-tuberculosis drugs. The concentrations of drugs added
were: rifampicin (40 μg/ml); isoniazid (0.2 μg/ml); ethambutol (2 μg/ml); pyrazinamide
(50 μg/ml) andstreptomycin (4 μg/ml). Following a sterility check by incubating the culture
bottles at 37˚C for one week, the bottles were inoculated with an M. tuberculosis suspension of
the previous culture. After 4–6 weeks incubation at 37˚C in incubator, growth on a drug-free
control medium was compared with growth on culture media containing each concentration
of anti-tuberculosis drug. Any growth of M. tuberculosis colonies on drug containing LJ media
were designated drug resistant while samples where no growth was observed on drug contain-
ing LJ media, were declared to be drug susceptible Mycobacterium tuberculosis.
DNA isolation and quantification
Sputum samples from the presumed susceptible group of patients were collected and then
DNA extraction was carried out. Both cultures (described above) and sputum samples were
extracted using the column based TIANamp genomic DNA isolation kit (TIANGEN Biotech
Beijing, China) method. Quantity and quality of the isolated genomic DNA was determined
by NanoDrop (Thermo Scientific, USA) using 1μL sample of purified DNA.
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rpoB analysis
The fragment containing 81bp Rifampicin Resistant Determining Region (RRDR) of the rpoB
gene of all strains were sequenced using published primers [13] and analysed in BIOEDIT
software using ClustalW alignment parameters (BioEdit version 7.2.5). The PCR was carried
out in a total volume of 50μl where 1μl of the DNA was added to the reaction containing
1xPCR reaction buffer, 1.5mM MgCl2, 0.2mM dNTPs (Invitrogen, UK), 20μM each of both
rpoB-RRDR forward (5’- CGATCACACCGCAGACGTTGA)and reverse primers (5’-GGCAC
GCTCACGTGACAGACC) and 5U recombinant Taq polymerase (Invitrogen, UK). The follow-
ing PCR conditions were carried out using a Veriti thermocycler (Applied Biosystems, UK):
94˚C for 2 min followed by 35 cycles of 94˚C for 30 sec, 60˚C for 30 sec and 72˚C for 1 min.
Finally, an extension of 72˚C for 10 min was performed before cleaning the products using
AmpureXP magnetic beads (Beckman Coulter, UK) according to the manufacturer’s protocol
and forward and reverse sequencing performed.
Ethics and consent
The present research work was approved by the ethical committee of University of the Punjab,
Lahore, Pakistan in accordance with the ethical standards of the responsible committee on
human experimentation and with the latest (2008) version of Helsinki Declaration of 1975
[14]. The purpose of the study was explained and written consents from the patients or guard-
ians were taken from all patients or from next of their kin, caretakers, or guardians/parents on
behalf of all child participants.
Results
GeneXpert testing
GeneXpert testing was positive for six of the samples of MDR group and further verified by
DST.
Drug susceptibility testing (DST)
Of the 130 MDR cultures tested for resistance to isoniazid (I), rifampicin (R), ethambutol (E),
pyrazinamide (P) and streptomycin (S), 96 were resistant to IREPS, 26 were resistant to IREP,
three were resistant to IR, two were resistant to IRES, one was resistant to IRP and two resis-
tant to IRPS. Streptomycin was added so that to kill any other bacterial contamination in the
culture in addition to drug sensitive mycobacteria.
rpoB analysis
An overview of the rpoB mutations seen in both groups is shown in Table 1. The isolated DNA
from all samples quantification was carried out by nanodrop and DNA quantity was found to
Table 1. Mutations seen in rifampicin resistance determining region (RRDR).
516 (WT = GAC- Asp) 526 (WT = CAC- His) 531 (WT = TCG- Ser)
SNP TAC GTC GGC TAC AAC CCC TTG TGG TGC
(AA change) (Tyr) (Val) (Gly) (Tyr) (Asn) (Pro) (Leu) (Trp) (Cys)
MDR group (n = 130) 8 7 2 4 2 1 49 1 1
ND group (n = 86) 2 2 0 0 0 0 8 2 0
Note: Multidrug resistant group (MDR), Newly diagnosed group (ND).
https://doi.org/10.1371/journal.pone.0183363.t001
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be in range of 70–90 ng/μl. Of the 130 MDR strains, 80 had mutations in the RRDR region of
rpoB (61.3%) (S1 Fig). In order of mutation frequency, 49 strains carried a single mutation at
position 531, TCG>TTG/Ser>Leu (65.3%), 8 strains carried a single mutation at position 516,
GAC>TAC/Asp>Tyr (10%), 7 strains carried a single mutation at position 516 GAC>GTC/
Asp>Val (8.8%), 4 strains carried a single mutation at position 526, CAC>TAC/His>Tyr
(5%), 2 strains carried a single mutation at position 516, GAC>GGC/Asp>Gly (2.5%), a fur-
ther 2 strains carried a single mutation at position 526, CAC>AAC/His>Gly (2.5%) and single
strains carried mutations at positions 526, CAC>CCC/His>Pro; 531, TCG>TGG/Ser>Trp;
TCG>TGC/Ser>Cys (all at 1.3%). The remaining mutations were as follows: one strain with
a deletion of positions 516 and 517; one strain with two mutations, the first at position 516,
GAC>GGC/Asp>Ala and the second at position 531, TCG>GCG/Ser>Ala; one strain with
two mutations, the first at position 526, CAC>CAG/His>Gln and the second at position 533,
CTG>CCG/Leu>Pro; one strain with a two amino acid deletion of 516/7 and two strains with
mutations just upstream of the RRDR.
For the ND group, 14/86 of the extracted DNAs (16.3%) carried mutations associated with
MDR status; the remainder showed wild type RRDR sequence. Of the 14, 8 DNAs carried a
single mutation at position 531, TCG>TTG/Ser>Leu (57.1%); 2 DNAs carried a single muta-
tion at position 531, TCG>TGG/Ser>Trp (14.3%); 2 DNAs carried a single mutation at posi-
tion 516, GAC>GTC/Asp>Val (14.3%) and a further 2 DNAs carried a single mutation at
position 516, GAC>TAC/Asp>Tyr (14.3%).
Discussion
Molecular screening of M. tuberculosis–containing sputum samples for drug resistance,
although recommended by the WHO, is expensive and inaccessible to many high incidence
areas such as Pakistan. To gain further information about the prevalence of MDR in newly
diagnosed patients in this area of Lahore, Pakistan, the RRDR region of the rpoB gene from
two groups was sequenced; the first group comprised extracted DNA from130 MDR strains
from patients diagnosed previously with TB, and with a history of resistance to first line anti-
tuberculosis drugs; the second group comprised 86, DNA extracts directly from sputum sam-
ples from consecutive newly diagnosed patients, with clinical symptoms of TB, positive in
sputum smear microscopy AFB, chest X-ray positive and presumed drug susceptible with no
history of resistance to any first line tuberculosis drugs. The most common mutation found in
both groups was in line with other studies, i.e. at position 531, TCG>TTG/Ser>Leu, and at
61.3% and 57.1% for MDR and ND groups respectively, at a similar prevalence.
Studies indicate that 96.1% of the rifampicin resistant strains worldwide will have rpoB
mutations (so a surrogate marker for MDR) studies [15, 16]. Comparison of the DST results
with the RRDR data from the MDR group in this study suggests that only 61.5% of strains
carry mutations in this region of the rpoB gene so sequencing the RRDR does not correlate
with rifampicin resistance as successfully. The reasons for this may be that resistance to rifam-
picin is conferred by mutations in other parts of the gene or genome or that the DST testing
was sub optimal in some way and indicated resistance when none was present, although all
patients from this group had a history of resistance to first line anti-tuberculosis drugs. Anti-
microbial resistance testing (AST) or Drug resistance testing was established in the 1960s [17]
and there is no consensus reference method for MIC determination against which the different
methods can be compared to determine common breakpoints.
The main finding of this study however is the high incidence of rifampicin resistance asso-
ciated mutations, which is often used as a surrogate marker for MDR. At 16.3%, it is consider-
ably higher than the WHO estimate of 3.9% of new cases of multi drug resistant tuberculosis
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[1]. This single piece of study needs to be justified with the help of future studies to support a
high percentage of rif resistant strains. The cost of rpoB sequencing in this study was approxi-
mately $10, the cost of a GeneXpert test in this region. The time taken to carry out rpoB
sequencing is slightly longer than GeneXpert testing but requires more complex testing and
analysis. GeneXpert testing or rpoB sequencing for detection of MDR TB in sputum samples is
much faster than waiting for results of culture and DST. The diagnosis and effective treatment
for individuals with MDR needs to be tailored and administered quickly by rapid molecular
tests and, as a consequence of that, the control of transmission of MDR tuberculosis will be
tightened. Only then will MDR tuberculosis infection and transmission be effectively con-
trolled in high incidence areas such as Pakistan, where it is most needed.
Supporting information
S1 Fig. Alignment of RRDR sequences from this research work.
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